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ABSTRACT
The objectives of this study were to monitor resistance to the antimicrobial growth 
promoter avilamycin on pig farms, with changes in resistance over time and in relation to 
avilamycin use of particular interest. The aims were to consider how best to measure 
resistance and to determine which organisms in the faecal flora, in particular which 
Enterococcus species, were expressing resistance. Resistance to therapeutic 
antimicrobials used in human medicine was also to be assessed.
In considering how best to measure resistance, standard statistical methods were used and 
novel epidemiological techniques were also developed. The findings suggested that 
standard statistical formulae should be applied to calculating sample numbers for 
antimicrobial resistance studies and that the organism, antimicrobial and animal 
population of interest should be clearly defined. Furthermore, the epidemiological models 
suggested that the sensitivity and specificity of the tests used must be defined and that the 
current practice of testing a small number of colonies from a small number of animals 
means that resistant organisms will be missed if the prevalence of resistance is very low, 
and that changes in resistance below 5 per cent prevalence cannot be monitored with 
accuracy. When the test used is not 100 per cent specific then the current practice of 
confirming the presence of resistance based on one bacterium testing positive is 
potentially misleading.
The relationship between resistance and antimicrobial use on farms was shown to be 
difficult to assess due to the many factors potentially influencing the prevalence of 
resistance. The use of Slanetz and Bartley medium was shown to be effective in isolating 
Enterococcus species with a prevalence of isolation ranging from 0.5 to 1 but to be 
poorly specific for this genus. E. faecium^ E, faecalis, E. hirae and E. durans were 
shown to be capable of expressing resistance to avilamycin and the relative proportion of 
these species was found to be different on different farms. Minimum inhibitory 
concentrations (MIC) of avilamycin ranged from 1 p,g/ml to >128|tg/ml in the 
enterococcal isolates tested. The large number of Escherichia spp. and smaller number of 
Yersinia spp. isolates tested were resistant to avilamycin with MIC >128frg/ml whilst the 
MIC in a small number of Campylobacter spp. isolates ranged from 8pg/ml to 128p,g/ml. 
Avilamycin resistant enterococci were isolated from all four farms studied and resistance 
had persisted or been reintroduced on one farm where avilamycin had been withdrawn 
from use two years previously. This was only detected when faeces were screened on 
avilamycin-containing medium and not by conventional individual isolate MIC 
detennination.
The prevalence of resistance to a panel of human therapeutic antimicrobials was assessed 
in enterococci and Escherichia spp. but few conclusions could be drawn due to the small 
sample numbers studied.
The molecular basis of avilamycin resistance was determined in 4 enterococcal isolates. 
Two E, faecium and one E. faecalis had substitutions in the gene encoding ribosomal 
protein L16 but one E. hirae and one E. faecium had sequences identical to the sensitive 
reference strain.
In summary, avilamycin resistance was detected on all 4 farms studied using 
conventional microbiological techniques but was difficult to quantify, and it was not 
possible to measure changes in prevalence over time with accuracy using these methods.
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CHAPTER 1 
INTRODUCTION AND REVIEW OF THE LITERATURE
1.1 Historical background to antimicrobial use
The use of antimicrobials to control bacterial infection is now commonplace in human
and veterinary medicine with 490 tonnes of active ingredient sold for use in animals
alone in 2000 (http://www.vmd.gov.uk). However, in historical terms, the
development of antibacterial agents is a relatively recent phenomenon. Prior to the
twentieth century, efforts at controlling bacterial infections were restricted mainly to
topical antiseptics with many of these substances developed from embalming
techniques used by the ancient Egyptians to preserve flesh (Nutton, 2001). However,
these agents were too toxic to be taken internally and work began in the early
twentieth century on developing agents that were selectively damaging to prokaryotic
but not eukaryotic cells (Greenwood, 1997; Weatherali, 2001).
In 1928, Scots physician Alexander Fleming first observed that a substance produced
by Pénicillium notatum, a mould sourced from air, could exert an inhibitory effect on
bacteria and the antibiotic era began (Fleming, 1929; Prescott, 2000). The first cases
of successful treatment of bacterial infection in humans were reported shortly
afterwards including the case of a 43 year old man from Oxford diagnosed as having a
disseminated Staphylococcus aureus and Streptococcus pyogenes infection whose
condition improved following the administration of penicillin. The patient relapsed
and died when penicillin supplies were exhausted but the successful treatment of a
case of streptococcal meningitis was described soon after (Abraham et at., 1941;
Fleming, 1943). Although its efficacy had been demonstrated, it was several years
following its discovery before penicillin was fully purified, its structure determined
1
and large-scale commercial production achieved (Greenwood, 1997). Chain and 
Florey were largely responsible for developing penicillin for clinical use and for these 
achievements they, as well as Fleming, were awarded the Nobel Prize for Medicine in 
1945 (Chain et al., 1940; Abraham et al., 1941).
Meanwhile, synthetic antimicrobials were developed before penicillin was produced 
in useful quantities and German (Gerhard Domagk) received the Nobel Prize in 
Physiology or Medicine in 1939 for his work on the compound sulphanilamide 
(Weatherali, 2001). Domagk had observed that prontosil, a red dye first synthesised in 
1932 by Klarer and Mietzsch, was effective in preventing disease in mice and rabbits 
dosed with staphylococci and streptococci and it was later discovered that the 
antibacterial activity of prontosil was due to the release of sulphanilamide (Domagk, 
1935; Horlein, 1935; Fuller, 1937). Prontosil was subsequently successfully used in 
the treatment of a woman suffering from puerperal fever in a London hospital in 
1936. The use of both sulphonamides and penicillins for the treatment of puerperal 
pyrexia was associated with a significant reduction in mortality following childbirth 
in the United Kingdom from the middle of the twentieth century (Colebrook and 
Kenny, 1936; Greenwood, 1997). Following these early advances, many other 
antibacterial agents were developed but in recent years the majority of antimicrobial 
drug development has been based on the expansion of existing drug classes and it now 
seems unlikely that any totally new, unrelated antimicrobial compounds remain to be 
discovered (Greenwood, 1997).
The widespread application of antimicrobials in the treatment of animals followed 
their use in human medicine and since their introduction, antimicrobials from many 
different chemical classes have been commonly used in the therapy of microbial 
disease in food animals (Miller and Flynn, 2000). Early examples of antimicrobial
' '''   '' ■
î
use in animals include a report on diseases of farm livestock by the National 
Veterinary Medical Association (later the British Veterinary Association) in 1941, iwhere it was suggested that cases of mastitis be treated with oral sulphonamides or, in 
less severe cases, by udder irrigation with acrifiavine (HMSO, 1965). Daily intra-
"■Ïmammary infusion of 100,000 units of penicillin in aqueous solution was also shown 
to be effective in the treatment of mastitis caused by Streptococcus agalactiae in an 
experimental herd at Weybridge (HMSO, 1965). However, in farm animals, 
antibiotics have not only been used in the treatment of disease, but also 
prophylactically to treat clinically normal but infected animals, and for growth 
promotion (Friendship, 2000).
1,2 Antimicrobial growth promoters
Growth promoters are feed additives, other than dietary nutrients, which increase 
growth rate and/or improve feed efficiency in healthy animals fed a balanced diet (van 
den Bogaard and Stobberingh, 1999) and antimicrobials used for this purpose are 
given to animals continuously in feed at low levels.
The “growth promoting” properties of antibiotics were first discovered in the late 
1940s when fermentation waste from tetracycline production was fed to chickens as a 
source of vitamin B^ .^ It was discovered that the chickens grew more rapidly than 
when on their normal diet and it was thought that these effects were due to some 
unknown substances in these fermentation products (Hill, 1948; Carlson et aL, 1949;
Stokstad et al., 1949; Jukes and Williams, 1953). However, the growth-promoting 
effect was later found to be due to residual tetracycline (aureomycin) (Carpenter,
1950; Jukes et at., 1950; Stokstad and Jukes, 1950; Whitehill et al., 1950) and further 
experiments in pigs and poultry confirmed that other antimicrobials including
penicillin and sulphonamides also exerted a growth-promoting effect (Moore et aL, 
1946; Luecke et al., 1950; Speer et al., 1951). These findings led to the subsequent 
commercial development of various antimicrobial growth promoters and their use has 
been commonplace in the United Kingdom since 1953 (Swann, 1969).
Antimicrobial growth promoters are generally used in young animals where they are 
also most effective (Stahly et aL, 1980; Lindemann et aL, 1985; Jones et aL, 1987) 
with young pigs, broilers, pre-ruminant and recently-weaned calves the most common 
recipients. Their use in adult ruminants is less common but they can be administered 
to this class of animal where it has been shown that their use increases milk yield (van 
Heijenoort et aL, 1987).
1.3 Consumption of antimicrobial growth promoters
In the UK, the Veterinary Medicines Directorate collates information on the sale of 
antimicrobials in veterinary medicine based on data provided voluntarily by the 
pharmaceutical industry, and information on antimicrobial sales is available on their 
website (www.vmd.gov.ukJ. In 1993, antimicrobial growth promoter sales in the UK 
were initially reported to be 83 tonnes of active ingredient, and this increased to a 
high of 122 tonnes in 1995 before falling again to 89 tonnes in 1998 
lwww.vmd.gov.uk/general/publications/mayra2a.html. However, these data were 
recently reviewed and the findings suggested that only 46 tonnes of antimicrobial 
growth promoter were sold in the UK in 1998 (VMD, 2001). Such discrepancies in 
the data available on antimicrobial sales make it difficult to assess trends in the 
quantities of antimicrobials prescribed in animals. In 1999 and 2000 sales were 
reported to be 28 and 24 tonnes of active ingredient, respectively, but it is 
acknowledged that some data are missing for these years (VMD, 2001). In 2001,
recorded sales were 43 tonnes of active ingredient, which represented 9 per cent of the 
total sale of antimicrobial products for food-producing animals (www.vmd.gov.ukl. 
In addition to the inconsistency of the available data on veterinary antimicrobial sales, 
at present it is also impossible to relate antimicrobial growth promoter sales to species 
in the UK as these data are not collected. However, this information is available for 
therapeutic antimicrobials where sales in pig-specific products have increased from 83 
tonnes active ingredient in 1998 to 109 tonnes active ingredient in 2001 
(www.vmd.gov.uk). This increase in therapeutic antimicrobial use has coincided with 
the ban on some growth promoting antimicrobials and the introduction of post- 
weaning multi-systemic wasting syndrome and porcine dermatitis and nephropathy 
syndrome which are likely to have increased the need for antimicrobial therapy. 
However, there has also been a reduction in the total live weight of pigs slaughtered 
over the same period from 1,402,000 tonnes in 1998 to 972,000 tonnes in 2001. A 
large component of this reduction in pig production has been due to contraction of the 
industry under economic pressure and under normal circumstances this would have 
been expected to be reflected in a reduction in antimicrobial sales. However, the 
introduction of these diseases has had a significant impact on pig productivity and 
may also have increased the need for therapeutic antimicrobial treatments and this 
makes these findings difficult to interpret.
1.4 Regulation of antimicrobial growth promoters
Within the EU, the use of antimicrobial growth promoters is tightly regulated. 
Permitted compounds may be incorporated in feed at specified concentrations for 
particular species as indicated in the classified Annexes of EC Directive 70/524/EEC 
The Feedingstuffs (Zootechnical Products) Regulations 1999. Under the above
directive, they may only be incorporated into animal feed at registered feed mills 
(Bishop, 2001). Farmers can purchase antimicrobial grovdh promoters from 
agricultural merchants and feed companies, which supply them in feed at the 
approved inclusion rate. Article 3 of the above directive states:
Community authorisation o f an additive shall be given only if:
a) when used in animal nutrition it has one o f the effects referred to in Article 2
(ay ;
b) taking into account the conditions o f use, it does not adversely affect human or 
animal health or the environment nor harm the consumer by altering the 
characteristics o f livestock products;
c) its presence can be monitored:
as an additive per se 
in premixtures
in feedingstuffs or, where appropriate, in feed materials
d) at the level permitted, treatment or prevention o f animal disease is excluded:
this condition does not apply to additives belonging to the group o f coccidiostats and
other medicinal substances;
e) for serious reasons concerning human or animal health its use must not be 
restricted to medicinal or veterinary purposes.
The growth promoters currently approved by the above legislation within the EU are 
avilamycin, flavophospholipol, salinomycin and monensin. Monensin and 
salinomycin are also approved for use as anticoccidials. Avilamycin is licensed as a 
growth promoter in pigs and chickens; flavophospholipol in cattle, pigs, poultry and 
rabbits; monensin as a growth promoter in non-Iactating cattle and as an anticoccidial
in poultry and salinomycin as a growth promoter in pigs and as an anticoccidial in 
poultry (Bishop, 2001).
1.5 Mode of action of antimicrobial growth promoters
Despite being the focus of many reports, the exact mechanisms of action of 
antimicrobial growth promoters are poorly described (Stockholm Commission on 
Antimicrobial Feed Additives, 1997; van den Bogaard and Stobberingh, 1999; 
Aarestrup, 2000a). Their effects, however, have been summarised as improved feed 
utilisation, improved growth rate and disease prevention and the proposed 
mechanisms by which they exert these effects include alteration of the normal 
microbial intestinal flora, preservation of nutrients and enzymes from degradation by 
microbes and alteration of villous structure and function (Stockholm Commission on 
Antimicrobial Feed Additives, 1997). In economic terms, their most important effect 
is improved feed efficiency (van den Bogaard and Stobberingh, 1999) although there 
is also a consequent reduction in the amount of waste products excreted in urine and 
faeces (Thomke and El winger, 1998).
Early evidence that antimicrobial growth promoters exerted their effect by inhibiting 
components of the intestinal microflora was that, unlike the situation in 
conventionally raised animals, growth in germ-free chickens was not enhanced by the 
administration of antimicrobial growth promoters (Lev and Forbes, 1959). 
Furthermore, the reduction in growth rate seen in germ-free chickens following the 
administration of Enterococcus faecium could be improved by the administration of 
penicillin (Lev and Forbes, 1959; Eyssen and DeSomer, 1967). It has been suggested 
that their inhibitory effect on microorganisms in the gastrointestinal tract reduces 
microbial degradation of useful nutrients and thereby increases metabolisable energy
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available to the animal but they are also thought to control weakly pathogenic 
organisms present in the gastrointestinal tract such as Enterococcus spp. and 
Clostridium spp. (Stockholm Commission on Antimicrobial Feed Additives, 1997; 
Shryock, 2000).
Early studies described changes in the physical properties of the gastrointestinal tract 
associated with the administration of growth promoters, with several authors reporting 
a reduction in weight of the small intestine (Pepper et al., 1953; Coates et aL, 1955). 
Thinning of the duodenal wall in antibiotic-fed birds was also described (Jukes et aL, 
1956). It was suggested that the gut-thinning effect observed was due to a reduction in 
bacterial toxin production and that this allowed improved absorption of dietary 
nutrients (Bogan et aL, 1983). A decline in mucosal cell turnover associated with a 
reduction in energy expenditure was also thought to be responsible for these 
observations and the consequent improved feed efficiency (Visek, 1978).
Other authors have suggested that the growth promoting effect of antimicrobials is 
due to altered metabolism of the enteric flora leading to an increase in the availability 
of dietary nutrients to the animal (Bogan et aL, 1983). Studies on the metabolism of 
nutrients by the enteric flora suggested that the inhibition of certain organisms 
including Streptococci, Enterococci and Lactobacilli resulted in a sparing of 
carbohydrates (Vervaeke et aL, 1976; Bogan et aL, 1983).
However, it has generally been acknowledged that antimicrobial growth promoters 
also have a role in disease prevention and because therapeutic antimicrobials 
including tetracycline and penicillin were initially used for this purpose (Smith, 
1975), it has been difficult to separate their effect on pathogenic microorganisms from 
their other microbiological effects. Therapeutic antimicrobials are no longer permitted 
for use as growth promoters in the European Union, although the situation is different
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in the U.S.A where, for example, oxytetracycline is still used for this purpose (van 
den Bogaard and Stobberingh, 1999). Although growth promoters are given at low 
“subtherapeutic” concentrations, this does not necessarily mean they do not have an 
inhibitory effect on the growth of pathogenic organisms and there are many accounts 
in the literature of growth promoters reducing the severity and incidence of clinical 
disease (Shryock, 2000).
The compounds avoparcin, bacitracin, virginiamycin and avilamycin have all been 
shown to be effective against necrotic enteritis in poultry caused by Clostridium 
perfringens at levels permitted for growth promotion (Wicker et aL, 1977; Stutz et aL, 
1983; Hofshagen and Kaldhusdal, 1992; Stockholm Commission on Antimicrobial 
Feed Additives, 1997; Bolder et aL, 1999). Monensin has been shown to reduce the 
clinical signs of swine dysentery caused by Brachyspira hyodysenteriae (Kyriakis,
1989) and avilamycin has been shown to reduce the severity and mortality associated 
with post-weaning diarrhoea in piglets, despite the fact that the most likely causal 
agent is Escherichia coli, a gram-negative organism (Kyriakis, 1989). Tylosin has 
been shown to be effective in preventing porcine proliferative enteropathy caused by 
Lawsonia intracellularis at growth-promoting levels (McOrist et aL, 1997) and 
flavophospholipol has been shown to have an inhibitory effect on the shedding of 
Clostridium spp, (Bolder et aL, 1999).
In cattle, antimicrobial growth promoters and ionophores in particular have proven 
efficacy in reducing the incidence of bloat, mastitis and non-infectious lameness in 
adult dairy cows (van Heijenoort et aL, 1987; Lowe et aL, 1991). However, the mode 
of action of growth promoters in ruminants is different to that in monogastrics with 
evidence to suggest that the main effects are a reduction in energy lost due to the 
production of methane gas and improved efficiency of rumen fermentation by
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alteration of volatile fatty acid production to favour propionic acid (Thornton et aL,
1976; Nevel and Demeyer, 1977; Chen and Wolin, 1978; Bogan et aL, 1983). The 
improved energy availability to the animal could explain why antimicrobial growth 
promoters have been associated with a reduction in the incidence of diseases 
associated with negative-energy balance rather than infectious diseases of the 
digestive tract in this class of animal. I
Further evidence of the role of growth promoters in disease prevention is that
■■"Ialthough they are said to be effective in both extensive and intensive systems 
(Gustafson and Bowen, 1997) studies comparing conventionally raised animals and 
germ-free animals have shown that only the growth response of conventional animals 
is improved by the administration of low concentrations of antibiotic (Stockholm 
Commission on Antimicrobial Feed Additives, 1997) and furthermore, that animals 
kept in scrupulously clean conditions respond less well to growth promoting 
antimicrobials (Lev and Forbes, 1959; Coates et aL, 1963; Eyssen and DeSomer,
1967; Shryock, 2000). A study in healthy pigs under good commercial management 
conditions suggested that constant improvements in live-weight gain of 30g per day 
could be obtained even in clinically healthy pigs kept in sanitary conditions by the 
administration of tylosin and this was thought to suggest that growth promotion 
occurred independent of disease status (Jones, 1978). However, it should be pointed 
out that although these animals were defined as healthy by clinical examination, there 
may have been underlying unidentified subclinical disease problems having an 
inhibitory effect on growth.
These findings suggest that antimicrobial growth promoters may be more useful when 
husbandry standards are poorer and that since the presence of disease undoubtedly has 
an inhibitory effect on growth and production, their effect in reducing disease is
inextricably linked to their growth-promoting effect. It has been suggested that 
targeting the administration of antimicrobial growth promoters over the period when 
animals are most likely to encounter pathogens or are most susceptible to disease 
allows the prevention of diseases and the economic losses associated with disease 
outbreaks and that there is less need for higher levels of therapeutic antimicrobials 
later (Gustafson and Bowen, 1997). In addition, the welfare of the animals concerned 
is protected because the stress and suffering caused by disease is prevented. However, 
recent experiences in countries where antimicrobial growth promoters have been 
withdrawn suggest that animal welfare and production is not compromised provided 
that husbandry standards are high and given the pressure to limit antimicrobial use in 
agriculture, the use of antimicrobials to compensate for poor hygiene and 
stocksmanship in animal production is unlikely to be tolerated in the future (Aarestrup 
et aL, 2001; SVARM, 2001).
In summary, it is likely that the action of antimicrobial growth promoters involves a 
complex interaction of microbiological, nutritional, physiological and disease- 
preventing effects and that the magnitude of their effect is modified by factors such as 
nutritional, environmental and health status of the animals. Although the mode of 
action of antimicrobial growth promoters is complex, their effect on growth is less 
pronounced in high-health status animals and there is little evidence to suggest that 
their use improves animal welfare unless husbandry standards are poor.
1.6 Structure of antimicrobial growth promoters
Avilamycin is an oligosaccharide antibiotic produced by Streptomyces 
viridochromogenes (Mertz et aL, 1986; Stockholm Commission on Antimicrobial 
Feed Additives, 1997; Bishop, 2001) and is structurally related to curamycin and the
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everninomycins, which have recently been considered for use in human medicine. It 
exerts its inhibitory effect on bacteria by blocking protein synthesis through inhibiting 
the function of the 30s ribosomal subunit (Wolf, 1973) and is poorly absorbed from 
the gastrointestinal tract (Magnussen et aL, 1991).
Flavophospholipol is a phosphorus-containing glycolipid produced by several 
Streptomyces spp. comprising S. bambergiensis, S. ghanaensis, S. geysirensis and S. 
ederensis and is active mainly against Gram-positive bacteria (Bogan et aL, 1983). It 
is a competitive enzyme inhibitor, which interferes with the transglycolase activities 
of penicillin-binding-proteins, thereby interfering with cell wall synthesis in Gram- 
positive bacteria (van Heijenoort et aL, 1987). Studies in chickens and pigs have 
shown that after oral administration it is almost completely eliminated as the intact 
molecule in the faeces and that no measurable residues are found in carcasses of 
animals fed flavophospholipol for several months (Bogan et aL, 1983). There are no 
compounds related to flavophospholipol used for therapy in either humans or animals. 
Monensin is a carboxylic ionophore produced by Streptomyces cinnamonensis and 
acts by altering membrane permeability, killing the bacterial cell by lowering 
intracellular pH (Prescott, 2000). It has limited antibacterial activity and is active 
against the six species of Eimeria known to be pathogenic in chickens (Bogan et aL, 
1983). Studies in cattle have shown that over seventy per cent of monensin is excreted 
unchanged in faeces and that at the levels permitted for growth promotion and 
coccidial prophylaxis, no residues are detectable in carcasses or eggs 24 hours after 
withdrawal (Bogan et aL, 1983).
Salinomycin is a monocarboxylic acid polyether ionophore produced by Streptomyces 
albus (Kinashi et aL, 1973) with a similar mechanism of action to monensin. No 
ionophore antimicrobials are used in human medicine.
1.7 Spectrum of activity of antimicrobial growth promoters
Not all antimicrobial agents are effective in improving growth in animals and those 
that are tend to be active mainly against Gram-positive organisms (von Wasielewski 
et aL, 1965; Bunyan et aL, 1977; Bogan et aL, 1983; Aarestrup, 2000a). However, the 
chemical structures of these compounds differ widely and there are a few 
antimicrobials mainly active against Gram-negative organisms, such as streptomycin, 
that have also been shown to have growth-promoting effects (Bunyan et aL, 1977). 
The primary site of action of antimicrobial growth promoters currently licensed for 
use in the European Union is the gastrointestinal tract, from which they are usually 
not absorbed (Bogan et aL, 1983; Gustafson and Bowen, 1997) and therefore the wide 
variety of Gram-negative and Gram-positive organisms in the gastrointestinal 
microflora are exposed to their action.
Avilamycin is reported to inhibit the growth of E, faecium, E. faecalis, C. perfringens 
and Staphylococcus spp. in vitro (Dutta and Devriese, 1982; Butaye et aL, 1998) and 
whilst there is variation in susceptibility to flavophosholipol amongst E. faecium 
strains (Aarestrup et aL, 1998), Clostridium spp.. Staphylococcus spp. and E. faecalis 
are reported to be susceptible (Devriese, 1980; Dutta and Devriese, 1982; Dutta and 
Devriese, 1984; Aarestrup et aL, 1998). Monensin and salinomycin are active against 
E. faecium and E. faecalis although these species are more susceptible to avilamycin 
in vitro (Aarestrup et aL, 1998) and monensin is also active against some 
Campylobacter spp., Brachyspira hyodysenteriae and Toxoplasma gondii (Prescott, 
2000). In addition, monensin and salinomycin also possesses anticoccidial activity 
(Bogan et aL, 1983; Prescott, 2000). Therefore, whilst antimicrobial growth 
promoters are active in the main against Gram-positive organisms, the ionophores in
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particular have the potential to inhibit the growth of Gram-negative organisms as well 
as protozoa.
i.S Significance and development of antimicrobial resistance in human 
pathogens
There are numerous accounts in the literature of the development of antimicrobial 
resistance and since the advent of antimicrobial use, it has been recognised and 
documented in many organisms (Abraham and Chain, 1940; Tenover, 1991; Neu, 
1992). There is also evidence to suggest that antimicrobial resistance is an increasing 
problem with some describing it as a worldwide epidemic (Hancock, 1997; O’Brien, 
1997; Salyers and Amabile-Cuevas, 1997; Hart, 1998; MAFF, 1998). Many of these 
papers and articles use very emotive language to describe the current state of the 
resistance problem, e.g., "Superbugs are beating at the gates" (Kmietowicz, 1999) and 
"Resistance to Antimicrobial Drugs -  a Worldwide Calamity" (Kunin, 1993). It is a 
subject that has a high priority on the current web pages of the World Health 
Organization (http://www.who.int/emc.amr.html) and the U.S Food and Drug 
Administration (http://www.fda.gov/oc/antimicrobial/taskforce2000.html) so there is 
little doubt that it is perceived to be a significant problem.
There are some differences of opinion as to the prevalence of resistance genes in the 
pre-antibiotic era with resistant bacteria extremely rare in patients 60 years ago 
(Hughes and Datta, 1983) and yet evidence suggests that antimicrobial resistance was 
present to some extent before antibiotics were introduced (Smith, 1967; Gould, 1999). 
However, there is general agreement that the further development and dissemination 
of resistance is inextricably linked to the use of antimicrobials (SMAC, 1998; Monroe 
and Polk, 2000).
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Shortly after the introduction of penicillin for clinical use, resistant strains of 
Staphylococcus aureus became apparent (Kirby, 1944; North and Christie, 1946) and 
since then, the development and use of novel antimicrobial drugs has been followed 
by the development of resistance to them in bacteria (Andersson and Levin, 1999) 
with more than 100 resistance genes now described and resistance a recognised 
clinical problem in many bacterial species (O’Brien, 1997). The increase in 
antimicrobial drug resistance in human medicine has been associated with the misuse 
and over use of antimicrobials (Salyers and Amabile-Cuevas, 1997; Andersson and 
Levin, 1999), is of economic significance and is responsible for an increase in 
morbidity and mortality associated with infectious disease. However, it has also been 
suggested that the use of antimicrobials in veterinary medicine, and agriculture in 
particular, has been partly responsible for the worldwide increase in antimicrobial 
resistance seen in human medicine (Wegener et aL, 1999; Lipsitch et aL, 2002).
1.9 The spread of resistance from animals to man
Resistance to therapeutic antimicrobials used in veterinary medicine has been 
documented since shortly after their introduction for clinical use (Smith, 1954; Smith 
and Crabb, 1956) and although resistance is perceived to be less of a clinical problem 
in veterinary medicine, reports of resistant organisms continue to be published (van 
den Bogaard and Stobberingh, 1999). As well as presenting a problem for the therapy 
of animal diseases, it is widely acknowledged that animals that enter the food chain 
can be sources of antimicrobial resistant pathogens in humans (MAFF, 1998; 
ACMSF, 1999). The transfer of resistant bacteria from animals to man is best 
described for enteric bacteria with faecal contamination of carcasses leading to the
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exposure of humans to organisms originating in the gastrointestinal tract of food 
animals.
Resistant Salmonellae were first documented in the 1960s with multiresistant 
Salmonella enterica first isolated from man in 1965, and S. enterica serovar 
Typhimurium DTI04 the most common multi-resistant strain isolated from humans in 
the UK in the 1990s (Threlfall et aL, 1997). Multiresistant clones of S. enterica 
serovar Typhimurium have been isolated from animals in the UK and the spread of 
multiresistance has been attributed to the use of antimicrobials in calf-rearing units 
(Helmuth and Protz, 1997). There is also good evidence, including the isolation of 
genetically similar ceftriaxone-resistant isolates from a child and a cattle herd in the 
USA, to suggest that resistant S. enterica strains have been transferred from animals 
to humans (Threlfall et aL, 1985; Threlfall et aL, 1994; Wall et aL, 1995; Calvert et 
aL, 1998; Fey at ah, 2000). Antibiotic resistance has also been shown to be 
transferable between human and animal strains of Escherichia coli (Smith, 1969) and 
resistant E. coli strains have been documented as contaminants of carcasses (Linton, 
1986). These findings in conjunction with other observations, including the 
emergence of fluoroquinolone resistance in human Campylobacter jejuni isolates 
following the introduction of fluoroquinolones in poultry (Endtz et aL, 1991) and the 
detection of apramycin/gentamicin resistant determinants in enterobacteriaceae from 
humans following apramycin use in animals (Johnson et aL, 1994), indicate that 
resistant organisms and resistance determinants have been transferred from animals to 
man via the food chain.
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1.10 Definition and nature of resistance to avilamycin
The definition of an organism as sensitive or resistant to an antimicrobial is made on 
clinical grounds and the laboratory determination of resistance is used as a predictor 
for the probability of successful treatment. Resistance is measured in vitro by 
minimum inhibitory concentration, MIC, which is defined as the lowest concentration 
of antimicrobial that will inhibit the visible growth of a microorganism after overnight 
incubation (BSAC, 1991). If the concentration of antimicrobial in the target tissue 
exceeds the MIC following treatment, tlien an isolate is categorised as susceptible or 
sensitive (NCCLS, 1999).
However, this definition is unsuitable for growth-promoting antimicrobials as they are 
not used to treat infection, they act primarily on commensal organisms and are poorly 
absorbed from the gastrointestinal tract. Therefore, breakpoints for resistance and 
sensitivity have been defined by population distributions so that where a bimodal 
distribution of MICs has been evident, organisms in the upper range have been 
considered resistant (Aarestrup et al., 1998; Butaye, Devriese and Haesebrouck, 
1999b). Breakpoints for enterococci to avilamycin, monensin, salinomycin and 
flavophospholipol have been described using this method (Aarestrup et aL, 1998). 
However, an alternative means of defining resistance would be to consider the 
inhibitory effect of the concentration of growth promoter achieved in the 
gastrointestinal tract, as this is the target site of these compounds. It has been 
suggested that inhibitory concentrations should be related to the intestinal 
concentrations of antimicrobial but these are largely unknown and breakpoints have 
not been defined in this manner to date (Butaye, Devriese and Haesebrouck, 1999b). 
There is no evidence to suggest that there has been any reduction in the efficacy of 
growth promoters due to resistance emerging in the gastrointestinal flora, and
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therefore there seems to be little biological significance in adopting this approach to 
categorise organisms under test.
Resistance to growth-promoting antimicrobials has primarily been considered in 
enterococci, particularly E. faecium, and has been most closely monitored in Denmark 
and Sweden (Danmap, 1997; Danmap, 1998; Danmap, 1999; Danmap, 2000; 
SVARM, 2000; Danmap, 2001; SVARM, 2001). Estimates of the prevalence of 
resistance to avilamycin amongst enterococci from animals have varied from country 
to country with for example, 12.4 per cent of E, faecium isolates fi-om broilers 
categorised as resistant in a recent Japanese study (Yoshimura et a l, 2000) compared 
to 5 per cent of Danish isolates (Danmap, 2001), whilst all 151 isolates tested in 
Sweden in 2000 were sensitive (SVARM, 2000). In Denmark in 2001, 175 E. faecium 
isolates from pigs were tested and all were found to be sensitive compared to 2 per 
cent that were resistant in 1997 (Danmap, 1997; Danmap, 2001) and less than 1 per 
cent of E. faecium isolated from pigs in Sweden in 2000 were resistant compared to 1 
per cent in 2001 (SVARM, 2000; SVARM, 2001).
There is some variation in the literature on the breakpoint MIC for avilamycin that 
defines resistance. Isolates with MICs greater than 12.5pg/ml have been considered 
resistant (Yoshimura et a l, 2000) whereas isolates with MICs greater than 16pg/ml 
(Danmap, 1997; Danmap, 1998; Danmap, 1999; Danmap, 2000; Danmap, 2001) and 
isolates with MICs greater than 8pg/ml (SVARM, 2000; SVARM, 2001) have been 
classified as resistant elsewhere. However, in a recent study (Aarestrup and Jensen, 
2000), isolates with genes conferring resistance to avilamycin had MICs of at least 
32pg/ml and in most cases 64pg/ml or above. Other authors have classified E. 
faecium strains with MICs of greater than 32pg/ml as resistant (Butaye, Devriese and 
Haesebrouck, 1999b).
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A genetic mechanism of resistance to avilamycin amongst enterococci was first 
described in Danish E. faecium and E. faecalis isolates in 2000 (Aarestrup and Jensen, 
2000). All the variations observed were within the gene encoding ribosomal protein 
L16 with the resistant E. faecalis isolates all containing the same base pair variation, 
while the same variation and two additional variations were found in the E. faecium 
isolates. However, recent work has also described mutations in 23 S rRNA that confer 
resistance to avilamycin and evemimicin (Mann et a l, 2001) and it seems clear that as 
for most antimicrobials, multiple mechanisms of resistance may exist.
1.11 The role of antimicrobial growth promoters in transfer of resistance to man
None of the growth promoters licensed for use within the UK in 2003 are related to 
any concurrently used human therapeutic antimicrobials. However, there is evidence 
that growth promoters used in the past may have possessed cross-resistance to human 
medical antimicrobials and thereby contributed to the human antimicrobial resistance 
problem (Witte, 1997; Bishop, 2001).
Vancomycin is a glycopeptide antimicrobial used primarily in the treatment of 
resistant Gram-positive infections in man and is structurally related to the growth 
promoter avoparcin, which was used in food animals in Europe prior to its withdrawal 
in 1997. Vancomycin-resistant enterococci, first isolated in Europe in 1986, were 
subsequently reported in the United States in 1987 and have since been documented 
world-wide where they are considered to be important nosocomial pathogens 
(Cetinkaya et a l, 2000). Five major phenotypes of glycopeptide resistance, designated 
vanA, vanB, vanC, vanD and vanE, have been described in enterococci (Arthur and 
Courvalin, 1993; Perichon et a l, 1997; Fines et a l, 1999) with the vanA phenotype, 
consisting of high level vancomycin and teicoplanin resistance (Leclercq and
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Courvalin, 1997), usually contained in a transposon, Tn 1546, as the vanA gene 
cluster (Wegener et a l, 1999).
VanA vancomycin-resistant enterococci have been isolated from food animals and 
foods in Europe (Bates et a l, 1994; Aarestrup, 1995; Bager et a l, 1997; Wegener et 
a l ,  1997) and there is evidence to suggest that the use of avoparcin selects for 
vancomycin-resistance (Witte, 1997). This evidence has led to the suggestion that 
there has been selection for vancomycin resistance in animals through the use of 
avoparcin and that resistance has been transferred to man via the food chain.
However, the prevalence of vancomycin-resistant enterococci (VRE) in animals has 
been low in some animal surveys (Ike et a l, 1999) and in a study in the Netherlands 
where the prevalence of VRE amongst farmers, turkeys, slaughterers and suburban 
residents was compared, only 2-4 per cent of enterococci were resistant in all groups, 
including farmers who did and did not use avoparcin (Stobberingh et al., 1999). 
Therefore the relative importance of avoparcin use in animals in terms of the problem 
of vancomycin resistance in man is hard to interpret. Further conflicting evidence is 
provided by the fact that the incidence of VRE in American hospitals is greater than 
that in Europe, despite the fact that avoparcin has never been used as a growth 
promoter in the USA (van den Bogaard et a l, 1997; Wegener et a l, 1999).
Resistance to avilamycin has frequently been detected in Enterococcus faecium 
isolated from poultry in Denmark (Aarestrup et a l, 1998) and recently a structurally 
related compound with a similar mechanism of action, evemimicin (Ziracin), has been 
developed for use in human medicine (Aarestmp and Jensen, 2000; McNicholas et a l, 
2000). Cross-resistance between avilamycin and evemimicin has been reported in 
Danish enterococcal isolates (Aarestrup, 1998; Aarestrup and Jensen, 2000) but the
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development of evemimicin for clinical use by manufacturers Schering Plough has 
currently been suspended (Shryock, 2001).
Virginiamycin was widely used as an antimicrobial growth promoter prior to the 
introduction of legislation banning its use in 1999 and in a Danish study in 1997, 66 
per cent of E. faecium  isolates from broilers were reported to be resistant to 
virginiamycin (Danmap, 1998). It is a streptogramin antimicrobial that inhibits the 
24S ribosomal protein (Witte, 1997) and is structurally related to the compounds 
quinupristin and dalfopristin, which have been developed for use in human medicine 
in combination. Quinupristin-dalfopristin (Synercid) is recommended for use against 
resistant Gram-positive infections including VRE although it is not active against E. 
faecalis (Mulazimoglu et aL, 1996; British National Formulary, 2003).
Cross-resistance between virginiamycin and quinupristin-dalfopristin has been 
demonstrated and several resistance mechanisms described (Welton et at., 1998; 
Werner et a i, 2002) and significantly, high levels of resistance to quinupristin- 
dalfopristin were described amongst pathogens in Taiwan, including vancomycin- 
resistant enterococci and methicillin-resistant Staphylococcus aureus, prior to clinical 
use (Luh et al., 2000) leading to the suggestion that the use of virginiamycin in 
animals has selected for resistance to quinupristin-dalfopristin.
1.12 History of use - withdrawal
Currently, the use of antimicrobials as growth promoters in food animals is at the 
centre of debate, with calls for the practice to be banned (Witte, 1997; Fidler, 1999; 
Courvalin, 2000) and the main reason for this controversy is the recent worldwide 
anxiety at the emergence of bacterial antimicrobial resistance as a serious threat to 
human healthcare (van den Bogaard and Stobberingh, 1999; Aarestrup, 2000a).
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The first significant attempt at regulation of antimicrobial feed additives followed the 
release of the Swann Report in 1969 (Swann, 1969) and this action was prompted by 
the emergence of evidence suggesting that the use of therapeutic antimicrobials such 
as tetracycline as growth promoters had led to resistance in bacteria including E. coli 
(Smith, 1975). The purpose of these regulations was to reduce antibiotic resistance in 
organisms colonising animals and therefore to reduce the risk of antimicrobial 
resistant organisms being transferred to humans and it was recommended that the use 
of penicillins, tetracyclines, tylosin and sulphonamides as growth promoters be 
banned (Gustafson and Bowen, 1997).
A subsequent report in 1986 in Sweden (Stockholm Commission on Antimicrobial 
Feed Additives, 1997) concluded that the benefits of antimicrobial growth promoters 
did not outweigh the risks and the use of antimicrobials for growth promotion was 
banned in Sweden from this time, although monensin and salinomycin were still 
permitted for use as coccidiostats. The controversy surrounding the issue was 
heightened in May 1995 when Denmark imposed a unilateral ban on the use of 
avoparcin in animal feeds, followed by the banning of avoparcin throughout the EU in 
April 1997 (Wegener et al., 1999). The introduction of this ban was due to concerns 
that its use in animals was contributing to the problem of vancomycin-resistant 
enterococci in man (MAFF, 1998; Acar et al., 2(XK)).
In 1998, a voluntary ban on the use of all antimicrobial growth promoters was 
adopted by the food animal industry in Denmark (Danmap, 1998) and the initial ban 
on avoparcin was extended in July 1999 when the growth promoters spiramycin, 
virginiamycin, bacitracin and tylosin were banned throughout the EU (Acar et al.,
2000) so that the only antimicrobial compounds currently licensed for use in the EU 
for growth promotion are avilamycin, flavophospholipol, monensin and salinomycin.
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1.13 Antimicrobial use, resistance and bacterial population dynamics
Before examining the effects of such legislative decisions, it is first necessary to 
consider the effects of antimicrobial use on bacterial populations. The proliferation of 
antimicrobial-resistant organisms is by some considered to be an example of adaptive 
evolution (Levin et aL, 2000) with gene substitution occurring under the selective 
pressure of the presence of antimicrobial. In most cases, however, the acquisition of 
resistance genes in bacteria has an associated fitness cost (Andersson and Levin, 
1999) and the magnitude of this fitness cost is considered one of the most important 
factors governing the frequency of resistance in a bacterial population (Bjorkman et 
al., 2000). If the fitness cost associated with resistance is high relative to non-resistant 
organisms, then the surviving non-resistant organisms would be expected to 
proliferate and become the dominant proportion of the population following 
withdrawal of the selective pressure.
However, evidence suggests that the effects of antimicrobial therapy on bacterial 
population dynamics are complex and that fitness costs are not the only factor 
influencing population dynamics. In the case of some drugs, resistance developed 
very quickly after their introduction for clinical use (Abraham and Chain, 1940) 
whereas for other drugs, resistance emerged much more slowly, or not at all, after 
several decades of use (French and Phillips, 1997). In a recent review (Andersson and 
Levin, 1999), little evidence was found for the existence of fitness costs associated 
with resistance. Experimental evidence has also suggested that the fitness costs 
associated witli resistance can be compensated for by additional mutations, e.g.. Levin 
et al. showed that although streptomycin resistance in E. coli associated with 
ribosomal mutations (rpsL) had a substantial associated fitness cost, when these 
strains were serially passaged without the presence of streptomycin, resistance to
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streptomycin was maintained and fitness increased by adaptive mutations (Levin et 
al., 2000). However, it should be noted that these strains were still less fit than wild- 
type strains.
Evidence from the clinical setting also suggests that although cessation of, or 
reduction in, antimicrobial use is usually associated with a reduction in antimicrobial 
resistance, resistant strains may still persist, albeit at a lower level (Nowak, 1994) and 
a recent survey in London found that 20 per cent of E. coli isolates were still 
streptomycin-resistant despite the fact that streptomycin had not been used against 
this organism for 25 years (Chiew et al., 1998). However, some hospital programmes 
aimed at modifying antimicrobial use have been successful in reducing the prevalence 
of resistant organisms (Monroe and Polk, 20(X)).
The fact that resistances may be cross-linked and that many resistance elements carry 
more than one set of resistance genes may also influence the persistence of resistance. 
For example, plasmids can carry resistance to multiple antibiotics (French and 
Phillips, 1997) and this has led to the development of multi-drug resistance in 
pathogens such as S. enterica serovar Typhimurium DT 204, DT204c and DTI93, 
which were prevalent in the early 1980s (Threlfall et al., 1978; Wray et al., 1987). 
Furthermore, following the spread of resistance elements between bacteria, multiple 
resistance genes have become integrated into the bacterial chromosome in some 
organisms and this is thought to be the basis of the multiple drug resistance seen in S. 
enterica serovar Typhimurium DT104, for example (Threlfall et al., 1994; Ridley and 
Threlfall, 1998; Sandvag et al., 1998). This means that the continued use of one 
antimicrobial can continue to select for resistance to other antimicrobials that have 
been withdrawn. For example, it has been suggested that glycopeptide resistance
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persisted in enterococci following avoparcin withdrawal because tylosin was still in 
use (Aarestrup et al., 2001).
Therefore, there is evidence to suggest that the fitness costs associated with the 
maintenance of resistance genes and the co-selection of resistance elements are both 
factors important in influencing whether antimicrobial resistance will decline 
following the withdrawal of an antimicrobial. Whilst attempts have been made to 
predict the effects of treatment regimes on the emergence of resistance in bacterial 
populations (Lipsitch and Levin, 1997b; Lipsitch and Levin, 1998), the situation in 
the field is apparently complex. For example, vancomycin-resistant enterococci have 
been detected in Denmark and Norway several years after the withdrawal of 
avoparcin (Borgen et al., 2000; Heuer et al., 2002). These findings suggest that even 
low levels of antibiotic use can lead to the development of resistance that can later 
persist following withdrawal.
1.14 Effects of the ban on antimicrobial growth promoters
The effects of banning antimicrobial growth promoters on animal health and 
production, antimicrobial usage and antimicrobial resistance have been monitored in 
Sweden and Denmark (Danmap, 1998; Danmap, 1999; Danmap, 2000; SVARM, 
2000; Danmap, 2001).
In Sweden, there has been a gradual reduction in the total amount of antimicrobials 
used in farm animals since the ban on growth promoters in 1986 with 17 tonnes of 
active ingredient sold in 2(X)0 compared to 20.6 tonnes sold in 1996 (SVARM, 2000) 
whilst in Denmark, there has been an increase in the use of therapeutic antimicrobials 
between 1996 and 2001 of 17 per cent to 94.2 tonnes active ingredient (Danmap,
2001). It is not possible to relate antimicrobial sales to individual animal species in
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either country, but it is felt that these changes in consumption are independent of 
changes in livestock numbers.
Information from the Danish broiler industry indicates that there have been disease 
and production problems in the period following the voluntary ban in that country, 
with mean feed consumption at slaughter increasing from 1.78 to 1.82kg, mean 
weight at slaughter (42 days) reduced by approximately 30g and an increase in the 
number of flocks suffering from necrotic enteritis and chronic hepatitis caused by 
Clostridium perfringens (Danmap, 1998). This is in agreement with the findings in 
Sweden where streptogramins were prescribed as prophylactics for necrotic enteritis 
in poultry following the growth promoter ban. This practice has now ceased and 
treatment of poultry in Sweden with therapeutic antimicrobials is reported to be 
uncommon (SVARM, 2000). However, it should be pointed out that ionophores are 
used as coccidiostats in most broiler flocks in Sweden (SVARM, 2001) and that these 
compounds are also active against Clostridium perfringens, the causative agent of 
necrotic enteritis. The amount of ionophoric anticoccidials prescribed for group 
treatment in Sweden also increased dramatically immediately following the 
withdrawal of growth promoters and has persisted at approximately 10, 000kg active 
ingredient per annum since (SVARM, 2001). It is possible that the use of these 
compounds has masked disease problems that would otherwise have developed 
following the withdrawal of growth promoters. Information on the prevalence of 
disease in pigs has not been published but the increase in therapeutic antimicrobials 
sold in Denmark since the ban suggests that there has been an increase in 
antimicrobial treatments (Danmap, 2000; Danmap, 2001).
Data on resistance in commensal bacteria in Sweden are not available before 2000 
making it difficult to associate trends in resistance with the withdrawal of
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antimicrobial growth promoters, but 2 per cent of E. faecium isolates tested from pigs 
were resistant to avilamycin in 2000, indicating that resistance has persisted albeit at a 
low prevalence (SVARM, 2000). The most recent data available from Denmark 
indicate that, in general, resistance to antimicrobial growth promoters has reduced in 
concordance with a decrease in their use (Aarestrup et al., 2001). Resistance to 
gly copeptides in enterococci isolated from broilers has fallen significantly, from 72.7 
per cent before avoparcin was banned in 1995, to 5.8 per cent in 2000 (Bager et al., 
1999).
A similar reduction in glycopeptide-resistant isolates from pigs was not seen until use 
of tylosin as a therapeutic antimicrobial was also decreased. Two reasons have been 
suggested for this observation. First, that the use of all-in all-out husbandry in broiler 
farms led to the gradual replacement of vancomycin-resistant enterococci with 
enterococci sensitive to vancomycin and second, that the continued use of tylosin in 
pigs co-selected for resistance to vancomycin (Bager et al., 1999). Evidence to 
support this was initially based on the demonstration of associations between 
resistance to therapeutic antimicrobials such as tetracycline and penicillin and 
resistance to vancomycin in enterococci but the association with tylosin resistance in 
pigs was not statistically significant (Bager et al., 1999). However, it was later shown 
that genes encoding macrolide and glycopeptide resistance were located close 
together on the same plasmid in enterococcal isolates from pigs (Aarestrup, 2000b) 
and the prevalence of vancomycin resistance in enterococci from pigs in Denmark did 
decline significantly following a reduction in tylosin use in 1998 and 1999 (Aarestrup 
et al., 2001). The reduction in tylosin use also resulted in a significant reduction in 
erythromycin resistance in enterococci isolated from pigs (Aarestrup et al., 2001).
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Virginiamycin resistance has also decreased in enterococci isolated from broilers 
since its ban in 1998 but persisted at a prevalence of 33.9 per cent in 2000. Finally, 
avilamycin resistance in enterococci isolated from broilers peaked in 1996 at 63.6 per 
cent but has since fallen to 4.8 per cent in 2000, in parallel with a reduction in its use 
(Aarestrup et aL, 2001). These results indicate that the withdrawal of these growth- 
promoting antimicrobials has generally been followed by a reduction in resistance 
amongst enterococci, but this has been complicated by the fact that resistances to 
some antimicrobials are genetically linked and therefore a decline in resistance has 
not always been immediately apparent.
1.15 Epidemiology of antimicrobial resistance and modelling resistance
In order to improve understanding of resistance in bacterial populations, mathematical 
models are beginning to be employed to explain differences in patterns of resistance 
between organisms and also to predict the behaviour of organisms following changes 
in antimicrobial use (Levin et al., 1999) but these models have primarily been 
directed towards the treatment of clinical infections in humans and have generally 
modelled bacterial population dynamics (Lipsitch and Levin, 1997a; Lipsitch and 
Levin, 1997b; Lipsitch and Levin 1998; Levin et al, 2000; Levin, 2001; Lipsitch et 
at., 2002). According to the predictions of these models, the most important factors 
governing the frequency of antimicrobial resistance include the duration of 
infectiousness of individuals, the incidence of drug treatment, the extent to which 
treatment reduces transmission, the degree to which resistance reduces the 
competitiveness of a microorganism in the absence of treatment and the probability 
that a drug-sensitive infection becomes resistant on treatment (Levin, 2001). These 
factors have been used to predict the different patterns of resistance development in
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genital herpes and influenza A and the population dynamics of bacteria and their 
response in evolutionary terms to antimicrobial therapy has been modelled 
quantitatively (Lipsitch and Levin, 1997a; Lipsitch and Levin, 1997b; Levin et aL, 
1997). The efficacy of different antimicrobial treatment regimes in tuberculosis has 
also been compared (Lipsitch and Levin, 1998) and the effects of different treatment 
regimes on resistance considered, with the aim of developing protocols to minimise 
its development (Bonhoeffer et al., 1997).
However, the situations represented by such models are specific to human medicine 
and are quite unlike the situation in veterinary medicine where intensive antimicrobial 
treatment is unusual and concern has not been primarily about successful clinical 
treatment in animals but about transfer of resistant organisms or resistance 
determinants to man via the food chain (MAFF, 1998; ACMSF, 1999)
Historically, much of the study of the epidemiology of resistance in animals has been 
observational, with the presence of genetically similar resistant organisms in animals 
and man taken as evidence of the spread of resistance (van den Bogaard et al., 1997; 
Threlfall et al., 1997; Fey et al., 2000) but the magnitude of this effect has been 
difficult to quantify (Lipsitch et al., 2002) and many sources have suggested that the 
surveillance of antimicrobial resistance in animals is important and should be 
improved (Williams and Ryan, 1998; House of Lords Select Committee on Science 
and Technology, 1998; ACMSF, 1999).
Currently, as far as resistance to growth-promoting antimicrobials is concerned, there 
are few published data, certainly in the United Kingdom. Surveillance of resistance to 
growth promoters has, however, been undertaken in Denmark since 1995 as part of a 
programme to monitor resistance in zoonotic bacteria, non-zoonotic pathogens and 
indicator (commensal) bacteria in animals, food and humans (Danmap, 1997;
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Aarestrup et aL, 1998; Danmap, 1998; Danmap, 1999; Danmap, 2000) and several 
other European countries have recognised the importance of antimicrobial resistance 
surveillance in animals and are developing their own programmes (Martel et aL, 
2000; Moreno et aL, 2000; Wray and Gnanou, 2000; SVARM, 2001).
However, there are many issues, including variation in laboratory methodologies, 
discrepancies in categorisation of organisms and lack of demographic data, which 
have meant that comparison of resistance data and analysis of trends has been difficult 
(Wray and Gnanou, 2000). The need to quantify resistance in order to estimate 
prevalence and also to monitor changes over time and in relation to antimicrobial use, 
has been highlighted (Davison et aL, 2000) but a quantitative approach to resistance 
surveillance has not yet been adopted with current surveillance even in the best 
programmes based on testing a relatively small number of isolates from a small 
proportion of the food animal population (Danmap, 2001; SVARM, 2001).
1.16 Conclusions
Antimicrobial resistance is a serious clinical problem in human medicine, which 
makes the treatment of bacterial disease more difficult, more Costly and less likely to 
be successful and for these reasons, it is necessary that resistance to antimicrobials is 
minimised in order that as many antimicrobials as possible can be preserved for the 
treatment of infection. Since the emergence of antimicrobial resistance is usually 
linked to antimicrobial use, it is important that the necessity of all antimicrobial use is 
evaluated.
Animal and human bacterial populations are linked by the food chain, so that not only 
may zoonotic pathogens be transferred, but also commensal organisms or their 
resistance elements may spread to the human microflora.
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Antimicrobial growth promoters have been used in agriculture for many years but a 
proper assessment of their contribution to antimicrobial resistance is now thought to 
be appropriate. In order to do this, it is necessary to consider the epidemiology of 
resistance; its genetic basis; and its biological impact, so that the contribution made to 
the global problem of antimicrobial resistance by antimicrobial growth promoter use 
can be properly evaluated. The withdrawal of several antimicrobials from use as 
growth promoters in Europe has been controversial and such decisions will only be 
vindicated if they can be shown to have reduced antimicrobial resistance and this, in 
turn, can only be achieved if resistance can be measured.
The aims of this project were to consider resistance to the growth promoter 
avilamycin and to assess how resistance could be measured at farm level. Resistance 
to therapeutic antimicrobials and their relationship to avilamycin use were also to be 
considered and the effect of avilamycin withdrawal on avilamycin resistance 
measured. Conventional bacteriological techniques in conjunction with 
epidemiological modelling and molecular methods were to be used to achieve these 
aims. The plan of work was based around the following chapter headings:
Sample size requirements for the detection of resistance
Isolation, enumeration and identification of target organisms
Resistance to avilamycin
Resistance to therapeutic antimicrobials
Molecular investigations
Epidemiological models
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CHAPTER 2
GENERAL MATERIALS AND METHODS
2.1 Introduction
The materials and methods used can be subdivided into three main subheadings: 
bacteriological materials and methods, selection of farms and sampling methods and 
epidemiological modelling methods. Listed below are the equipment, media, reagents 
and conditions of cultivation used in the isolation, identification and sensitivity testing 
of the organisms studied as well as an overview of the farms selected for study and 
the software used to simulate the epidemiological models. A comprehensive list is 
provided here for completeness but the methods used for specific pieces of work are 
briefly described in each of the proceeding chapters.
2.2 Bacteriological materials and methods
2.2.1 Equipment used
1. Incubator, (37°C, aerobic). Swallow, Jencons PLS, Forest Row Business Park, 
Station Rd., Forest Row, East Sussex, RH18 5DW.
2. Incubator, (44°C, aerobic), Mini/75, Genlab Mini-Series Incubator, Jencons 
PLS, Forest Row Business Park, Station Rd., Forest Row, East Sussex, RH18 
5DW.
3. Incubator, (44''C, aerobic), Shake’n’Stack, Hybaid Ltd., Action Court, 
Ashford Rd., Ashford, Middlesex, TW15 IXB.
4. Incubator, (37°C, microaerobic), MACS-VA500-microaerobic workstation, 
Don Whitley Scientific Ltd., 14 Otley Rd., Shipley, West Yorkshire, BD17 
7SE.
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5. Ultra-low temperature freezer, (-86°C), Sanyo Electric Co. Ltd. Refrigeration 
Products Division, Sakota Oizumi-Machi Ora-Gun, Gunma 370-0596, Japan.
6. Refrigerator (3°C), Indesit, Merloni House, 3 Cowley Business Park, High 
Street, Cowley, Uxbridge, Middlesex UB8 2AD.
7. Electronic pipettor, Jencons Sealpette, Jencons, Cherrycourt Way, Stanbridge 
Rd., Leighton Buzzard, Bedfordshire, LU7 4UA.
8. Vortex, Vortex-Genie 2, Jencons, Cherrycourt Way, Stanbridge Rd., Leighton 
Buzzard, Bedfordshire, LU7 4UA.
9. Water Bath, (50°C), NEI Range Clifton Unstirred Bath, Nickel Electro Ltd., 
Oldmixon Crescent, Weston-Super-Mare, North Somerset, B824 9BL.
10. Disc dispenser, Oxoid Ltd., Wade Rd., Basingstoke, Hampshire, RG24 OPW.
11. Nephelometer, Biomerieux Ltd., Grafton House, Grafton Way, Basingstoke,
Hampshire, RG22 6HY.
12. Multipoint inoculator, A 4(X) Multipoint Inoculator, Denley Ltd. Billingshurst, 
Sussex, RHI4 9SJ.
13. Balance, Oertling HB63.
14. Safety cabinet, Holliday Fielding Hocking Ltd., Wesley Works, Wesley Place,
Leeds, LS9 8HA.
15. Centrifuge, MSE Micro Centaur, model no. MSB010.CX1.5, Sanyo Electric 
Co. Ltd. Sakota Oizumi-Machi Ora-Gun, Gunma 370-0596, Japan.
16. PCR machine, PCRExpress, Hybaid UK Ltd. Action Court, Ashford Place, 
Ashford, Middlesex TW15 IXB
17. Sequencer, ABI Prism 3100 Genetic Analyzer, Applied Biosystems, 850 
Lincoln Centre Drive, Foster City, CA 94404 U.S.A.
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2.2.2 Media and reagents used
The following media and materials were used throughout the study for general 
cultivation and maintenance. They were prepared according to the manufacturers 
instructions and used in the form given below.
1. Nutrient agar plates (Oxoid Ltd., Wade Rd., Basingstoke, Hampshire, RG24 
OPW, CM0003).
2. 5 per cent horse blood agar.
20ml defibrinated horse blood (E and O Laboratories Ltd., Burnhouse, 
Bonnybridge, Stirlingshire, FK4 2HH) was added to 400ml blood agar base 
No. 2 (Oxoid Ltd., CM0271).
3. 5 per cent sheep blood agar.
20ml formalised sheep blood, E and O Laboratories Ltd., Burnhouse, 
Bonnybridge, Stirlingshire FK4 2HH, was added to 400ml blood agar base 
No. 2 (Oxoid Ltd., CM0271).
4. MacConkey agar plates, Oxoid Ltd., CM0007.
5. Slanetz and Bartley agar plates, Oxoid Ltd., CM0377.
6. Preston Campylobacter medium, Oxoid Ltd., CM689, SROl 17E.
7. Skirrow Campylobacter medium, Oxoid Ltd., CM689, SR0069E.
8. CIN agar plates, Oxoid Ltd., CM0653, SROl09.
9. Mueller Hinton agar pre-poured plates, Oxoid Ltd., P0152A.
10. Mueller Hinton agar with 5% Sheep Blood pre-poured plates, Oxoid Ltd., 
PB0413A.
11. Phosphate buffered saline.
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Dulbecco A tablets (Oxoid Ltd., BR0014a) were dissolved in distilled water 
according to the manufacturers instructions. The sodium chloride 
concentration was 0.85 per cent. It was sterilised before use.
12. Physiological saline.
The sodium chloride concentration was 0.85 per cent in deionised water. It 
was sterilised before use.
13. Glycerol, “AnalaR” about 87 per cent, BDH Ltd., Merck House, Poole, Dorset 
BH15, ITD.
14. Tryptone-soya broth, Oxoid Ltd., CM0129.
15. API Identification, Biomerieux Ltd., Grafton House, Grafton Way, 
Basingstoke, Hampshire, RG22 6HY.
The following API kits were used with associated reagents for the identification of 
appropriate organisms:
API 20E Enterobacteriaceae 201(K)
API Campy Campylobacter species 20800
API 20 Strep Streptococcus and Enterococcus species 20600
16. Antimicrobial discs, Oxoid Ltd.
The following antimicrobial discs were used for susceptibility testing throughout the 
study:
Amoxycillin/clavulanic acid 2:1 30txg CT0223B
Ampicillin lOpg CT0003B
Cefuroxime sodium 30p,g CT0127B
Ciprofloxacin 5pg CT0425B
Erythromycin 15jig CT0020B
Gentamicin lOpg CT0024B
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Gentamicin 120pg CT0794B
Linezolid 30|Ag CT1650B
Oxacillin Ipg CT0159B
Penicillin G lOunits CT0043B
Quinupristin/dalfopristin 15trg CT1644B
Sulphamethoxazole/trimethoprim 19:1 25 pg CT0052B
Teicoplanin 30pg CT0647B
Tetracycline 30pg CT0054B
Vancomycin 30pg CT0058B
2.2.3 Conditions of cultivation
2.2.3.1 Atmospheric conditions
Cultures were incubated aerobically or, where appropriate, in microaerobic 
conditions.
Aerobic cultures were incubated in the following incubators:
Incubator, (37°C, aerobic). Swallow, Jencons PLS, Forest Row Business Park, Station 
Rd., Forest Row, East Sussex, RH18 5DW.
Incubator, (44°C, aerobic), Mini/75, Genlab Mini-Series Incubator, Jencons PLS, 
Forest Row Business Park, Station Rd., Forest Row, East Sussex, RH18 5DW. 
Incubator, (44°C, aerobic), Shake’n’Stack, Hybaid Ltd., Action Court, Ashford Rd., 
Ashford, Middlesex, TW15 IXB.
Microaerobic cultures were incubated in the microaerobic cabinet, Don Whitley 
Scientific Ltd., 14 Otley Rd., Shipley, West Yorkshire, BD17 7SE.
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2.2.3.2 Temperature of incubation
Cultures were incubated at 37°C except Slanetz and Bartley plates that were 
incubated at 37°C for 2-4 hours and subsequently at 44°C for a further 44-46 hours.
2.2.3.3 Period of incubation
All primary cultures on non-selective media and MacConkey agar plates were 
incubated for 18-24 hours.
All primary cultures on Slanetz and Bartley agar plates were incubated for 24 hours, 
examined and then reincubated for a further 18-24 hours.
All primary cultures on Campylobacter selective media were incubated for 42-48 
hours.
All primary cultures on CIN agar plates were incubated for 18-24 hours.
2.2.4 Identification of bacterial isolates
2.2.4.1 Colonial morphology
The examination of colonies was by the unaided eye and, where necessary, by hand 
lens. The morphological characteristics of colonies (colour, size, elevation etc.) were 
noted. Many different colony types were present on initial cultures on non-selective 
media. On selective media, colonies typical of the organisms of interest were 
subcultured to purity.
2.2.4.2 Morphology of bacterial cells
This was determined by the microscopic examination of air-dried heat-fixed smears 
made from cultures and stained by Gram’s method.
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2.2 4.3 Biochemical tests
Oxidase tests were carried out using sterile swabs dipped in the reagent (1 per cent 
NNN’N-tetramethyl-P-phenylenediamine dihydrochloride).
Catalase tests were carried out using loopfuls of 24 hour or 48 hour cultures of the 
organism under test, grown on nutrient agar or the blood medium described above. 
The organism under test was emulsified with a few drops of 3 per cent hydrogen 
peroxide (B.D.H. Ltd, Merck House, Poole, Dorset BH15 ITD) on a microscope 
slide. Suspensions were examined for bubbles of gas immediately and after 5 minutes. 
Further biochemical tests were carried out using the API identification system 
(Biomerieux Ltd.).
2.2.5 Examinations for specific bacteria
2.2.5.1 Enterococcus species.
Faecal specimens or their dilutions were inoculated on Slanetz and Bartley agar and 
incubated in aerobic conditions at 37°C for 48 hours in initial investigations. In later 
investigations, faecal specimens or their dilutions were inoculated on Slanetz and 
Bartley agar and incubated in aerobic conditions at 37°C for 2-4 hours then at 44°C 
for a further 44-46 hours. Typical colonies were subcultured on 5 per cent horse blood 
agar or nutrient agar. Smears were made and stained by Gram’s method and catalase 
tests performed on each isolate. Catalase-negative, Gram-positive cocci were 
identified to species using the API 20 Strep kit, Biomerieux Ltd.
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2.2.5.2 Coliforms
Faecal specimens or their dilutions were inoculated onto MacConkey agar and 
incubated aerobically for 18-24 hours at 37°C. Typical lactose-fermenting colonies 
were subcultured and identified biochemically using the API 20E kit, Biomerieux Ltd.
2.2.5.3 Yersinia species
Faecal specimens were inoculated onto CIN agar and incubated aerobically for 18-24 
hours at 37°C. Faeces were also diluted in phosphate-buffered saline (approximately 5 
per cent by volume) and maintained at 3°C in the refrigerator for three weeks, during 
which time CIN agar was inoculated weekly and incubated as above. Typical red 
colonies were subcultured and identified biochemically using the API 20E kit, 
Biomerieux Ltd.
2.2.5.4 Campylobacter species.
Skirrow’s agar plates and Preston agar plates were inoculated with faeces or faecal 
dilutions and were incubated at 37°C for 48 hours in microaerobic conditions. Smears 
of colonies growing on the media were stained by Gram’s method to ascertain 
whether they contained vibrios. All colonies that did contain vibrios were subcultured 
to purity and incubation in microaerobic and aerobic conditions were used in 
duplicate for each subculture in order to identify and eliminate organisms other than 
Campylobacter species. The oxidase test was performed on all colonies as described 
above and further biochemical testing was performed using the API Campy kit, 
Biomerieux Ltd.
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2.2.6 Maintenance of cultures
Each pure culture isolated was maintained by subculture onto blood agar or nutrient 
agar at appropriate intervals. Pure cultures were then inoculated into vials containing 
cryopreservative (Microbank, Pro-Lab Diagnostics, 7 Westwood Court 
Neston, South Wirral, Cheshire CH64 3UJ) and stored at -70°C.
2.3 Selection of farms and sampling
2.3.1 Selection of farms
Four farms were selected for sampling on the basis of their use (or not) of the growth 
promoter avilamycin. Avilamycin use was recorded and the inclusion of copper and 
zinc in feeds was also noted (Table 2.1). All four farms were farrow-to-fînish units 
and Farms 1, 2 and 3 were located in west central Scotland whilst Farm 4 was located 
in north east Scotland. Farms 1 and 2 were commercial units producing pigs for 
slaughter and there were approximately 200 and 60 breeding sows on these farms, 
respectively. Farm 3 was a multiplier unit of approximately 200 breeding sows and 
Farm 4 was a fully integrated breeding and finishing unit of approximately 2000 
breeding sows. On Farm 1, avilamycin was included in rations-from weaning until the 
end of the finishing period. On Farm 2, avilamycin was included in feed given to 
weaners only, salinomycin was included in feed given to growing pigs, and finishing 
pigs did not receive any growth promoters. On Farm 3, avilamycin was included in 
feed given to weaners only. Avilamycin was withdrawn from use on Farm 4 two years 
before the start of the study and none of the pigs received any growth promoters.
In addition, the farmers were asked about their use of therapeutic antimicrobials 
(Table 2.2). A formal assessment of therapeutic antimicrobial use on these farms was 
beyond the scope of this work and was not carried out.
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2.3.2 Collection and handling of samples
Faecal samples were collected from the floors of pens in sterile plastic universal 
containers, with freshly voided faeces collected where possible. Slurry samples were 
also collected into sterile plastic universal containers using sterile plastic pipettes. The 
samples were placed on ice and transported to the laboratory. The time taken from 
collection of samples on farm until arriving at the laboratory varied from 1-2 hours for 
Farms 1-3 and 6-8 hours for Farm 4. For Farms 1-3, samples were kept on ice in the 
laboratory for approximately 1 hour whilst samples were weighed into Ig aliquots. 
For Farm 4, samples were kept refrigerated at 3°C overnight before being weighed 
into Ig aliquots. Where samples were stored before analysis, each Ig aliquot of faeces 
or 1ml aliquot of slurry was added to 4.5ml sterile glycerol and 4.5ml tryptone-soya 
broth, mixed and frozen at -70°C.
2,4 Epidemiological modelling methods
All of the models described were written in Microsoft Excel (Microsoft, Redmont, 
WA 98052-6399, USA) and the stochastic models were simulated using @Risk 
(Palisade, Newfield, NY), a software package allowing Latin Hypercube simulation.
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Table 2.1 Use of avilamycin, salinomycin, zinc and copper as non-nutrient 
feed additives on the farms selected for testing, mg/kg of feed.
Farm Compound Weaners Growers Finishers
Farm 1 Avilamycin 40mg/kg 40mg/kg 20mg/kg
Zinc 2.5g/kg - «
Copper 175mg/kg 165mg/kg 90mg/kg
Farm 2 Avilamycin 40mg/kg - -
Salinomycin - 50mg/kg -
Zinc 2.5g/kg - -
Copper 175mg/kg 165mg/kg 90mg/kg
Farm 3 Avilamycin 40mg/kg - -
Zinc 2.5g/kg -
Copper 175mg/kg 165mg/kg 90mg/kg
Farm 4 Zinc 2.5g/kg “
Copper 175mg/kg 165mg/kg 90mg/kg
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Table 2.2 Therapeutic antimicrobials used in the previous twelve months on 
the farms selected for testing.
Farm Group Antimicrobial (route of 
administration)
Reason for use
Farm 1 Piglets Tetracycline (spray) Tail-docking
Piglets Enrofloxacin (oral 
doser)
Diarrhoea
W eaners/Gro wers Tetracycline (water) General debility
Weaners/Growers Penicillin (feed) Meningitis,
pleuropneumonia
Gilts (incoming) Lincomycin (water) Arthritis due to Mycoplasma 
synoviae
Sows Penicillin/streptomycin
(paienteral)
General malaise
Farm 2 W eaners/Gro wers Amoxycillin (water) Meningitis
Farm 3 All groups Penicillin/ streptomycin 
(parenteral)
General malaise
Farm 4 Piglets Enrofloxacin (oral 
doser)
Diarrhoea
Piglets Tetracycline (water) Diarrhoea/Glasser’s Disease
Piglets Penicillin/ streptomycin 
(parenteral)
Glasser’s Disease
Weaners Tylosin (feed) Spirochaetal diarrhoea
Growers Tetracycline (water) Routine, for 1 week
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CHAPTER 3
SAMPLE SIZE REQUIREMENTS FOR THE DETECTION OF RESISTANCE
3.1 Introduction
The first stage in designing studies to measure resistance on the farms selected was to 
consider the necessary sample numbers required. Previously, published data on 
antimicrobial resistance has been criticised because sample size estimates have not 
been considered and this has hampered interpretation of the results of surveillance 
studies (MAFF, 1998; Davison et a l,  2000). It has been suggested that rigorous 
epidemiological studies of resistant bacteria need to be carried out in human and 
animal populations and that standard statistical formulae should be used to estimate 
sample sizes for such studies (Davison et a l , 2000). Prior determination of the sample 
size has also been recognised as essential in a well-designed study of any kind 
(Dawson-Saunders et a l, 1994).
In order to decide how many animals or organisms should be sampled, the objectives 
of the investigation must first be considered. When the aim of a study is to determine 
the prevalence of a disease or organism, the main factors to be considered from a 
statistical point of view are the desired precision of the prevalence estimate and the 
expected frequency of the disease or organism. However, when the aim is to detect 
the presence or absence of a disease or organism, the prevalence of disease, the 
desired confidence limits and the population size must be considered (Cannon and 
Roe, 1982; Thrusfield, 1995).
Prior to conducting the fieldwork involved in the project, sample size estimation was 
considered and some of the available literature on antimicrobial resistance in pigs was
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examined with a view to using prevalence estimates from these data in order to 
estimate sample sizes for the study.
3.2 Materials and Methods
Two statistical methods of estimating sample size were considered; the sample size 
needed to estimate the prevalence of resistance (Equation 3.1) and the sample size 
needed to detect the presence or absence of resistance (Equation 3.2), (Cannon and 
Roe, 1982; Thrusfield, 1995):
1 .9 6  ^ e x p ( l ” ^ e x p )n  = ------------------------------------------   Equation 3.1
where n is required sample size, Pexp is the expected prevalence, d  is the desired 
absolute precision, simple random sampling is applied, the size of the study 
population is large in relation to the sample and the confidence level is 95 per cent.
- V  d\l  — ( l  — ----- + 1  Equation 3.2A  ^  /
/ n
n  -
\  }
where n is required sample size, pi is the probability of finding at least one case in the 
sample, d is the number of affected animals in the population and N  is the population 
size.
Surveillance data from Denmark were used as a source of information on the 
prevalence of resistance amongst enterococci isolated from pigs (Danmap, 1999) and 
confidence intervals and ideal sample size estimates were calculated using these data.
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3.3 Results
First, the sample numbers needed to estimate prevalence of resistance and to detect 
the presence of resistance were considered and compared for a wide range of expected 
prevalences (Tables 3.1 and 3.2). Estimates of the prevalence of resistance to various 
antimicrobials amongst E.faecium isolated from pigs (Danmap, 1999) were then used 
to calculate confidence intervals (Table 3.3).
Table 3.1 Sample numbers required in order to estimate the prevalence of 
resistance with 95% confidence and 5% absolute precision.
Expected prevalence of resistance Sample numbers required to 
estimate prevalence of resistance
l% or99% 15
2% or 98% 30
3% or 97% 45
5% or 95% 73
10% or 90% 138
20% or 80% 246
30% or 70% 323
40% or 60% 369
50% 384
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Table 3.2 Sample numbers required to have a 95% probability of detecting 
the presence of resistance*.
Population 
size (bacteria 
or animals)
Prevalence of resistance, Pj {%)
0.1 1 5 10 20 30 40 50
00 2995 299 59 29 14 9 6 5
5000 2253 290 59 29 14 9 6 5
1000 950 258 57 29 14 9 6 5
100 100 96 45 25 13 8 6 5
50 50 50 35 22 12 8 6 5
* (Thrusfield, 1995).
Table 3.3 Estimated prevalence of resistance amongst E, faecium  isolated 
from pigs in Denmark* and associated confidence intervals.
Antimicrobial Estimated prevalence of 
resistance
95 per cent confidence 
interval
Tetracycline 0.53 0.46-0.60
Penicillin 0.39 0.32-0.46
Erythromycin 0.48 0.41-0.55
Streptomycin 0.27 0.21-0.33
Vancomycin 0.06 0.03-0.09
Quinupristin-dalfopristin 0.19 0.14-0.24
Virginiamycin 0.08 0.04-0.12
Avilamycin 0.01 0.00-0.02
* Danmap, 1999, 202 isolates tested.
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Sample sizes were then calculated for a total animal population of 2.3 X 10  ^
(Danmap, 1999) using the methods described and the data in Table 3.3 (Table 3.4).
Table 3.4 Number of animals to be tested in order to estimate prevalence of 
resistance with 95% confidence and 5% absolute precision (prevalence 
estimation) and to have 95% probability of detecting resistance 
(presence/absence detection). Prevalence data taken from Table 3.3 and total 
animal population of 2.3 X 10 *.
Antimicrobial Sample numbers needed for 
prevalence estimation
Sample numbers needed for 
presence/absence detection
Tetracycline 383 5
Penicillin 366 7
Erythromycin 384 6
Streptomycin 303 11
Vancomycin 87 49
Quinupristin-
dalfopristin 236 15
Virginiamycin 113 37
Avilamycin 15 299
*Danmap, 1999 
3,4 Discussion
The calculation of sample sizes using standard statistical formulae described above
has highlighted the important factors to be considered in the design of antimicrobial
resistance studies. Prevalence of resistance, population size and the reliability of the
conclusions, have all been shovm to be important considerations and although these
factors are routine issues in the design of animal health surveys, their importance in
antimicrobial resistance studies has only recently been suggested (Davison et a l ,
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2000). In a recent paper that aimed at defining the minimum epidemiological 
requirements for establishing surveillance of antimicrobial resistance in animals 
throughout Europe, sample size requirements were not even discussed (Caprioli et a l, 
2000) and the above calculations suggest that this is a glaring omission that will 
seriously affect the interpretation of surveillance data of any kind and prevent useful 
comparisons between countries. Unless the population of interest and the confidence 
level required are defined and the estimated prevalence of resistance is taken into 
account, then studies will have little statistical power.
In addition, key differences in sample size determination for studies designed to 
detect the presence or absence of resistant organisms and to determine the prevalence 
of resistance have also been demonstrated, with the objective of a study having a 
crucial influence on the sample numbers required. Although the output from most of 
the surveillance of antimicrobial resistance conducted in animals to date has been 
prevalence data, legislative changes leading to the withdrawal of certain 
antimicrobials have resulted in prevalence data being used to monitor the decline in 
resistance over time and to demonstrate freedom jfrom resistance without a reappraisal 
of sample size (SVARM, 2000; Danmap, 2001) and given the above findings, this is 
perhaps inappropriate.
In general, the sample numbers required to detect the presence of resistance were 
lower than those required to estimate prevalence (Table 3.4). However, this was 
dependent upon the estimated prevalence of resistance and for avilamycin, the sample 
numbers required for resistance detection were very high (299) (Table 3.4) because of 
the very low estimated prevalence of resistance and this should be borne in mind 
when data from prevalence studies are used to demonstrate the absence of resistance 
from an animal population. In prevalence studies, sample size estimates were greatest
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when prevalence was 50% (Table 3.1), whereas in presence/absence studies, sample 
size estimates were greatest when prevalence was very close to zero and the estimate 
of sample size required increased as the study population increased (Table 3.2).
However, in small populations, the sample size estimate was a greater proportion of 
the total population than when the study population was very large (Table 3.2). These 
features of sampling design have been highlighted before (Cannon and Roe, 1982;
Thrusfield, 1995) but have rarely been considered in antimicrobial resistance studies.
Notably, for five of the eight antimicrobials listed, sample size estimates for
Ï;
prevalence estimation were greater than the actual number of samples taken in the |
study referred to (202) (Danmap, 1999) and the confidence intervals calculated for the 
different antimicrobials tested varied markedly dependent upon the estimated 
prevalence of resistance. These differences should be taken into account when sample 
sizes for antimicrobial resistance studies are being calculated and the aims of 
surveillance should be clearly defined.
In the data used for sample size calculations, the estimated prevalence of resistance 
varied widely for the different antimicrobials tested. For example, one percent of 
isolates were resistant to avilamycin compared to fifty-three percent that were 
resistant to tetracycline (Table 3.3). However, the prevalence of resistance is likely to 
vary not only for different antimicrobials but also for different organisms and 
therefore, if a multi-organism or multi-antimicrobial study is to be undertaken, sample 
numbers should ideally be based on the largest estimate in order to be confident of 
detecting resistance/estimating prevalence for all organism/antimicrobial 
combinations. In much of the currently available surveillance data, this has not been 
considered and confidence intervals surrounding prevalence estimates have not been 
presented (Danmap, 1997; Danmap, 1998; Danmap, 1999; Danmap, 2000).
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The estimates of sample size described apply when simple random sampling is used 
to select a sample of animals or bacteria from the study population. This means that 
every animal or bacterium has an equal chance of being sampled. For animals, this 
usually involves numbering each animal and then using a table of random numbers to 
select the animals to be sampled. However, for bacteria this would obviously not be 
possible and it may be that factors influencing the growth of bacteria on isolation 
media determine which are selected for testing. This could be particularly important 
in antimicrobial resistance studies as it has been shown that the acquisition and 
maintenance of resistance genes in a bacterial population can have an associated 
fitness cost (Andersson and Levin, 1999). If resistant bacteria in a population require 
a greater concentration of nutrients for growth or grow at a slightly slower rate on 
culture media than sensitive organisms, then they may be less likely to be selected for 
testing and although the effect of using visual cues on the selection of animals for 
testing has been considered, the selection of bacteria for testing could be an equally 
important source of bias (Singer et aL, 2001). The data described from Denmark was 
obtained from samples taken at abattoirs and therefore does not represent a true 
random sample of the pig population in Denmark (Danmap, 1999) and if simple 
random sampling is not applied to the selection of bacteria or animals for sampling, 
then even larger sample sizes are required (Cannon and Roe, 1982).
In addition, the sample size calculations described do not take account of the variation 
that can occur between clusters of animals. Clusters of animals could be groups within 
a farm or different farms, for instance. If cluster sampling is applied then the between- 
cluster variance must first be calculated (Equation 3.3).
 ^ KjcV K2P{1-PŸ
r^(c- i)  T Equation 3.3
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where Vc is between cluster variance component, c is the total number of clusters in 
the sample, T is the total number of animals sampled, Ki is equal to (C -  c)!C where 
C is the number of clusters in the population, K2 is equal to {N — T)!N where N  is the 
total number of animals in the population, V is equal to P^(2)n^) — 2P{^nm) + (2^^) 
where P is the estimate of overall prevalence, n is the number of animals sampled in 
each cluster and m is the number of diseased animals sampled in each cluster 
(Thrusfield, 1995). The equations then to be used to calculate sample numbers 
required are dependent on whether cluster sampling is one-stage or two-stage and are 
given in standard texts (Thrusfield, 1995).
Furthermore, the definition of the population being studied is also important. For 
example, the distinction between E. faecium and other Enterococcus spp. may not 
always be clear on selection of isolates from selective media or on biochemical testing 
(Devriese et a l, 1994) but there may be differences in the prevalence of resistance 
between different species that affect ideal sample sizes. The definition of the animal 
population of interest in terms of pen, age-group or farm is also important in 
estimating sample size requirements as it provides denominator information so that 
results can be related to the total study population.
The sample size calculations discussed do not take into account the performance of 
diagnostic tests and although the effect of test performance has been considered for 
the interpretation of tests performed on a proportion of animals within a herd (Jordan 
and McEwen, 1998), it has not been considered for the calculation of sample size 
requirements or for antimicrobial resistance studies. These issues are discussed in 
Chapter 8.
In summary, sample size estimation is a necessary consideration prior to conducting 
antimicrobial resistance studies and despite the implications of sample size estimates
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on the cost and labour-intensity of such studies, these estimates cannot be ignored. If 
optimal sample sizes cannot be applied, then an inevitable consequence is that less 
confidence can be placed in the conclusions of a study, whether it describes the 
prevalence of resistance or the presence or absence of resistance in a population. 
However, despite the strength of these conclusions, the labour-intensive nature of the 
work conducted in the studies discussed in Chapters 4, 5 and 6 and the poor 
sensitivity of isolation of enterococci did not allow the application of standard sample 
size estimates to the sampling regimes adopted and the consequences of this are 
discussed in the relevant chapters.
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CHAPTER 4
ISOLATION, ENUMERATION AND IDENTIFICATION OF TARGET 
ORGANISMS
4.1 Introduction
Having calculated ideal sample size requirements, the next process was to consider 
the organisms to be studied. Organisms present in the normal faecal flora of pigs were 
chosen because of their presence in the site of action of avilamycin and their 
importance in the transfer of resistance to man. Enterococci were considered to be 
particularly important because of their importance as a reservoir of resistance to 
growth promoting antimicrobials.
Enterococcus spp. and Escherichia coli are commensal organisms of animals and man 
that are also capable of causing disease and which have been implicated in the transfer 
of antimicrobial resistance from animals to humans (van den Bogaard and 
Stobberingh, 2000). They are both present in animal faeces and although the 
epidemiology of the diseases they cause in humans is quite different, they are both 
thought to represent reservoirs of antimicrobial resistance and therefore are important 
indicator organisms in which resistance should be measured (Caprioli et a l, 2000; 
Witte, 2000).
Enterococcus spp. are occasional pathogens of humans implicated particularly in 
nosocomial infections and which have readily acquired resistance to therapeutic 
antimicrobials (Cetinkaya et a l , 2000) whilst Escherichia coli is responsible for a 
spectrum of disease in animals and man and certain strains are important zoonotic 
pathogens (Griffin and Tauxe, 1991).
54
The pathogenic strains of E. coli are well described and the isolation, identification 
and enumeration of E. coli is also relatively straightforward (Ogden et a l, 2002). The 
pathogenicity of enterococci and the distinction between disease-causing strains and 
commensals is not as clear as they are essentially opportunistic pathogens. E, faecalis 
and E. faecium  are responsible for the majority of cases of disease in man but E. 
durans and E. hirae have also been implicated (Knijff et a l, 2001). The identification 
of enterococcal species by biochemical means alone is also acknowledged to be 
difficult (Singer et a l, 1996; Tsakris et a l, 1998) and the importance of different 
enterococcal species in disease is poorly understood.
The aim of this part of the study was to attempt to quantify E. coli and Enterococcus 
spp. in pig faeces and to determine the composition of Enterococcus species present 
using simple dilution techniques and commercially available biochemical kits (API, 
Biomerieux).
4.2 Materials and Methods
4.2.1 Sample collection and handling
Faecal samples were collected from the floors of pens and ti;ansported on ice to the 
laboratory. The time from collection of samples on farm to arrival at the laboratory 
varied from 1-2 hours for Farms 1, 2 and 3 to approximately 18 hours for Farm 4. In 
initial investigations, each faecal sample was weighed into Ig aliquots and each Ig 
aliquot was gently mixed with 4.5ml sterile glycerol and 4.5ml sterile tryptone-soya 
broth (Oxoid Ltd.) and frozen at -70°C in glass universals. The frozen samples were 
later thawed and serial tenfold dilutions made in phosphate-buffered saline for the 
culture and enumeration of enterococci and coliforms. In later investigations, faecal 
samples were weighed into Ig aliquots and one aliquot from each sample was added
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to 9ml phosphate-buffered saline and gently mixed. Serial ten-fold dilutions were 
made in phosphate buffered saline and plates inoculated directly with fresh faecal 
dilutions.
4.2.2 Inoculation of media and incubation
Slanetz and Bartley and MacConkey agar plates were inoculated with 20pl of each 
dilution of faeces from 1 x 10'  ^ to 1 x 10"^ . Plates were allowed to dry on the bench 
for no more than fifteen minutes before being inverted and transferred to incubators. 
MacConkey plates were incubated at 37°C in aerobic conditions for 18-24 hours. In 
the initial investigations, Slanetz and Bartley plates were incubated at 37°C in aerobic 
conditions for 48 hours. Following the conclusions from these initial investigations, 
Slanetz and Bartley plates were incubated at 37®C in aerobic conditions for 2-4 hours 
before being transferred to another incubator for a further 44-46 hours incubation at 
44°C in aerobic conditions.
4.2.3 Enumeration and identification
Counts were made of each morphologically distinct colony-type at the lowest 
readable dilution on each plate. For isolation on MacConkey agar this included 
lactose-fermenting colonies of different textures, for example rough or smooth, and 
for isolation on Slanetz and Bartley agar this included maroon or pink colonies of 
different sizes. One or more representative colonies of each type were subcultured to 
purity and identified to species biochemically using the methods described in Chapter 
2.
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4.3 Results
4.3.1 Availability and nature of sample material
The material available for collection was highly dependent upon the housing systems 
in which animals were kept. For example, the only animals housed in individual pens 
on any of the farms visited were iactating sows. Samples collected from these pens 
were therefore individual animal samples. All other animals, including piglets, were 
contained in groups within pens. However, the type of flooring present also 
influenced whether or not the faecal material on the floors of pens was likely to have 
been voided by individual animals. In pens with slatted floors, which included 
farrowing pens on Farm 1 and flatdeck accommodation for weaner pigs on Farms 1 
and 3, there was very little faecal material present and any faeces that was present was 
most likely to have been voided by an individual animal, although this could not be 
confirmed. These samples therefore probably represented individual animals within 
these pens. Where animals were housed on solid floors with straw bedding, (finishers 
aged 16-18 weeks on Farm 4), faecal material appeared to have been voided by 
individual animals as there was no pooling of faeces on pen floors but again, it was 
not possible to confirm this.
Where animals were housed on solid floors without bedding material, (Farm 1 
growers and finishers; Farm 2 finishers; Farm 3 finishers and Farm 4 finishers from 
approximately 20 weeks of age), faecal material tended to be mixed with urine and 
was pooled in a corner of the pens. Therefore, samples from these pens were likely to 
be pooled samples although it was not possible to determine how many animals were 
represented by a sample.
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4.3.2 Influence of incubation temperature on the isolation of enterococci and 
colonial morphology as an indicator of genus
The first samples to be examined were collected from pens of weaner pigs on Farm 1. 
In order to maximise the yield of enterococci from the samples and also to culture all 
species of enterococci that may have been present, Slanetz and Bartley agar plates 
were inoculated as described above and incubated at 37°C in aerobic conditions for 48 
hours. On examination, the majority of the colonies present on the plates were pink 
although a few maroon colonies were also present. Regardless of colour, colonies were 
generally less than 0.5mm in diameter. Counts were made of both type of colony 
(Table 4.1). Where possible, two pink and two maroon colonies were subcultured from 
each plate and identified as described (Table 4.2). None of the pink colonies were 
identified as Enterococcus spp. whereas the majority of maroon colonies were. The 
distinction between maroon and pink colonies was not always obvious and colonies 
classed as maroon/pink from samples one and two were identified as Enterococcus 
spp. However, as maroon colonies had been shown to be more likely to be identified 
as Enterococcus spp., pink colonies were disregarded in all future examinations.
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Table 4.1 Morphology and counts of colonies present on Slanetz and Bartley 
agar Inoculated with the faeces of weaner pigs following incubation at 37°C in 
aerobic conditions for 48 hours.
Sample Colony description Colony count (CFUs/g)
1 Maroon/pink 5.5x10^
2 Maroon/pink 3x10’
3 Pink 5.5 xlO’
4 Maroon/Pink 3x10*
5 Pink 7x10*
6 Maroon 2x10*
6 Pink 2.25 xlO’
7 Maroon 9.5x10*
7 Pink ' 1.75x10’
8 Pink 1 xlO’
9 Pink 3.5x10’
10 Maroon 1 xlO’
10 Pink 1.5x10®
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Table 4.2 Identification of colonies cultured from Slanetz and Bartley plates 
inoculated with weaner faeces and incubated at 37°C in aerobic conditions for 48 
hours.
Sample Colony description Species identification
1 Maroon/Pink Enterococcus faecalis
1 Maroon/Pink E. faecalis
2 Maroon/Pink E. faecalis
2 Maroon/Pink E. faecalis
3 Pink Streptococcus bovis
3 Pink S. bovis
3 Dark pink S, bovis
3 Dark pink S. bovis
4 Pink Aerococcus viridans
4 Pink A. viridans
4 Maroon Enterococcus faecium
4 Maroon E. faecalis/Lactococcus lactis 
lactis
5 Pink L. lactis lactis
5 Pink Leuconostoc spp.
6 Maroon E lactis lactis
7 Maroon E. faecium
7 Maroon E. faecium
7 Pink A. viridans
7 Pink A. viridans
8 Pink S. bovis
10 Maroon E. faecium
10 Maroon E. faecium
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The next set of samples to be examined were from piglets and as a poor yield of 
enterococcal isolates was obtained from weaner faecal samples incubated at 37°C, 
faeces from these samples were inoculated onto two sets of plates; one set that was 
incubated at 37®C and one that was incubated at 37°C for 2-4 hours before being 
incubated at 44°C for a further 44-46 hours.
Following incubation, it was noted that some of the maroon colonies on the plates 
incubated initially at 37°C and then at 44°C were larger (>0.5mm diameter) (Figure 
4.1) than the maroon or pink colonies on the plates incubated at 37°C. Counts of 
maroon colonies only were performed for the plates incubated at 37°C, and counts of 
maroon colonies >0.5mm in diameter were performed for the plates incubated at 37‘^ C 
followed by incubation at 44°C (Table 4.3) (Figure 4.2). The mean and median counts 
of maroon colonies on plates incubated at 37®C were 5.3 xlO* CFUs/g and 1.8 xlO^ 
CFUs/g, respectively, compared to a mean count of 1.1 xlO^ CFUs/g and a median 
count of 2.8 xlO* CFUs/g of large maroon colonies on plates incubated first at 37°C 
and then at 44°C.
6 1
Figure 4.1 Appearance of large maroon colonies (>Smm diameter) on Slanetz 
and Bartley agar inoculated with faeces following incubation at 37"C for 2-4 
hours followed by incubation at 44**C for a further 44-46 hours.
Figure 4.2 Slanetz and Bartley agar plate inoculated with faecal dilutions, after 
incubation at 37**C for 2-4 hours followed by incubation at 44"C for 44-46 hours, 
with variation in size of maroon colonies evident
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Table 4,3 Counts of presumptive Enterococcus spp> on Slanetz and Bartley 
plates inoculated with piglet faeces and incubated at 37°C in aerobic conditions 
for 48 hours and at 37°C for 2-4 hours followed by 44-48 hours at 44°C in 
aerobic conditions.
Sample Colony count (maroon) 37°C 
incubation (CFUs/g)
Colony count (large maroon) 37°C 
followed by 44°C incubation 
(CFUs/g)
1 0 1.5 xlO*
2 1.6x10* 1.3 xlO*
3 5x10'' 1.5x10“
4 5x10’ 7x10*
5 2.5 xlO* 0
6 2x10* 8x10“
7 2.5 xlO* 3x10“
8 5x10“ 2 xlO“
9 2x10* 1.35x10*
10 2x10“ 2.5 xlO“
Where possible, two to four maroon colonies were subcultured from each plate and 
the organisms identified to species (Table 4.4). Where a sartiple is not listed for a 
particular incubation temperature that is because no gram-positive cocci were 
isolated. Nine of the ten samples yielded Enterococcus spp. when an incubation 
temperature of 44°C was used and only large maroon colonies were selected 
compared to only 3 samples from which Enterococcus spp. were isolated when an 
incubation temperature of 37°C was used throughout and only small maroon colonies 
were available to select for identification. Following these findings, all Slanetz and 
Bartley plates were incubated at 37°C for 2-4 hours and then at 44°C for 44-46 hours
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and only maroon colonies greater than 0.5mm in diameter were counted and 
subcultured for identification.
Table 4,4 Identification of organisms isolated from piglet faeces collected 
from Farm 1 using Slanetz and Bartley plates incubated at 37°C and Slanetz and 
Bartley plates incubated initially at 37°C and then at 44°C.
Sample Predominant incubation 
temperature
Identification of isolates obtained
1 44°C E. faecium (3 isolates); E. durans
2 37°C E. faecium, (2 isolates)
2 44°C E. faecium, (4 isolates)
3 37°C S. bovis, (2 isolates)
3 44°C E. faecium, (4 isolates)
4 37°C E. durans, E. faecium
4 44°C E. faecium, (4 isolates)
5 37°C S. bovis, (2 isolates)
6 37°C E. faecium, E. durans
6 44°C E. faecium, (4 isolates)
7 44°C E. faecium
8 44°C E. faecium
9 44°C E. faecium
10 44°C E. faecalis
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4 3 3  Enumeration of presumptive enterococci
Counts of presumptive Enterococcus spp. (maroon colonies of at least 0.5mm 
diameter) were performed for all the samples collected (Figure 4.3). Samples from 
sows, piglets, weaners and growers on Farm 1 were frozen at -70°C before use and 
the other samples were used directly following collection. The counts observed varied 
widely between different age groups on the same farm and between different farms 
but this did not appear to be a direct result of sample storage as counts of presumptive 
enterococci from weaners and growers on Farm 1 were very high. The counts 
observed in faecal samples from within the same group of animals were also very 
variable with no presumptive enterococcal colonies detected for some samples and 
this can be seen from the large standard deviation in counts observed (Figure 4.3).
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Figure 43  Counts of presumptive Enterococcus spp, (maroon colonies >0.5mm 
diameter) in samples collected from Farms 1-4 (F1-F4) with standard deviation 
shown (CFUs/ml).
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4.3,4 Identification of presumptive enterococci
One to four presumptive enterococcal colonies were subcultured from each sample 
and identified to species (Table 4.5).
Table 4.5 Proportion of faecal samples collected from different groups on 
Farms 1-4 and cultured on Slanetz and Bartley agar from which Enterococcus 
spp. were isolated and identified.
Farm Production
stage
Proportion of samples 
from which enterococci 
were isolated
Enterococcal species isolated 
(number of isolates)
1 Sow 1 (10 of 10) E. faecium  (11); E. durans (5); 
E. faecalis (3)
1 Piglet 0.9 (18 of 20) E. faecium (35); E. faecalis (5); 
E. durans (2)
1 Weaner 0.5 (5 of 10) E. faecium (6); E. faecalis (4)
3 Weaner 0.8 (8 of 10) E. durans (4); E. gallinarum (3); 
E. faecalis (1)
1 Grower 0.33 (3 of 9) E. faecium (2); E. faecalis (1)
2 Finisher 1 (4 of 4) E. faecalis (6); E. faecium (1)
3 Finisher 0.4 (4 of 10) E. faecalis (2); E. faecium (I); E. 
durans (1) ,
4 Finisher (16- 
18 weeks)
1 (10 of 10) E. faecium (18); E. durans (1)
4 Finisher (20- 
22 weeks)
0.6 (6 of 10) E. faecium (5); E. durans (2)
4,3.5 Enumeration and identification of coliforms
Counts were made of lactose fermenting colonies on MacConkey agar for each 
sample (Figure 4.4). The counts observed varied between groups but also varied
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widely within groups. This can be seen from the large standard deviation in counts 
observed (Figure 4.4).
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Figure 4.4 Counts of presumptive E, coU (lactose-fermenting colonies) in samples 
collected from Farms 1-3 (F1-F3) with standard deviation shown (CFUs/ml).
One colony of each morphological type (rough, smooth etc.) was then subcultured and 
identified to species. The vast majority of organisms were identified as E, coli but 
seven isolates from finishers and two from growers on Farm 1 were identified as E. 
fergusonnii (Table 4.6). Other organisms that were occasionally isolated included 
Morganella morgani, Proteus vulgaris, Citrobacter freundii, Providencia rettgeri; 
Klebsiella pneumoniae and Serraiia fonticola.
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Table 4.6 Proportion of faecal samples collected from different groups on 
Farms 1-3 and cultured on MacConkey agar from which E. coli was isolated and 
identified.
Farm Production
stage
P ro p o rtio n  o f 
sam p les from  
w hich E. coli 
isolated
Other organisms isolated 
(number of isolates)
1 Sow 1 (10 of 10) C.jreundii (1); P. vulgaris (2)
1 Piglet 0.85 (17 of 20) M morganii (1); f .  rettgeri (1)
1 Weaner 1 (10 of 10) -
3 Weaner 0.9 (9 of 10) S. fonticola (1); Æ pneumoniae 
(1)
1 Grower 1 (10 of 10) E. fergusonii (2)
1 Finisher 1 (10 of 10) E. fergusonii (7)
3 Finisher 1 (10 of 10) -
4.4 Discussion
One of the aims of these preliminary investigations was to determine the availability 
of faecal material for sampling on the pig farms under investigation. The findings 
suggest that this is highly variable and that the inconsistent nature of flooring, bedding 
and group sizes on pig farms means that the quantification of resistant bacteria in such 
samples would not be meaningful. Therefore, the results presented are not intended to 
allow the comparison of numbers or types of organisms present in different groups of 
animals, but merely to compare the different available sample material in these 
groups. As a relatively small volume of faeces (10-20ml) was collected and used for 
analysis, it is possible that a sample could represent only an individual animal, unless 
thorough mixing of faecal material had occurred within the pens, and if animal-to- 
animal variation is significant as has been suggested before (Dunlop et al,, 1999) this
6 8
could be misleading. The frequency of cleaning of pens may also have influenced the 
age of available faecal material and there was no means of determining this. All of 
these factors might have influenced the numbers and types of organisms present in 
faecal samples. Therefore, the only sensible conclusion is that such environmental 
sampling is suitable only for studies aimed at detecting the presence or absence of 
resistant bacteria rather than at quantifying them and that individual animal sampling 
as described elsewhere (Melin et a l, 1997; Jensen-Waern et a l, 1998) is the only 
suitable method for the latter. The most straightforward method of ensuring faecal 
samples are fresh and represent only individual animals is to collect faeces from the 
rectum but in the UK this procedure can only be performed under Home Office 
license and therefore this method is unlikely to be suitable for routine monitoring of 
antimicrobial resistance on farms.
Another aim was to determine the nature of the enterococcal flora and the findings 
suggest that a variety of enterococcal species are present in pig faeces and that 
different species predominated on different farms. E. faecium has been reported to be 
the most common enterococcus species present in pig faeces (Devriese et a l, 1994) 
and this was the case in samples from Farms 1 and 4 in this study. However, E. 
durans was the most frequent isolate on Farm 3 and E. faecalis was found more 
commonly in samples from Farm 2. That said, the biochemical methods used have 
been shown to identify correctly only 77 per cent of enterococcal strains in foods 
(Devriese et a l , 1995) and E, faecium, E. durans and E. hirae are very closely related 
(Devriese, Pot and Collins, 1993) so it is likely that some strains in this study have 
been misclassified. The vast majority of coliforms isolated on all farms were 
Escherichia coli and the sensitivity of isolation was much higher for this organism 
than for enterococci.
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These preliminary studies into the isolation, enumeration and identification 
Enterococcus spp, and E. coli have highlighted several potential problems when the 
conventional bacteriological techniques described are used in antimicrobial resistance 
studies.
First, the use of selective media and colonial morphology as a means of determining 
species identity had a high specificity for E. coli but was of limited use for 
Enterococcus spp. Even when temperature was manipulated to inhibit the growth of 
other organisms and a strict morphological description of colonies was applied, many 
of the organisms that were presumed to be enterococci were not. Although the 
majority of lactose fermenting colonies on MacConkey agar were later confirmed to 
be E, coli, other enterobacterial organisms were also occasionally isolated.
Another problem with this approach was that colonial morphology is very subjective. 
As described, the distinction between different colours or sizes was not always cleai’. 
Therefore, growth on selective media and colony description does not appear to be a 
reliable method of identifying enterococci. Culture on Slanetz and Bartley agar 
followed by subculture of up to three colonies on aesculin-azide agar has been used in 
some prevalence studies to increase the specificity of selection based on colonial 
morphology (Danmap, 1999; Danmap, 2000; Danmap, 2001; SVARM, 2000; 
SVARM, 2001) but biochemical identification has still been necessary to confirm that 
these organisms were enterococci. Enrichment media have also been used prior to 
culture on Slanetz and Bartley agar to increase the sensitivity of culture (Danmap, 
1999; Danmap, 2000; Danmap, 2001) but it would not be possible to enumerate 
enterococci in faeces using either of these methods. In contrast, faecal counts of E. 
coli have been estimated using selective media and colonial morphology alone 
(Humphry et a l, 2002) and whilst this may be justified by the greater specificity of
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the media used, these counts should not be considered to be absolutely specific for 
this organism.
Second, estimating the numbers of bacteria present in faeces based on colony counts 
was also difficult. This is of course related to the specificity of the selective media 
used and counts of presumptive enterococci on Slanetz and Bartley agar were 
virtually meaningless because of the poor specificity of colonial morphology as an 
indicator of genus/species. However, for Enterococcus spp. in particular there was 
also significant variation in colony counts between samples from the same groups of 
animals and there were also occasional samples from most groups of animals from 
which the colonies selected were not identified as Enterococcus spp. or E. coli. This 
variation could represent true pen-to-pen variation, variation in sample age/treatment, 
variation in performance of culture media or some inherent factor in the bacteria such 
as tendency to clump. Whatever the reason, these findings cast doubt over the 
usefulness of colony counting as a means of enumerating enterococci in faecal 
samples. The reason for attempting morphological identification and enumeration of 
enterococci was in order that resistant bacteria could be related to the enterococcal 
population either proportionately or in numbers. These preliminary findings suggest 
that this is not possible using the methods described.
The identification and quantification of resistant bacteria in animal faeces using spiral 
plating and colony counting has been described (Dunlop et a l, 1998c; Humphry et 
a l , 2002). However, these methods were used to quantify resistant E. coli and the 
problems of colony identification described above would still hinder their usefulness 
for enterococci. A reliable method of enumerating resistant enterococci in faeces has 
not yet been described and from the findings of this small study, it seems important
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that methods of isolating and identifying enterococci on selective media are improved 
if this is to be achieved.
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CHAPTER 5
RESISTANCE TO AVILAMYCIN
5.1 Introduction
Having determined the limitations of conventional bacteriological techniques for the 
isolation, identification and quantification of Enterococcus spp. and E. coli in the 
faecal samples available, the next aspect to be considered was the measurement of 
resistance to avilamycin in these bacterial populations. Avilamycin resistance has 
been reported in Enterococcus faecium and Enterococcus faecalis isolated from pigs 
and broilers in Denmark and has been monitored annually in these organisms since 
1995 (Danmap, 1997; Aarestrup et a l, 1998, Danmap, 1998; Danmap, 1999; 
Danmap, 2000; Danmap, 2001). No such systematic monitoring is carried out in the 
UK for resistance to avilamycin or other growth promoter.
As there is no clinical definition of resistance for antimicrobial agents used as growth 
promoters, breakpoints for resistance to avilamycin based on population distributions 
have been suggested. A bimodal distribution of avilamycin MICs in E. faecium has 
been described in studies in Denmark and Belgium with the majority of isolates in 
both studies having minimum inhibitory concentrations (MICs) of 2pg/ml or less 
whilst a small number of isolates were distinctly less susceptible (one Danish isolate 
having an MIC of 64pg/ml and two Belgian isolates having MICs of 32pg/ml) 
(Aarestrup et a l, 1998; Butaye, Devriese and Haesebrouck, 1999b). However, in 
other studies where avilamycin MICs in E. faecium from broilers and pigs ranged 
from 0.12 to greater than 256pg/ml, the strains with high MICs were simply classified 
as less susceptible rather than resistant because of the lack of breakpoint definitions
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for susceptibility and resistance to growth-promoting antimicrobials (Butaye et a l, 
2001). Susceptibility to avilamycin has also been determined in control strains of 
enterococci but primarily to assess the effect of different test conditions, (Butaye et 
a l ,  1998). The relevance of avilamycin resistance to therapeutic antimicrobial 
resistance is that it has also been shown that avilamycin-resistant E. faecium and E. 
faecalis with MICs of >64pg/ml have reduced susceptibility to evernimicin (SCH 
27899), an oligosaccharide antimicrobial that was at one time considered for use in 
human medicine but there is no evidence that cross-resistance to any currently used 
therapeutic antimicrobials exists (Aarestrup, 1998; Aarestrup and Jensen, 2000). 
Avilamycin resistance in organisms other than enterococci has rarely been considered 
(Devriese et a l, 1993; Aarestrup, 2000a) and longitudinal monitoring of resistance in 
herds or flocks has not been carried out for avilamycin or other growth promoters. 
However, changes in the prevalence of avilamycin resistance in E. faecium have been 
monitored at national level in Denmark (Aarestrup et a l, 2000). Avilamycin 
resistance, defined as MIC greater than or equal to 16pg/ml, amongst E. faecium 
isolates tested in Denmark declined from 77.4 per cent in 1996 to 5.0 per cent in 
2001 in broilers, and from 1.3 per cent in 1996 to 0 per cent in 2001 in pigs, and this 
decline was associated with the voluntary ban of growth promoter use in 1998 with 
avilamycin use in farm animals in Denmark declining from 2740kg active compound 
to 3kg active compound per annum over the same period (Aarestrup et a l, 2001). 
Resistance to avilamycin in E. faecium has also been shown to be associated with 
antimicrobial use on broiler farms, with farms that used avilamycin having a higher 
prevalence of resistant isolates (Aarestrup, Bager and Andersen, 2000). However, 
little is known about the persistence of, or decline in, resistance on individual farms
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following the withdrawal of avilamycin either for managemental reasons or for 
conversion to growth promoter-free production.
Improved surveillance of antimicrobial resistance in farm animals has been called for 
in the UK (ACMSF, 1999; VPC, 2003) and worldwide (WHO, 2000). Commensal 
bacteria including enterococci, E. coli and Campylobacter species have also been 
identified as important indicator organisms and it has been suggested that the use of 
antimicrobial growth promoters should be constrained (ACMSF, 1999).
The aims of this part of the study were to determine which organisms in the faecal 
flora of pigs express resistance to avilamycin; to assess the best method of monitoring 
resistance in these organisms and, in doing so, to gain information on the 
epidemiology of resistance to avilamycin within farms and to relate this to patterns of 
avilamycin use.
5.2 Materials and methods
Two methods of assessing resistance to avilamycin were used in the study.
5.2.1 Breakpoint MICs by agar dilution
First, breakpoint minimum inhibitory concentrations (MICs) were determined for 
individual organisms isolated in pure culture from faecal samples by the agar 
dilution/plate MIC method according to NCCLS guidelines (NCCLS, 2000). 
However, as no such guidelines were available for Campylobacter spp., the method 
used for these organisms was based on that recommended for Helicobacter pylori 
with a saline suspension equivalent to a 2.0 McFarland standard used without further 
dilution to inoculate Mueller-Hinton agar plates supplemented with horse blood, 5% 
v/v (Oxoid Ltd.) and plates read after incubation at 37°C in microaerobic conditions
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for 48 hours (NCCLS, 2001). When each batch of isolates was tested, a set of control
organisms was included to validate the testing procedure (Table 5.1).
Table 5.1 Sensitivity breakpoints to avilamycin of Gram-positive control 
strains as determined by agar dilution.
Control organism Origin MIC to avilamycin 
(pg/ml)
E. faecalis 29212 American Type Culture Collection 
(ATTC)
1
E. faecalis 202 Human hospital strain 1
E. faecalis 203 Human hospital strain 1
E. faecium 206 Human hospital strain I
S. aureus (MRSA) Human hospital strain 4
S. aureus 25923 ATTC 4
E. faecium 98-30223-1 Danish broiler strain >128*
*MIC on primary isolation as determined by Aarestrup and Jensen, 2000, >64pg/ml.
An additional set of control organisms were used when MICs were being assessed in 
Enterobacteriaceae (Table 5.2) and Campylobacter spp. (Table 5.3).
Table 5.2 Sensitivity breakpoints to avilamycin of Gram-negative control 
strains as determined by agar dilution.
Control organism Origin MIC to avilamycin (pg/ml)
E. coli 25922 ATTC >128
E, coli 35218 ATTC >128
P. aeruginosa 27853 ATTC >128
Y. enterocolitica 9610 ATTC 64
S. enteritidis 13076 ATTC >128
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Table 5.3 Sensitivity breakpoints to avilamycin of Campylobacter spp.
control strains as determined by agar dilution.
Control organism Origin MIC to avilamycin (pg/ml)
C. jejuni N82 Human inflammatory diarrhoea 8
C. jejuni 081 Human watery diarrhoea 8
C. jejuni X Human inflammatory diarrhoea 8
C. jejuni L115 Human inflammatory diarrhoea, 
causes severe pathology
8
C. jejuni GI pldA Human Guillain Barre 
syndrome isolate
8
Whilst this method provided breakpoint MICs for individual isolates that could then 
be related to Farm or Group animal populations, it was acknowledged that only a 
limited number of isolates (usually one to four colonies from any one sample) could 
be tested in this way due to the labour intensity of isolating organisms in pure culture, 
identifying them and then testing them. Using this method, it was possible that 
resistant organisms would be missed and samples or farms misclassified and 
therefore, a second method of screening samples for avilamycin-resistant isolates was 
developed.
5.2.2 Avilamycin screening plates
This method was developed and adopted for the organisms of most interest, le.,  
Enterococcus spp.
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5.2.2.1 Preparation of media
Slanetz and Bartley medium was prepared according to the manufacturer’s 
instructions and a measured volume (249ml) poured into each of eight sterile bottles. 
The bottles were held at 50°C in the waterbath. An additional bottle containing 250ml 
Slanetz and Bartley agar was also prepared and held at 50‘’C in the waterbath.
Two hundred and fifty milligrams of avilamycin (potency 1286 units) was weighed 
and incorporated in 1.953ml acetone to give a solution with a concentration of 
128mg/ml. Serial doubling dilutions of this solution were prepared in acetone to give 
solutions of 64, 32, 16, 8, 4 ,2 , 1, 0.5 and 0.25mg/ml. One millilitre of each solution 
from 32mg/ml to 0.25mg/ml was added to a different one of the eight bottles of 249ml 
molten Slanetz and Bartley agar to give bottles with concentrations of 128, 64, 32, 16, 
8, 4, 2 and Ipg/ml. Each bottle was mixed thoroughly. Ten to twelve plates were 
poured from each of the nine bottles. Plates were tested for depth and pH, and sterility 
and growth controls tested (NCCLS, 2000).
5.2.2.2 Inoculation of media
Faeces were weighed and Ig of each faecal sample or 1ml of each slurry sample 
suspended in 9ml of phosphate-buffered saline. Serial tenfold dilutions of this 
suspension were then prepared using phosphate-buffered saline. Twenty microlitres of 
each dilution (from 1:10 to 1:10^) were inoculated onto the surface of each of the 
series of Slanetz and Bartley plates using a pipette, starting with plain Slanetz and 
Bartley agar followed by plates containing doubling concentrations of avilamycin 
from Ipg/ml to 128pg/ml, and finishing with a plate containing plain Slanetz and 
Bartley agar.
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5.2.2.S Incubation and reading of plates
Plates were left on the bench for not more than fifteen minutes to allow drying, before 
being inverted, placed in racks and transferred to an aerobic incubator where they 
were incubated at 37°C for two to four hours. The plates were then transferred to 
another aerobic incubator where they were incubated at 44°C for a further forty-four 
to forty-six hours. The plates were then removed from the incubator, growth and 
sterility controls checked, and counts made of typical large (>0.5mm diameter) 
maroon enterococcal colonies at each dilution of faeces on each plate. Where 
possible, for each sample, two typical enterococcal colonies were subcultured from 
plates of 32pg/ml, 64pg/ml and 128pg/ml. These isolates were subcultured to purity 
on 7 percent horse blood agar and identified by API as described in Chapter 2.
5.3 Results
5.3.1 Breakpoint MICs, enterococci Farm 1
Enterococci isolated from sows, piglets and weaners on Farm 1, as described in 
Chapter 4, were tested for susceptibility to avilamycin by the agar dilution method 
(Tables 5.4-5.7).
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Table 5.4 Sensitivity breakpoints to avilamycin of Enterococcus spp. isolates
from sows on Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Sows 1 E, faecium 4
Sows 2 E.faecium 4
Sows 2 E. faecium 4
Sows 3 E. durans 4
Sows 4 E. durans 4
Sows 4 E. faecium 4
Sows 5 E. durans 4
Sows 5 E. faecium 4
Sows 6 E. faecium 4
Sows 6 E. faecium 4
Sows 7 E. faecium 4
Sows 8 E. faecium 4
Sows 9 E. faecalis 4
Sows 9 E. durans 4
Sows 10 E. faecalis 4
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Table 5.5 Sensitivity breakpoints to avilamycin of Enterococcus spp. isolates
from piglets on Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Piglets 1 E. faecium 64
Piglets 2 E. faecium 8
Piglets 3 E.faecium 4
Piglets 4 E.faecium 4
Piglets 6 E.faecium 4
Piglets 7 E. faecium 4
Piglets 8 E. faecium 4
Piglets 9 E. faecium 4
Piglets 10 E. faecalis 4
Piglets 11 E.faecium 4
Piglets 12 E. faecium 4
Piglets 13 E. faecalis 4
Piglets 14 E. faecium 4
Piglets 15 E.faecium 4
Piglets 16 E.faecium , >128
Piglets 17 E. faecalis 4
Piglets 18 E. faecium 4
Piglets 19 E. faecium 4
Piglets 20 E.faecium 4
8 1
Table 5.6 Sensitivity breakpoints to avilamycin of Enterococcus spp. isolates
from weaners on Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Weaners 1 E. faecalis >128
Weaners 2 E. faecalis >128
Weaners 4 E. faecium >128
Weaners 7 E. faecium >128
Weaners 10 E. faecium >128
Table 5.7 Sensitivity breakpoints to avilamycin of organisms isolated on 
Slanetz and Bartley agar from growers on Farm 1 as determined by agar 
dilution.
Group Sample number Species MIC (pg/ml)
Growers 1 L. lactis 4
Growers 2 L. lactis 8
Growers 3 L. lactis 8
Growers 4 S. salivarius 32
Growers 5 L. lactis 4
Growers 6 L. lactis 4
Growers 7 L. lactis 2
Growers 8 L. lactis 8
Growers 9 L. lactis 4
Growers 10 E.faecium >128
All 15 isolates tested from sows were found to be sensitive to avilamycin with MICs 
of 4pg/mi (Table 5.4). Of the 19 isolates tested from piglet samples, 17 were sensitive
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to avilamycin; 16 had an MIC of 4pg/ml and one E. faecium isolate had an MIC of 
8pg/ml (Table 5.5). Two isolates from piglets were resistant to avilamycin (MICs of 
32pg/ml or greater). Both were identified as E. faecium and had MICs of 64pg/ml and 
>128pg/ml.
Three E. faecium and two E. faecalis isolates from weaners were tested and all were 
resistant to avilamycin (MIC >128pg/ml) (Table 5.6).
Ten organisms presumed to be enterococci before biochemical testing, that were 
isolated from grower samples on Slanetz and Bartley plates were also tested but only 
one of the organisms was identified as belonging to the genus Enterococcus (Table 
5.7). It was identified as E. faecium  and was resistant to avilamycin (MIC 
>128pg/ml). However, eight organisms identified as Lactococcus lactis lactis isolated 
from grower samples on Slanetz and Bartley medium were tested and found to be 
sensitive (MICs of between 2 and 8pg/ml). The single Streptococcus salivarius isolate 
was resistant (MIC 32p,g/ml).
5.3.2 Breakpoint MICs, enterococci Farm 4
In total, 27 isolates of Enterococcus spp. from Farm 4 were tested and all were 
sensitive to avilamycin (MICs of Ipg/ml) (Table 5.8). The majority of these isolates 
were E. faecium but three were identified as E. durans and one E. faecalis isolate 
from slurry was also tested and found to be sensitive.
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Table 5.8 Sensitivity breakpoints to avilamycin of Enterococcus spp. isolates
from finishers on Farm 4 as determined by agar dilution.
Group/Origin Sample number Species MIC (pg/ml)
Finishers 1 E. faecium 1
Finishers 1 E. faecium 1
Finishers 2 E. faecium 1
Finishers 2 E.faecium 1
Finishers 3 E. faecium 1
Finishers 3 E.faecium 1
Finishers 4 E. faecium 1
Finishers 4 E. faecium 1
Finishers 5 E. faecium 1
Finishers 5 E. faecium 1
Finishers 6 E. durans 1
Finishers 6 E.faecium 1
Finishers 7 E.faecium 1
Finishers 7 E. faecium 1
Finishers 8 E. faecium 1
Finishers 8 E. faecium 1
Finishers 9 E. faecium 1
Finishers 10 E.faecium
Finishers 10 E.faecium 1
Finishers 11 E.faecium 1
Finishers 14 E. faecium 1
Finishers 14 E. faecium 1
Finishers 15 E.faecium 1
Finishers 17 E.faecium 1
Finishers 19 E. durans 1
Finishers 20 E. durans 1
Slurry 21 E. faecalis 1
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5.3.3 Breakpoint MICs, coliforms, Farm 1
Several gram-negative control strains including E. coU, Yersinia enterocolitica. 
Salmonella enteritidis and Pseudomonas aeruginosa were tested and they were all 
resistant to avilamycin, (Table5.2). They had MICs of greater than 128|ag/ml except 
for the Y. enterocolitica^ which had an MIC of 64pg/ml.
A total of 20 E. coli isolates from piglets and 17 Æ coli and E. fergusonii isolates 
from finishers on Farm 1 were tested and all were found to be resistant to avilamycin 
(MICs >128pg/ml) (Tables 5.9 and 5.10).
All of the eight Yersinia spp. isolates from finishers on Farm 1 were also resistant to 
avilamycin (Table 5.11). Seven of these isolates had MICs of greater than 128pg/ml 
and one Y. pseudotuberculosis isolate had an MIC of 64pg/ml.
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Table 5.9 Sensitivity breakpoints to avilamycin of Escherichia spp. isolates
from piglets on Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Piglets 1 E. coli >128
Piglets 1 E. coli >128
Piglets 2 E. coli >128
Piglets 2 E. coli >128
Piglets 3 E. coli >128
Piglets 3 E. coli >128
Piglets 3 E. coli >128
Piglets 4 E. coli >128
Piglets 5 E, coli >128
Piglets 6 E. coli >128
Piglets 6 E. coli >128
Piglets 7 E. coli >128
Piglets 7 E. coli >128
Piglets 8 E. coli >128
Piglets 8 E. coli , >128
Piglets 8 E. coli >128
Piglets 9 E. coli >128
Piglets 9 E. coli >128
Piglets 10 E, coli >128
Piglets 10 E. coli >128
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Table 5.10 Sensitivity breakpoints to avilamycin of Escherichia spp. isolates
from finishers on Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Finishers 1 E. coli >128
Finishers 1 E. fergusonii >128
Finishers 2 E. coli >128
Finishers 2 E. fergusonii >128
Finishers 3 E. coli >128
Finishers 3 E. fergusonii >128
Finishers 4 E. coli >128
Finishers 5 E. fergusonii >128
Finishers 6 E. coli >128
Finishers 7 E. coli >128
Finishers 7 E. fergusonii >128
Finishers 8 E. coli >128
Finishers 8 E. coli >128
Finishers 9 E. coli >128
Finishers 9 E. fergusonii . >128
Finishers 10 E. coli >128
Finishers 10 E. fergusonii >128
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Table 5.11 Sensitivity breakpoints to avilamycin of Yersinia spp. isolates from
Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Finishers 2 Yersinia spp. >128
Finishers 3 Y. enterocolitica >128
Finishers 4 Yersinia spp. >128
Finishers 5 Yersinia spp. >128
Finishers 6 T. pseudotuberculosis 64
Finishers 7 Yersinia spp. >128
Finishers 9 Yersinia spp. >128
Finishers 10 Yersinia spp. >128
5.3.4 Breakpoint MICs, Campylobacter spp.. Farms 1,3 and 4
First, several control strains of Campylobacter jejuni isolated from humans were 
tested. They were all sensitive to avilamycin with MICs of 8pg/ml (Table 5.3).
Only a small number of Campylobacter spp. isolates were available for testing from 
Farm 1. Of these, the one piglet isolate tested was sensitive to avilamycin (MIC 
S^ig/ml) and the other six isolates, (one from sows, five from weaners), were resistant, 
with MICs of 64 to >128pg/ml (Table 5.12).
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Table 5.12 Sensitivity breakpoints to avilamycin of Campylobacter spp,
isolates from Farm 1 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Sows 20 Campylobacter spp. >128
Piglets 16 Campylobacter spp. 8
Weaners 2 C. jejuni jejuni >128
Weaners 6 C. coli >128
Weaners 8 C. coli >128
Weaners 9 C. coli >128
Weaners 10 C. jejuni jejuni 64
On Farm 3, four Campylobacter spp. isolates were tested from piglets, one from 
weaners on the fourth day of exposure to avilamycin in feed, three from weaners on 
exposed to avilamycin in feed for two weeks, two from growers from which 
avilamycin had been withdrawn four weeks previously and one from finishers from 
which avilamycin had been withdrawn approximately 8 weeks previously. Of these, 
the piglet isolates were sensitive to avilamycin with MICs of 4 to 8pg/ml and all other 
isolates were resistant with MICs of >128pg/ml (Table 5.13).
On Farm 4, two Campylobacter spp. isolates were tested from each of two samples 
from finishers. The two isolates from the first sample were resistant to avilamycin, 
with MICs of 64pg/ml and the two isolates from the second sample were sensitive 
with MICs of 8pg/ml (Table 5.14).
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Table 5.13 Sensitivity breakpoints to avilamycin of Campylobacter spp,
isolates from Farm 3 as determined by agar dilution.
Group Sample
number
Species MIC (pg/ml)
Piglets B1 C. coli 8
Piglets B2 C. coli 8
Piglets B5 C. coli 8
Piglets B6 C. coli 4
Weaners, 4 days on Maxus A1 C. coli >128
Weaners, 2 weeks on 
Maxus
C6 C. coli >128
Weaners, 2 weeks on 
Maxus
C7 C. coli >128
Weaners, 2 weeks on 
Maxus
C8 C. coli >128
Growers, off Maxus 4 
weeks
D3 C. coli >128
Growers, off Maxus 4 
weeks
D6 C. coli >128
Finishers E5 C. coli >128
Table 5.14 Sensitivity breakpoints to avilamycin of Campylobacter spp. 
isolates from Farm 4 as determined by agar dilution.
Group Sample number Species MIC (pg/ml)
Finishers 14 C. coli 64
Finishers 14 Campylobacter spp. 64
Finishers 20 C. coli 8
Finishers 20 C. coli 8
90
5.3.5 Avilamycin screening plates, Farm 1
From Farm 1, nine faecal samples collected from grower pens and six faecal samples 
collected from finisher pens were screened for avilamycin-resistant enterococci. Of 
the nine grower samples, eight were classified as resistant based on examination of 
the screening plates (typical maroon enterococcal colonies present on plates with 
avilamycin concentrations of 32pg/ml or above), and counts of typical enterococcal 
colonies were recorded at each concentration of avilamycin (Figure 5.1). All six of the 
finisher samples were classified as resistant using the same criteria (Figure 5.2).
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Figure 5.1 Mean counts (CFUs/g) and standard deviation of typical enterococcal 
colonies on Slanetz and Bartley agar containing doubling concentrations of 
avilamycin inoculated with faeces from growers on Farm I.
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Figure 5.2 Mean counts (CFUs/g) and standard deviation of typical enterococcal 
colonies on Slanetz and Bartley agar inoculated with faeces from finishers on 
Farm 1.
However, following subculture of resistant colonies, (where possible, two colonies 
from plates with concentration 32, 64 and 128pg/ml were subcultured for each grower 
sample and two colonies from plates with concentration 128(ig/ml for each finisher 
sample), only seven of the grower samples and five of the finisher samples yielded 
isolates identified as enterococci (Table 5.15). Where there is no isolate identified for 
a sample or isolation plate, it is either because the organisms cultured from that plate 
and sample were not Gram-positive cocci and were therefore not identified to species, 
or, they failed to grow on subculture. Of the 24 avilamycin-resistant enterococcal 
isolates cultured from Farm 1,15 were identified as E. durans, six as E. faecium and 
three as E. faecalis.
92
Table 5.15 Species identification of presumptive resistant enterococci isolated
from avilamycin screening plates inoculated with faeces from Farm 1.
Group Sample Avilamycin concentration of 
isolation plate (pg/ml)
Species identification
Grower 3 32 E. faecium
Grower 4 64 Leuconostoc spp.
Grower 5 32 E. faecalis
Grower 6 32 E. durans
Grower 6 32 E. durans
Grower 6 64 E. faecium
Grower 7 128 E. durans
Grower 8 64 E. durans
Grower 9 32 E. durans
Grower 9 32 E. durans
Grower 9 64 E.faecium
Grower 9 128 E. durans
Grower 10 32 E. faecalis
Grower 10 32 L. lactis
Grower 10 64 E.faecium
Grower 10 64 E.durans
Grower 10 128 E. faecalis
Finisher 1 128 E. durans
Finisher 1 128 E. durans
Finisher 2 128 E. durans
Finisher 3 128 E. durans
Finisher 3 128 E. durans
Finisher 5 128 E.faecium
Finisher 5 128 E. faecium
Finisher 6 128 E. durans
Finisher 6 128 E. durans
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53.6 Avilamycin screening plates, Farm 2
Four pooled faecal samples from finisher pens and two whole-farm slurry samples 
from Farm 2 were screened for avilamycin-resistant enterococci. Both slurry samples 
were classified as resistant based on the examination of screening plates, but no 
typical enterococcal colonies were present on finisher sample plates containing 
4pg/ml of avilamycin or above (Figure 5.3).
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Figure 5.3 Mean counts (CFUs/g) and standard deviation of typical enterococcal 
colonies on Slanetz and Bartley agar containing doubling concentrations of 
avilamycin inoculated with faeces from finishers and slurry from Farm 2.
Following subculture of resistant colonies, E. faecium was isolated from the first 
slurry sample from plates containing 32, 64 and 128pg/ml, and E. faecium was also 
isolated from the second slurry sample from a plate containing 64pg/ml.
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53.1 Avilamycin screening plates. Farm 3
Ten faecal samples from weaner pens on Farm 3 were screened for avilamycin- 
resistant enterococci. Five of the ten samples were classified as resistant (presumptive 
enterococcal colonies on plates containing 32pg/ml of avilamycin or above) based on 
the examination of screening plates and counts were recorded as before (Figure 5.4).
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Figure 5.4 Mean counts (CFUs/g) and standard deviation of ^ ic a l  enterococcal 
colonies on Slanetz and Bartley agar containing doubling concentrations of 
avilamycin inoculated with faeces from weaners on Farm 3.
Enterococci were cultured from all five of these resistant samples (Table 5.16). Of the 
eleven isolates, ten were identified as E. durans and one as E. faecalis.
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Table 5.16 Species identification of presumptive resistant enteroeocci isolated
from avilamycin screening plates, Farm 3.
Group Sample Avilamycin 
concentration of 
isolation plate (pg/ml)
Species
identification
Weaners 2 32 E. durans
Weaners 2 64 E. faecalis
Weaners 2 128 E, durans
Weaners 3 32 E. durans
Weaners 5 32 E. durans
Weaners 5 64 E. durans
Weaners 5 128 E, durans
Weaners 7 32 E. durans
Weaners 7 64 E. durans
Weaners 7 128 E. durans
Weaners 8 32 E. durans
Finishers 2 64 E. faecalis/L. lactis
Finishers 2 128 E. faecalis/L, lactis
Finishers 3 32 L. lactis
Finishers 3 64 E. faecalis/L lactis
Finishers 4 128 E. faecalis/L. lactis
Finishers 6 128 E. durans
Ten faecal samples from finisher pens on Farm 3 were also screened for avilamycin- 
resistant enterococci. Four samples were classified as resistant based on examination 
of screening plates, and counts recorded (Figure 5.5).
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Figure 5.5 Mean counts (CFUs/g) and standard deviation of typical enterococcal 
colonies on Slanetz and Bartley agar containing doubling concentrations of 
avilamycin inoculated with faeces from finishers on Farm 3.
However, when resistant colonies were subcultured, only one isolate was identified 
clearly by biochemical testing as belonging to the genus Enterococcus (Table 5.16). 
This organism was isolated from a plate containing 128pg/ml of avilamycin 
inoculated with faeces from sample number six and was identified as E. durans. The 
organisms successfully cultured from the other three samples were poorly 
discriminated by biochemical testing and were most likely to be E. faecalis or L. lactis 
isolates. Repeated biochemical testing of these isolates produced the same equivocal 
results.
5.3.8 Avilamycin screening plates Farm 4
Twenty faecal samples from finisher pigs and one whole-farm slurry sample from 
Farm 4 were screened for avilamycin-resistant enterococci. Ten of the faecal samples 
were collected from animals of 16 to 18 weeks of age bedded on straw and these
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samples were most likely to be individual animal samples, although this could not be 
confirmed. The other ten faecal samples were pooled faecal samples collected from 
the floor of concrete pens; five were collected from pens containing animals of twenty 
weeks of age and five were collected from pens containing animals of twenty-two 
weeks of age.
Four faecal samples were classified as resistant based on the examination of screening 
plates and all four were samples from the sixteen to eighteen week old animals but 
there were no typical enterococcal colonies on plates of 16pg/ml or above inoculated 
with the other faecal samples or the slurry sample. Counts of typical enterococcal 
colonies were recorded (Figure 5.6).
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Figure 5.6 Mean counts (CFUs/g) and standard deviation of typical enterococcal 
colonies on Slanetz and Bartley agar containing doubling concentrations of 
avilamycin inoculated with faeces from finishers on Farm 4.
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However, only two of the four samples from Farm 4 classified as resistant yielded 
enterococci when resistant colonies were subcultured and identified (Table 5.17). E. 
faecium was isolated from two samples from plates containing 32pg/ml avilamycin 
and also from one of these samples from a plate containing 128pg/ml of avilamycin.
Table 5,17 Species identification of presumptive resistant enterococci isolated 
from avilamycin screening plates inoculated with faeces from finishers on Farm 
3.
Group Sample Avilamycin concentration of 
isolation plate (pg/ml)
Species
identification
Finishers, 16-18wks 1 32 E. faecium
Finishers, 16-18wks 1 128 E. faecium
Finishers, 16-18 wks 8 32 E. faecium
5.4 Discussion
From the results obtained, it is clear that whilst the majority of enterococci in pig 
faeces are sensitive to avilamycin, there are some strains with reduced susceptibility 
and this is in agreement with the findings of previous authors, (Aarestrup et al., 2000; 
Aarestrup and Jensen, 2000; Mann et al., 2001). However, there did not always 
appear to be a clear bimodal distribution in MICs as described in Danish and Belgian 
studies where individual isolates rather than the faecal population of enterococci were 
tested (Aarestrup et al., 1998; Butaye, Devriese and Haesebrouck, 1999b). Therefore, 
it is difficult to say whether isolates with intermediate MICs, say 8 or 16pg/ml, should 
be considered to be resistant or not, although for the purposes of this study only
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organisms with MICs of 32pg/ml or above were considered to be resistant based on 
the findings of previous authors (Aarestrup and Jensen, 2000).
On Farms 1 and 3 counts of presumptive enterococci from weaners, growers and 
finishers were relatively constant throughout the range of avilamycin concentrations 
tested (Figures 5.1, 5.2, 5.4 and 5.5) whilst the distribution of counts from finishers on
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Farm 4 (Figure 5.6) did appear to be bimodal with the highest counts of presumptive 
enterococci observed on Slanetz and Bartley agar without avilamycin and a second 
peak in presumptive enterococci at around 64pg/ml. On Farm 2, counts of 
presumptive enterococci were greatest on Slanetz and Bartley agar without 
avilamycin and decreased to zero by 4pg/ml (Figure 5.3) suggesting that the 
population was uniformally sensitive. These findings are interesting and may suggest 
that the distinction between sensitive and resistant populations is unclear during 
avilamycin use and in the period immediately following withdrawal. However, as 
discussed below, the poor sensitivity of Slanetz and Bartley agar and the wide 
variation in counts observed within groups means that these findings should be 
interpreted with caution, e.g., the enterococcal population on Farm 2 may not have 
been truly unimodal as resistant enterococci may have been missed due to the small 
number of samples tested.
This study has also shown that reduced susceptibility to avilamycin is present not just 
in Enterococcus faecium and Enterococcus faecalis, but also in Enterococcus durans.
Indeed, when avilamycin screening plates were used, a large proportion of the 
resistant isolates were identified as E. durans. This finding is significant as E. durans 
has been associated with disease in animals (Cardona et al., 1993; Cheon and Chae,
1996) and is an occasional cause of bacteraemia in humans (Watanakunakorn and 
Patel, 1993) and also as surveillance for antimicrobial resistance in enterococci has to
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date focussed exclusively on E. faecalis and E. faecium (Danmap, 1998; Danmap, 
1999; Danmap, 2000; Danmap, 2001).
The findings also suggest that resistance to avilamycin can be acquired by 
enterococci, either by vertical or horizontal transmission, since the enterococcal 
control strains isolated from humans were sensitive to avilamycin, whereas resistant 
strains were isolated from all of the pig farms in the study and all of these farms had 
at some point in the past used avilamycin for growth promotion. These findings are 
similar to those of authors who have described sensitive control strains and resistant 
isolates of E. faecium and E. faecalis from pigs and poultry (Aarestrup and Jensen, 
2000).
However, all of the Escherichia spp. and Yersinia spp. isolates tested, including 
control strains isolated from humans, displayed high MICs to avilamycin. This 
strongly suggests that resistance is inherent and is not influenced by avilamycin use 
and this is to be expected since avilamycin is reported to have a relatively narrow 
spectrum of activity, being active mainly against Gram-positive organisms 
(Aarestrup, 2000a). However, an E. coli strain susceptible to the related antimicrobial, 
evernimicin has been described, (McNicholas et a i, 2000).
A range of sensitivity to avilamycin was found amongst Campylobacter spp. isolates. 
Control strains of C. jejuni isolated from humans were sensitive whereas many 
isolates from test samples were resistant. This suggests that avilamycin resistance may 
also be acquired by Campylobacter spp. and although there is no published 
information in the literature on avilamycin resistance in Campylobacter spp., the 
findings of a small study using an oral model of colonisation in chickens also 
suggested that resistance in C. jejuni can be induced by exposure to avilamycin 
(Stapleton et a l, 2002).
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The pattern of resistant isolates on Farms 1 and 3 also suggests that resistance to 
avilamycin is acquired by Campylobacter spp. following the use of avilamycin in 
feed. All of the isolates from weaners, growers and finishers on Farms 1 and 3 were 
resistant to avilamycin whereas piglet isolates were sensitive. The isolation of an 
avilamycin-resistant C. coli from animals that received rations medicated with 
avilamycin for four days suggests that resistant organisms are quickly acquired or if 
they are present at a low prevalence initially, quickly proliferate to an easily 
detectable prevalence. However, the results suggest that avilamycin resistance may 
not be so quickly lost, as both an isolate from sows on Farm 1 and an isolate from 
finishers on Farm 4 were also resistant. The sows on Farm 1 were not receiving any 
avilamycin at the time of sampling but may have done previously, and none of the 
animals on Farm 4 had ever received avilamycin but it had been used routinely on that 
farm up until two years previously. This suggests that avilamycin-resistance in 
Campylobacter spp. has either persisted on the farm or been re-introduced following 
withdrawal. However, the small numbers of isolates tested means that these findings 
should be interpreted cautiously.
Several studies have described a higher prevalence of resistance to other 
antimicrobials including erythromycin and ciprofloxacin in isolates of C. coli from 
pigs and meat than in C. jejuni isolates (van Looveren et a i, 2001; Ge et aL, 2003; 
Pezzotti et aL, 2003) and as the majority of the isolates tested in this study were C. 
coli it is possible that there is also a higher prevalence of resistance to avilamycin in 
this species. However, the numbers of Campylobacter spp. isolates tested were very 
small and without further testing it is not possible to confirm the suggestions made 
about the epidemiology of avilamycin resistance in Campylobacter spp.. Nonetheless,
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the results suggest that further study of avilamycin resistance in Campylobacter spp. 
is warranted.
The determination of individual isolate MICs combined with the use of avilamycin 
screening plates were useful in describing avilamycin-resistance in Enterococcus spp. 
on the farms tested. Based on the testing of enterococci isolated from non-selective 
medium, the presence of avilamycin resistance was confirmed on Farm 1 in piglets 
(two of 19 isolates resistant), weaners (all 5 isolates resistant) and growers (1 isolate 
resistant). Using the same method, 27 isolates tested from Farm 4 were all sensitive to 
avilamycin, suggesting that resistance had disappeared following the withdrawal of 
avilamycin two years previously and this is in common with the findings in Denmark 
where the same methodology has been used to describe the decline in avilamycin 
resistance following its withdrawal on a national basis (Aarestrup et at., 2001).
When avilamycin screening plates were used, avilamycin resistance was confirmed in 
grower and finisher samples from Farm 1. However, using the same samples from 
Farm 4 from which the sensitive enterococcal isolates were cultured, 4 of the 20 
samples appeared to contain avilamycin-resistant enterococci. The presence of 
avilamycin-resistant enterococci was confirmed on culture from 2 of these 4 samples. 
This suggests that avilamycin-resistant enterococci have persisted or been 
reintroduced on Farm 4 following the withdrawal of avilamycin. Avilamycin-resistant 
E.faecium have been isolated from avilamycin-free broiler farms before but it was not 
known whether or when avilamycin had been used previously on these farms 
(Aarestrup, Bager and Andersen, 2000).
However, avilamycin-resistance was not detected even when 27 isolates from Farm 4 
were tested by plate MIC. This suggests that the prevalence of avilamycin resistance 
amongst enterococci is low on Farm 4 and that sample numbers of this order are
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insufficient to detect any resistant bacteria. This, in turn, suggests that using 
individual isolate MICs to determine whether or not resistance is present in a group of 
animals or a bacterial population is poorly sensitive and this finding is significant 
given that this is the method currently most commonly used for monitoring 
antimicrobial resistance in both pathogens and commensal organisms (SVARM, 
2000; Danmap, 2001; Humphry e ta l,  2002)
On Farm 2, the four faecal samples tested did not appear to contain avilamycin- 
resistant enterococci and yet resistance was confirmed in two slurry samples. This 
suggests that either resistance is present on Farm 2 but is lost following withdrawal of 
avilamycin at the end of the weaner stage, or, resistant organisms were not detected 
because of the low prevalence of resistance and small number of samples tested.
The screening plates also indicated that resistance was present on Farm 3 in both 
weaner and finisher samples, suggesting that resistance has persisted in animals on 
Farm 3 following the withdrawal of avilamycin at the end of the weaning stage. 
However, only one resistant isolate from finisher samples was confirmed as belonging 
to the genus Enterococcus. The decline of resistance to avilamycin following its 
withdrawal has not been studied before except at national level where results suggest 
that the prevalence of resistance has reduced following withdrawal (Aarestrup et aL, 
2000; Aarestrup, Bager and Andersen, 2000). However, Aarestrup et al.'s findings are 
based on the examination of a relatively small number of isolates (one per animal 
sampled) and a small proportion of the animal population and as the findings above 
suggest, this could be misleading.
Throughout the study when the screening plate method was used, regardless of the 
origin of the sample, some samples were classified as resistant but the presence of 
resistant enterococci could not be confirmed. This was because some of the organisms
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presumed to be resistant enterococci on the screening plates did not belong to the 
genus Enterococcus. This suggests that because of the subjectivity of identifying 
enterococcal colonies on Slanetz and Bartley agar, the screening plate method of -Î
detecting resistance is of high sensitivity but poor specificity. This should be borne in 
mind when interpreting the results of screening plates, particularly if the presence of 
resistant enterococci is not confirmed by biochemical or molecular testing. The use of 
Slanetz and Bartley medium for the isolation of enterococci from food and water is 
described elsewhere and has been found to be a sensitive method which compares
■ifavourably with other media for enterococci (Butaye, Devriese and Haesebrouck,
.11999a and 1999b). However, it has also been acknowledged that further testing is 
required to confirm the identity of isolates (Niemi and Ahtiainen, 1995) and this is 
supported by the findings in this study. These findings also demonstrate the 
importance of accurate spéciation of resistant enterococci in antimicrobial resistance 
studies.
Another potential problem of using this method is the possibility that by inoculating 
sample material onto successive concentrations of antimicrobial, resistance could 
somehow have been induced. However, as culture on plates containing antimicrobial 
was not repeated and as care was taken not to allow pipette tips to come into contact 
with the plate surface, this seems unlikely to have been significant.
Finally, although counts of organisms were made at each dilution, the variability of 
these counts, as discussed in Chapter 4, and the poor specificity of Slanetz and Bartley 
agar, reduced their usefulness as a measure of either the numbers of resistant 
enterococci present, or, of the proportion of enterococci expressing resistance. For 
example, in many cases typical enterococcal colonies were absent at low 
concentrations of avilamycin (as shown by a standard deviation greater or equal to the
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mean count of presumptive enterococci) and yet present at higher concentrations 
inoculated with the same sample, suggesting that there is variation in the performance 
of the isolation technique used or that enterococci were not uniformly distributed in 
the sample material following thorough mixing. This made the proportional 
relationship between avilamycin-resistant enterococci and the enterococcal population 
as a whole difficult to assess and therefore the method was viewed as a means of 
determining whether or not resistant enterococci were present rather than as a 
quantitative method. Nonetheless, the use of avilamycin screening plates has been 
shown to be a useful method of determining the presence or absence of avilamycin- 
resistant enterococci in faecal and slurry samples with a higher sensitivity than 
determining MICs for a small number of individual enterococcal isolates. Whilst 
carrying out MIC tests on individual isolates may be the only way of quantifying the 
extent to which an individual organism is resistant, this method has a low sensitivity 
when used on a limited number of individual isolates from a sample and the findings 
suggest that this is of particular importance when the prevalence of resistance is low. 
This should be borne in mind when resistance in commensal organisms is being 
monitored because the commensal bacterial population may be more heterogenous 
than a rapidly expanding clonal population of pathogenic organisms and the 
prevalence of resistant organisms may therefore be low (Humphry et al., 2002). The 
poor sensitivity of this method also has implications for the longitudinal monitoring of 
resistance following the withdrawal of a growth promoter, as it seems likely that low 
numbers of resistant organisms would be missed.
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CHAPTER 6
RESISTANCE TO THERAPEUTIC ANTIMICROBIALS
6,1 Introduction
Another aspect of resistance monitoring in relation to antimicrobial growth promoters 
is consideration of the relationship between their use and resistance to therapeutic 
antimicrobials. Since the late 1960s, there has been concern surrounding the use of 
antimicrobials as growth promoters because of the possibility that their use may 
contribute to resistance to antimicrobials used for therapy in animals and humans 
(Swann, 1969). For example, evidence suggesting that the use of the growth promoter 
avoparcin contributed to the pool of vancomycin-resistant enterococci in humans 
(Stobberingh et a l, 1999; Bonten et a l, 2001) lead to the banning of avoparcin in the 
EU in April 1997 and it has since been shown that the prevalence of glycopeptide 
resistance in E. faecium isolated from broilers in Denmark has declined (Bager et a l , 
1999).
A relationship between growth promoter use and resistance to a related therapeutic 
antimicrobial has also been suggested for avilamycin and evemimicin (Aarestrup, 
1998; Aarestrup and Jensen, 2000), tylosin and erythromycin (Aarestrup and 
Cartensen, 1998) and virginiamycin and quinupristin-dalfopristin (Welton et a l,
1998). Of these, avilamycin is the only growth promoter still licensed for use within 
the EU. Cross-resistance to evemimicin, an antimicrobial considered for clinical use 
against Gram-positive infections in humans, has been demonstrated (Aarestrup and 
Jensen, 2000) but the development of evemimicin for clinical use has been suspended 
for other reasons.
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It is also possible for growth promoter use to co-select for resistance to unrelated 
antimicrobials: It has been suggested that the prevalence of glycopeptide resistance 
amongst E. faecium in pigs in Denmark did not decline significantly until tylosin use 
decreased because genes encoding resistance to glycopeptides and macrolides were 
located close together on the same plasmid (Aarestrup, Bager and Andersen, 2000; 
Aarestrup et a l, 2001). This suggests that the influence of growth promoter use on 
resistance to therapeutic antimicrobials is not restricted to structurally related 
compounds and whilst cross resistance between avilamycin and evemimicin has been 
demonstrated, the effect of avilamycin use on resistance to other therapeutic 
antimicrobials has not been considered.
The aim of this part of the study was to carry out farm studies on antimicrobial 
resistance in commensal organisms, primarily E. coH and enterococci but also 
Yersinia spp., and to see if the use of avilamycin on farms had any influence on 
patterns of resistance to therapeutic antimicrobials.
6.2 Materials and Methods
6.2.1 Selection of Bacterial Isolates for Testing
The organisms selected for susceptibility testing were isolated in pure culture as 
described in Chapter 2 and identified to species using the API system (Biomerieux). 
Attempts were made to isolate enterococci firom every sample taken fiom each of the 
four study farms and to isolate Escherichia spp. fiom samples on Farms 1, 2 and 3 but 
these were not always successful due to the poor sensitivity and specificity of the 
isolation techniques used as discussed in Chapter 5.
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6.2.2 Susceptibility Testing Methodology
The method used for determining susceptibility to therapeutic antimicrobials was disc 
diffusion and the testing was carried out following NCCLS guidelines (NCCLS,
1999), using discs containing known amounts of antimicrobial (Oxoid Ltd., 
Basingstoke). Zones of inhibition were measured and recorded in millimetres and this 
information used to classify organisms as sensitive, resistant or intermediately 
resistant (NCCLS, 1999; NCCLS, 2000a). Control organisms, (& aureus ATTC 
25923, E. coli ATTC 25922, E. coli ATTC 35218 and P. aeruginosa ATTC 27853) 
were tested daily for 30 days initially and then weekly to validate the testing 
procedure. Where there was any doubt about the integrity of the testing procedure or 
the interpretation of results, the isolate was re-tested. Similarly, where individual 
colonies were present within a zone of inhibition, these were subcultured and re­
tested.
Results were described in terms of prevalence of resistance amongst isolates and 
prevalence of resistance amongst samples. In some cases, more than one isolate of the 
same species was cultured from a sample and conversely, in some cases, culture did 
not yield the organism of interest.
Although zone size measurements were interpreted as indicating sensitive, 
intermediately resistant or resistant, for the purpose of analysis, all intermediately 
resistant and resistant isolates were grouped together as resistant.
6.3 Results
6.3.1 Enterococci, Farml
Enterococcal isolates were grouped according to their origin on the farm. The number 
of organisms tested for susceptibility to each antimicrobial is shown in Table 6.1.
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Only a selection of isolates were tested for resistance to teicoplanin, linezolid and 
quinupristin/dalfopristin.
Table 6.1 Number of samples taken and enterococcal isolates tested from 
different production stages, Farm 1.
Production stage Sows Piglets Weaners Growers
Number of samples taken 10 20 10 10
Proportion of samples from which 
enterococci were isolated
1 0.9 0.5 0.8
Number of isolates tested for 
susceptibility to Tec, Lzd and QD
11 10 4 8
Number of isolates tested for 
susceptibility to all other 
antimicrobials
19 42 10 8
KEY ; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin-dalfopristin.
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Resistance was considered within several different population levels: The number of 
resistant/intermediately resistant enterococcal isolates as a proportion of the total 
number of enterococcal isolates (Figure 6.1); the number o^ samples from which 
resistant/intermediately resistant enterococci were isolated as a proportion of the total 
number of samples (Figure 6.2); and the number samples from which 
resistant/intermediately resistant enterococci were isolated as a proportion of the 
number of samples from which enterococci were isolated (Figure 6.3).
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KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.1 Bar chart of prevalence of resistance/intermediate resistance 
amongst enterococcal isolates from Farm I. 95% confidence intervals are shown.
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KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.2 Bar chart of the proportion of total samples from which 
resistant/intermediately resistant enterococci were isolated from Farm 1. 95% 
confidence intervals are shown.
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KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.3 Bar chart of the proportion of samples from which enterococci 
were isolated from Farm 1 from which at least one isolate tested 
resistant/intermediately resistant. 95% confidence intervals are shown.
As some samples failed to yield any enterococcal isolates, the prevalence of resistance 
amongst the total sample population (Figure 6.2) was generally lower than the 
prevalence of resistance amongst samples that yielded enterococci (Figure 6.3) or the 
prevalence of resistance amongst enterococcal isolates (Figure 6.1).
In general, high prevalences of resistance to penicillin, tetracycline, erythromycin and 
quinupristin-dalfopristin were observed throughout the farm, although no penicillin- 
resistant isolates were cultured from the samples taken from growers. Confidence 
intervals around the estimates of quinupristin-dalfopristin resistance are particularly 
large because E. faecalis is intrinsically resistant to this compound and all such 
isolates were excluded.
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A high proportion of isolates were resistant to gentamicin. However, these isolates 
were subsequently tested for high-level gentamicin resistance and found to be 
sensitive, indicating that only low-level gentamicin resistance was prevalent.
Six isolates (four E. faecalis and two E. faecium) were intermediately-resistant to 
vancomycin but none of the isolates were classified as resistant by the test. Similarly, 
although intermediate-resistance to quinupristin-dalfopristin was common (sixteen 
isolates), a smaller number of isolates, (nine), were classified as resistant by the test. 
None of the isolates from Farm 1 were resistant to teicoplanin and all the organisms 
isolated from the growers were also sensitive to penicillin and ampiciilin.
Results were also expressed in relation to E. faecium for the whole farm (Figure 6.4).
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KEY: Pen = penicillin; Amp -  ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.4 Bar chart of the prevalence of resistance/intermediate resistance 
amongst E. faecium isolates and Enterococcus spp. isolates, and number of 
samples from which at least one E. faecium isolate tested resistant/intermediately 
resistant as a proportion of E, /aec/ifm-positive samples and total samples for 
Farm 1.
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For all of the antimicrobials tested, the prevalence of resistance amongst E. faecium 
was higher than amongst the total number of isolates of all enterococcal species. 
Resistance was not expressed in relation to other individual enterococcal species due 
to the small number of isolates.
6.3.2 Enterococci, Farm 2
Twelve enterococcal isolates were cultured from two faecal samples from finisher 
pens and one whole-farm slurry sample. Seven E. faecalis and one E. faecium were 
isolated from the faecal samples and two E. faecium, one E. faecalis and one E. 
durans were isolated from the slurry. All twelve isolates were sensitive to penicillin, 
ampiciilin and vancomycin, and the four isolates tested were susceptible to 
teicoplanin and linezolid. All twelve isolates exhibited low-level gentamicin 
resistance, four were resistant to erythromycin and the only isolate sensitive to 
tetracycline was an E. durans isolated from slurry.
6.3.3 Enterococci Farm 3
Enterococci were cultured from eight of ten samples taken from weaner pens, of 
which four isolates were identified as E. durans, three as E. gallinarum and one as E. 
faecalis. Of the ten samples taken from finisher pens, only four yielded enterococci, 
of which two were identified as E. faecalis, one as E. durans and one as E. faecium. 
Due to the small number of isolates, the prevalence of resistance is described for the 
total isolates and samples from both groups as well as on a group basis, (Figures 6.5 
and 6.6). All of the enterococcal isolates from Farm 3 were sensitive to ampiciilin, 
teicoplanin and linezolid and the four isolates from the finisher samples were also
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sensitive to penicillin. An E. faecalis isolated from the finisher samples was classified 
as intermediately resistant to vancomycin and three E. durans isolates from weaner 
samples were intermediately resistant to quinupristin-dalfopristin. There was a high 
prevalence of resistance to tetracycline, erythromycin and low-level gentamicin 
amongst isolates and samples from Farm 3.
5  ^ 0
5 - 0
o X 0
Pen Amp Te Va Cn Tec Lzd QD
[^w eaners B finishers B combined |
KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.5 Bar chart of the prevalence of resistance/intermediate resistance 
amongst enterococcal isolates from Farm 3. 95% confidence intervals are shown.
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KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.6 Bar chart of the proportion of samples from which enterococci 
were isolated from Farm 3 from which at least one isolate tested 
resistant/intermediately resistant. 95% confidence intervals are shown.
6.3.4 Enterococci, Farm 4
Ten E.faecium were isolated from five samples taken from pens containing gilts aged 
16-18wks of age and nine E. faecium and one E. durans were isolated from five 
samples taken from pens of castrates aged 16-18 weeks. All of the samples yielded at 
least one enterococcal isolate. Of ten faecal samples taken from pens containing a 
mixture of gilts and castrates aged 20-22weeks of age, enterococci were cultured from 
only six. Five E. faecium isolates and two E. durans isolates were cultured in total 
from these two groups and an E. faecalis was isolated from a whole-farm slurry 
sample. Due to the low microbiological sensitivity of isolation in the samples taken 
from the pens of older animals and the proximity of all four groups in terms of
117
production stage, all isolates and samples from Farm 4 were considered together 
(Figure 6.7).
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KEY: Pen = penicillin; Amp = ampiciilin; Te = tetracycline; E = erythromycin; Va = 
vancomycin; Cn = gentamicin; Tec = teicoplanin; Lzd = linezolid; QD = quinupristin- 
dalfopristin.
Figure 6.7 Bar chart of the prevalence of resistance/intermediate resistance 
amongst enterococcal isolates and of the proportion of samples from which 
enterococci were isolated from which at least one isolate tested 
resistant/intermediately for Farm 4. 95% confidence intervals are shown.
Of the twenty-seven isolates tested from Farm 4, all were sensitive to ampiciilin, 
vancomycin, teicoplanin and linezolid and all were resistant to low-level gentamicin. 
There was a high prevalence of resistance to tetracycline and twenty-four isolates 
were resistant or intermediately resistant to erythromycin. Twelve isolates were 
resistant to penicillin and 53 percent of samples from which enterococci were isolated 
yielded at least one resistant isolate. Two isolates were resistant to quinupristin- 
dalfopristin and four were intermediately resistant.
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6.3.5 Coliforms Farm 1
The sensitivity of isolation of Escherichia spp. was much higher than for 
Enterococcus spp. with the vast majority of samples yielding at least one isolate 
(Table 6.2).
Table 6.2 Number of samples taken and Escherichia spp. isolates tested from 
Farm 1.
Production stage Sows Piglets Weaners Growers Finishers
Number of samples taken 10 20 10 10 10
Proportion of samples 
from which Escherichia 
spp. was isolated
1 0.9 1 1 1
Number of Escherischia 
spp. isolates tested
16 33 15 19 17
Results are described in terms of the number of resistant/intermediately resistant 
Escherichia spp. isolates as a proportion of the total number of Escherichia spp. 
isolates (Figure 6.8) and the number samples from which resistant/intermediately 
resistant Escherichia spp. were isolated as a proportion of the number of samples 
from which Escherichia spp. were isolated (Figure 6.9).
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KEY: Amp = ampiciilin; Te = tetracycline; Sxt = trimethoprim-sulphamethoxazole; 
Cip = ciprofloxacin; Cxm = cefuroxime; Cn = gentamicin; Amc = amoxicillin- 
clavulanic acid.
Figure 6.8 Bar chart of the prevalence of resistance amongst Escherichia spp. 
isolates from Farm 1.95% confidence intervals are shown.
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KEY: Amp = ampiciilin; Te = tetracycline; Sxt = trimethoprim-sulphamethoxazole; 
Cip = ciprofloxacin; Cxm = cefuroxime; Cn = gentamicin; Amc = amoxicillin- 
clavulanic acid.
Figure 6.9 Bar chart of the proportion of samples from which Escherichia 
spp, were isolated from Farm 1 from which at least one isolate tested resistant. 
%% confidence intervals are shown.
In general, there was a high prevalence of resistance to tetracycline, trimethoprim- 
sulphamethoxazole and cefuroxime amongst Escherichia spp. isolates from Farm 1 
and the prevalence of resistant isolates from grower samples was lower than most 
other groups for most antimicrobials. In particular, there was a higher prevalence of 
resistance to tetracycline and trimethoprim-sulphamethoxazole amongst isolates from 
piglets and a higher prevalence of resistance to cefuroxime amongst isolates from 
finishers, than amongst isolates from other production stages. All the organisms tested 
were sensitive to gentamiein and ciprofloxacin and only five isolates from finishers 
were resistant to amoxicillin-clavulanic acid.
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When considered at the sample level (Figure 6.9) the prevalence of resistance to the 
antimicrobials tested was generally higher than when considered at isolate level 
(Figure 6.8). For example, 50 per cent of Escherichia spp. isolates from sow samples 
were resistant to ampiciilin but at least one resistant organism was isolated from 70 
per cent of samples.
6.3.6 Coliforms Farm 2
Twelve E. coli were isolated from four finisher samples and two whole-farm slurry 
samples on Farm 2 and all were sensitive to ampiciilin, ciprofloxacin, gentamicin and 
amoxicillin-clavulanic acid. Eight of the twelve isolates were resistant to tetracycline, 
two isolates from two finisher samples were resistant to cefuroxime and one isolate 
from slimy was resistant to trimethoprim-sulphamethoxazole.
6.3.7 Coliforms Farm 3
Nineteen E. coli isolated from ten samples from finisher pens and fourteen E. coli 
isolated from ten samples from weaner pens were tested (Figure 6.10).
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KEY: Amp = ampiciilin; Te = tetracycline; Sxt = trimethoprim-sulphamethoxazole; 
Cip = ciprofloxacin; Cxm = cefuroxime; Cn = gentamicin; Amc = amoxicillin- 
clavulanic acid.
Figure 6.10 Bar chart of the prevalence of resistance amongst Escherichia spp. 
isolates and the proportion of samples from which Escherichia spp, were isolated 
from which at least one isolate tested resistant for Farm 3. 95% confidence 
intervals are shown.
In general, the prevalence of resistance was higher amongst isolates and samples from 
weaners than from finishers, and resistance to trimethoprim-sulphamethoxazole, 
gentamicin and amoxicillin-clavulanic acid was only found in weaner samples. There 
was a very high prevalence of resistance to tetracycline amongst weaner isolates with 
twelve out of fourteen isolates resistant and at least one resistant organism isolated 
from every sample. All the isolates tested from Farm 3 were sensitive to 
ciprofloxacin.
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6.3.8 Yersinia spp.
Eight isolates of Yersinia spp. from finisher samples on Farm 1 were tested for 
susceptibility to the same panel of antimicrobials as Escherichia spp. isolates and 
three of these isolates (two Y. enterocolitica and one Yersinia spp.) were resistant to 
ampiciilin but all eight isolates were sensitive to all other antimicrobials tested. Three 
of four Yersinia spp. isolates from finisher and slurry samples from Farm 2 were 
resistant to ampiciilin and all four isolates were sensitive to the other antimicrobials 
tested. One Yersinia enterocolitica was isolated from a finisher sample from Farm 3 
and it was resistant to ampiciilin hut sensitive to all other antimicrobials tested.
6.3.9 Comparisons Between Groups and Farms
As described above, different prevalences of resistance were observed on testing 
samples from different farms and different groups within farms. However, the sample 
and isolate numbers were such that confident comparison between such groups could 
not be made using descriptive statistics alone.
As the number of isolates of each enterococcal species were small and prevalence of 
isolation relatively poor, it was considered that the best comparison to use between 
groups was the proportion of enterococcus-positive samples or Escherichia spp.- 
positive samples from which at least one resistant Enterococcus spp. or Escherichia 
spp. was isolated and these data were used for further analysis. The prevalence of 
resistance amongst Enterococcus spp. and Escherichia spp. isolates was also 
compared. Chi-squared analysis was used to compare different groups on Farm 1 and 
Fisher’s exact test was used to compare the same groups on different farms, with a p- 
value of less than 0.05 considered significant.
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Amongst enterococci (isolates and samples) from Farm 1, there was a significant 
difference (p<0.05) between groups in prevalence of resistance to penicillin (100 per 
cent of grower isolates sensitive), ampiciilin (100 per cent of grower and piglet 
isolates sensitive) and erythromycin (only 37.5 per cent of grower isolates and 
samples resistant). Psmongsi Escherichia spp. isolates and samples from Farm 1, there 
was a significant difference (p<0.05) in the prevalence of resistance to trimethoprim- 
sulphamethoxazole (83.3 per cent of piglet isolates and samples resistant and 90 per 
cent of sow samples resistant), cefuroxime (100 per cent of finisher and 90 per cent of 
sow samples resistant) and amoxicillin-clavulanic acid (29.4 per cent of isolates and 
40 per cent of samples from finishers resistant).
When different farms were compared, the prevalence of resistance on Farm 1 was 
significantly higher for some, hut not all, antimicrobials. The prevalence of resistance 
amongst enterococci to tetracycline was significantly higher in samples from weaners 
and growers on Farm 1 (100 per cent of samples resistant) than in samples from 
weaners (62.5 per cent of samples resistant) and finishers (75 percent of samples 
resistant) on Farm 3 (p<0.05). However, the prevalence of resistance to penicillin 
(100 per cent of isolates and samples sensitive) and erythromycin (37.5 per cent of 
isolates and samples resistant) from Farm 1 growers was significantly lower than in 
samples (52.9 per cent resistant to penicillin and 88.2 per cent resistant to 
erythromycin) and isolates (44.4 per cent resistant to penicillin and 88.9 per cent 
resistant to eryhtromycin) from Farm 4 finishers (p<0.05).
Amongst Escherichia spp. there was a significantly higher prevalence of resistance to 
several antimicrobials in samples and isolates from Farm 1 than from other farms. The 
prevalence of resistance to ampiciilin amongst Escherichia spp. was significantly 
higher in Farm 1 weaners (26.7 per cent of isolates and 40 per cent of samples
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resistant) and finishers (41.2 per cent of isolates and 60 per cent of samples) than in 
weaners (14.3 per cent of isolates and 22.2 per cent of samples resistant) and finishers 
(5.3 per cent of isolates and 10 per cent of samples resistant) from Farm 3 (p<0.05). 
The prevalence of resistance to ampiciilin in finishers on Farm 2 (100 per cent of 
isolates and samples sensitive) was also significantly lower than in finishers on Farm 
1(41.2 per cent of isolates and 60 per cent of samples) (p<0.05). On Farm 1, the 
proportion of isolates and samples resistant to trimethoprim-sulphamethoxazole (33.3 
per cent of weaner isolates, 40 per cent of weaner samples, 29.4 per cent of finisher 
isolates and 50 per cent of finisher samples resistant) and tetracycline (86.7 per cent 
of weaner isolates, 90 per cent of weaner samples, 70.6 per cent of finisher isolates 
and 90 per cent of finisher samples resistant) was also significantly higher than in 
isolates and samples from the same groups on Farm 3 (7 per cent of weaner isolates 
and 11.1 per cent of weaner samples resistant, 100 per cent of finisher isolates and 
samples sensitive) (p<0.05). The prevalence of resistance to cefuroxime was 
significantly higher in Farm 1 finishers (82.3 per cent of isolates and 100 per cent of 
samples resistant) than in finishers from Farm 2 (16.7 per cent of isolates and 33 per 
cent of samples resistant) and 3 (21 per cent of isolates and 40 per cent of samples 
resistant) (p<0.05). However, the prevalence of resistance to gentamicin was 
significantly higher in weaners (28.6 per cent of isolates and 44.4 per cent of samples 
resistant) and finishers (100 per cent of isolates and samples sensitive) from Farm 3 
when these were considered together than in samples from the same groups on Farm 1 
(100 per cent of isolates and samples sensitive) (p<0.05).
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6.4 Discussion
The reason for carrying out studies on resistance to therapeutic antimicrobials on the 
four selected farms was first to estimate the prevalence of resistance on each farm and 
secondly to identify any differences between farms or groups on farms that might be 
explained by or related to avilamycin use.
The prevalences of resistance amongst enterococci to therapeutic antimicrobials 
observed are similar to those described by previous authors, with a high proportion of 
isolates resistant to erythromycin and tetracycline (Aarestrup et a l,  2002). Similarly, 
several authors have described low prevalences of 7 per cent or less of resistance to 
vancomycin amongst enterococci isolated from pigs (Bager et a l, 1997; Danmap, 
2000; Herrero et a l, 2000) and this is in agreement with the findings of this study. 
However, much higher prevalence levels of vancomycin resistance of up to 17 per 
cent have been described amongst E. faecium in Denmark (Aarestrup et a l, 2002) and 
it is recognised that enrichment is a much more sensitive method of detecting 
vancomycin-resistant enterococci than the method used in this study (Butaye, 
Devriese and Haesebrouck, 1999a). The prevalences of resistance to most of the 
antimicrobials tested are higher than those described in Swedish enterococcal isolates 
and it has already been suggested that the low proportion of resistant bacteria isolated 
from farm animals in Sweden is a consequence of the low antimicrobial use in that 
country (SVARM, 2000; Aarestrup et a l, 2002).
It should also be borne in mind that isolates classified as intermediately resistant were 
considered resistant for the purposes of this study. The rationale behind this approach 
was that in a clinical setting, these antimicrobials would not be considered effective 
for treatment. This approach may have lead to higher estimates of prevalence than 
those described elsewhere if different methodologies or criteria were used. However,
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even with more accurate methods of sensitivity testing such as breakpoint MIC 
determination, some isolates would still have been classified as intermediately 
resistant.
The prevalences of resistance observed amongst the Escherichia spp. isolates were 
similar to those described elsewhere in commensal E. coli isolates, with a high 
proportion of isolates resistant to trimethoprim-sulphamethoxazole, tetracycline and 
ampicillin (Das, 1984; Dunlop et a l,  1998a). Although lower prevalences of 
resistance have been described in Denmark (Danmap, 1999; Danmap, 2000) the 
isolates tested were taken from abattoirs and therefore the animals sampled were 
unlikely to have been treated recently with therapeutic antimicrobials.
The prevalence of resistance on the four study farms has been estimated, but the large 
confidence intervals surrounding all of the estimates means that there is uncertainty 
about the estimated prevalences, making comparisons between groups and farms 
difficult, and this has highlighted one of the greatest problems in carrying out farm 
studies on antimicrobial resistance: attaining sufficient sample numbers to achieve 
accuracy and statistical power. One of the factors that contributed to the relatively 
small numbers of isolates tested in these studies was the fact that enterococci were not 
cultured from every sample (Table 6.1) and this is in common with the findings of 
other authors who have described prevalences of E. faecium in pig faecal samples 
ranging from as low as 9 per cent (Devriese ei a l, 1994) to 29 per cent (Danmap, 
2000). However, even for Escherichia spp. where the prevalence of isolation was 
much higher (Table 6.1) sample numbers were still generally insufficient to allow 
comparisons between groups or farms to be made with confidence using descriptive 
statistics alone.
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The surveillance of antimicrobial resistance in pigs and other farm animals has largely 
been directed towards animals of slaughter age because of their proximity to the food 
chain (Danmap, 1998; Danmap, 1999; Dunlop et a l, 1999; Danmap, 2000; SVARM, 
2000; Danmap, 2001) but one of the objectives of this study was to compare the 
prevalence of resistance in different age-groups of pigs. When the prevalence of 
resistance amongst groups on Farm 1 was compared using Chi-squared analysis with 
a p-value of less than 0.05 considered significant, the results suggested that resistance 
to penicillin and erythromycin was less common in grower pigs than in piglets and 
that ampicillin and erythromycin resistance were both more common in sows than in 
grower pigs on this farm. The results for Escherichia spp. isolates suggest that 
trimethoprim-sulphamethoxazole resistance was more prevalent in sows and piglets 
but that the prevalence of resistance to cefiiroxime and amoxicillin-clavulanic acid 
was higher in finishers than in other groups on Farm 1. Although the surveillance of 
slaughter-age animals is a priority for public health this information suggests that 
there are significant differences between resistance patterns in different age groups of 
animals within farms and this is in agreement with the findings of similar studies in 
cattle that suggested the prevalence of resistance was significantly higher in young 
calves (Gunn, 2000).
When the prevalence of resistance on different farms was compared using Fisher’s 
exact test with a p-value of less than 0.05 considered significant, several significant 
differences between farms were identified. However, there was no clear relationship 
between avilamycin use on farms and the proportion of resistant isolates observed, 
with the prevalence of resistance higher on Farm 1 to certain antimicrobials e.g. 
trimethoprim-sulphamethoxazole and tetracycline but lower for others, e.g., penicillin 
and erythromycin. One possible explanation for the higher prevalence of resistance to
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tetracycline on Farml is the fact that this antimicrobial has been used on the farm for 
the medication of hospitalized pigs, but as penicillin has been used on all the farms, 
the reason for the higher prevalence of resistance on Farm 4 is not known. Significant 
differences in the prevalence of antimicrobial resistance according to antimicrobial 
usage between farms have been described for vancomycin-resistant enterococci 
(Aarestrup, 1995; Bager et a l, 1997) and differences between the prevalence of 
vancomycin-resistant enterococci have been described in countries with different 
antibiotic policies. Antimicrobial usage in pigs has also been associated with 
resistance in E. coli (Dunlop et a l, 1998b) but the findings of this small study suggest 
that the development and persistence of resistance to antimicrobials on farms is 
complex and multifactorial and therefore it is difficult to draw firm conclusions from 
such farm studies because of the many potential variations in therapeutic 
antimicrobial use and management practices that may affect antimicrobial resistance. 
However, based on the results for both enterococci and Escherichia spp., there seems 
little evidence to suggest that exposure to avilamycin has led to resistance to any of 
the other antimicrobials tested as, in general, the prevalence of resistance in animals 
exposed to avilamycin for the longest time (growers and finishers) was lower than 
that observed in the younger animals or sows (Figures 6.3, 6.6, 6.9 and 6.10). The 
only exception to this was resistance to amoxicillin-clavulanic acid, which was 
present only in isolates from finishers on Farm 1 and as there is no record of use of 
this antimicrobial on the farm, there is no obvious explanation for this observation. 
Cefiiroxime resistance was also prevalent in finishers on Farm 1 but a high proportion 
of isolates from sows were resistant as well and, again, there is no record of use of 
any cephalosporin on the farm. The only difference in resistance patterns that can be 
explained by therapeutic antimicrobial use is the higher prevalence of resistance to
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, itetracycline on Farm 1 where this antimicrobial had been used to medicate 
hospitalized pigs.
It is possible that resistance to some of the antimicrobials tested may be linked as has 
been described before for other antimicrobials (Aarestrup, Bager and Andersen, 2000;
Aarestrup et a l, 2001) and therefore resistance to tetracycline may be driving 
resistance to other antimicrobials, e.g., trimethoprim-sulphamethoxazole on this farm, 
or vice versa. It is also notable that despite the use of enrofloxacin to tieat diarrhoea in 
piglets on Farm 1, no ciprofloxacin-resistant organisms were isolated, indicating that 
the relationship between antimicrobial use and resistance is not straightforward.
From an epidemiological point of view, the studies have highlighted some of the 
issues to be addressed when considering testing regimes for determining the 
prevalence of antimicrobial resistance and also when relating results to underlying 
sample and animal populations. One of the features of the antimicrobial resistance 
patterns described is the heterogeneity of the underlying bacterial population, which is 
indicated by the higher prevalence of resistant samples than resistant isolates and this 
has been suggested before in commensal bacterial populations but is not normally 
taken into account when isolates are selected for testing (Humphry et a l, 2002).
Although on most occasions the sensitivity pattern of isolates from an individual 
sample were identical, on some occasions different sensitivity patterns were observed 
and this occurred even where organisms were identified as belonging to the same 
species and where samples were taken from an individual animal. This suggests that 
multiple isolates of the same species should be tested from an individual sample, 
rather than classifying a sample or as sensitive or resistant based on the classification 
of an individual isolate.
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This raises the question of how best to express resistance in relation to the underlying 
bacterial, sample and animal populations. In the studies described, multiple 
enterococcal isolates were cultured and tested where possible but there were samples 
from which enterococci were not isolated and this meant that some samples were 
over-represented when results were expressed in terms of prevalence of resistant 
isolates and this is significant because this is the usual method by which the results of 
surveillance data are expressed (SVARM, 2000; Danmap, 2001). Conversely, 
expressing results in terms of the number of samples fi-om which resistant enterococci 
were isolated as a proportion of the total number of samples underestimated the 
prevalence of resistance in the enterococcal population because prevalence of 
isolation was poor. For these reasons, results were also expressed in terms of the 
number of samples from which resistant/intermediately resistant enterococci were 
isolated as a proportion of the total number of samples fi-om which enterococci were 
isolated. However, although this approach went some way to addressing the low 
prevalence of isolation, it did not incorporate the heterogeneity in the underlying 
bacterial population and by describing resistance on the farm by sample alone, 
information about the underlying bacterial population was lost.
Furthermore, thé results suggest that resistance should ideally be related to a 
particular bacterial species rather than a genus and that accurate spéciation is 
important because species-specific differences in resistance exist. For example, E. 
faecalis is intrinsically resistant to quinupristin-dalfopristin whereas E. faecium is not 
(Singh et al., 2002) and although insufficient numbers of each enterococcus species 
were isolated to evaluate interspecies differences with statistical power, it would 
appear that on Farm 1, E. faecium  isolates were more likely to be resistant to most 
antimicrobials tested than E. durans isolates, for instance. This means that unless
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organisms are speciated accurately then comparisons are inaccurate, but the different 
composition of enterococcus species isolated from each farm in these studies made 
species-specific comparisons between farms difficult. However, it should be borne in 
mind that the significant differences in resistance patterns highlighted incorporated all 
enterococcal species isolated and therefore may be a reflection of the enterococcal 
flora present on a farm rather than a true comparison of the prevalence of resistance 
and this may also be the case where isolates are not carefully speciated.
In summary, the farm studies conducted have highlighted some of the problems of 
quantifying antimicrobial resistance in commensal organisms, of relating the data 
generated to underlying bacterial and animal populations and of making meaningful 
comparisons between farms and groups in field studies. Finally, although a small 
number of significant differences in resistance patterns were noted between farms and 
groups, there was no evidence to suggest that these differences were related to the use 
of avilamycin and any such relationship was also difficult to assess because of the 
many other factors that may have influenced the resistance patterns observed, 
including the complex relationship between therapeutic antimicrobial use and 
resistance and the large confidence intervals surrounding prevalence estimates.
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CHAPTER 7 
MOLECULAR INVESTIGATIONS
7.1 Introduction
It was apparent from the studies discussed in Chapters 4, 5 and 6 that the application 
of conventional bacteriological methods to the measurement of resistance to both 
avilamycin and therapeutic antimicrobials had limitations. More sensitive and specific 
techniques would be required to quantify resistance and particularly to monitor 
changes over time. One approach that was considered was the detection of genotypic 
resistance instead of phenotypic resistance and in order to develop this approach, 
molecular biological techniques including polymerase chain reaction (PCR) and DNA 
sequencing were used to determine the genetic basis of avilamycin resistance in 
enterococci isolated from Farm 1 as described in Chapter 5.
Following the first description of the polymerase chain reaction (PCR) in 1987 
(Mullis and Faloona, 1987) it has been widely applied in microbiological research. 
The technique involves temperature cycling to cause the repeated dissociation and 
annealing of specific oligonucleotide primers to a DNA template. A thermostable 
DNA polymerase elongates the primers using deoxyribonucleoside triphosphates 
(dNTPs) thus amplifying the target sequence. The specific nature of the primers 
means that only the target sequence increases exponentially and by choosing primers 
that will anneal to unique regions, PCR can be used to detect the presence of DNA 
from bacteria or viruses.
In clinical laboratories, PCR has been used both to detect and identify 
microorganisms as well as to detect the presence of antimicrobial resistance (Fluit et
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al., 2001). For example, several PCRs have been developed in the last decade for the 
detection of methicillin resistant Staphylococcus aureus (MRSA) (Archer and
j:
Pennell, 1990; Ligozzi et at., 1991; Murakami et al., 1991; Brakstad et al., 1993 and
-f
Towner et al., 1998). These techniques have been shown to be both rapid and 
sensitive and the mecA PCR is now considered the gold standard technique for the 
detection of this organism (Kampf et al., 1997). Similarly, both single and multiplex
?'
PCRs have been developed for the detection of glycopeptide resistance in enterococci 
where detection of the van gene cluster has been useful in the surveillance of 
vancomycin resistance (Dutka-Malen et al., 1995; Miele et al., 1995; Sahm et al.,
1997 and Reed et al., 1999).
DNA sequencing is also being more frequently used in diagnostic laboratories (Fluit 
et a l, 2001). The most commonly used method is the chain termination method first 
described in 1977 (Sanger et al., 1977). In this method, DNA is sequenced by the 
synthesis of DNA fragments using DNA polymerase and dNTPs as described above 
for PCR. However, in each reaction one of the dNTPs is designed to halt elongation 
of the newly synthesised DNA. Each reaction thus produces chains of various lengths 
terminating at one of the dNTPs. When fluorescence detection is used, each of the 4 
dNTPs is primed with a tag that fluoresces at a different wavelength. The DNA 
sequence can thus be determined by fluorescence measurements at the four different 
wavelengths.
Some of the genes responsible for antimicrobial resistance in clinically important 
organisms have been sequenced. For example, at least 24 different tetracycline 
resistance (Tet) determinants have been described (Levy et al., 1988; Roberts, 1996 
and Taylor and Chau, 1996), and the sequence of several different beta-lactamase
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genes is now known (Bush et al., 1995). New resistance determinants are being 
identified continually in a variety of organisms.
The growth-promoting antimicrobial avilamycin inhibits protein synthesis by binding 
to bacterial ribosomes (Wolf, 1973). A related compound, evernimicin (SCH27899), 
has been considered for use in human medicine (Nakashio et al., 1995; Urban et al., 
1996; Marshall et al., 1999), and it has been shown that the binding sites of 
avilamycin and evernimicin overlap. Resistance to evernimicin and avilamycin has 
also been shown to be co-transferable in E. faecium  in vitro (Aarestrup and 
McNichoIas, 2002). Following the description of mutations in ribosomal protein L I6 
conferring resistance to evernimicin in Streptococcus pneumoniae (Adrian et al., 
2000), similar mutations conferring high-level avilamycin and low-level evernimicin 
resistance were described in enterococci isolated from pigs and broilers in Denmark 
(Aarestrup and Jensen, 2000).
The aim of this part of the study was to amplify and sequence the L I6 gene in 
avilamycin-resistant enterococcal isolates obtained from the farm studies (Chapter 5) 
and to assess whether molecular methods could be used in the detection of 
avilamycin-resistant enterococci.
7.2 Materials and methods
7.2.1 Selection of bacterial strains
Five bacterial isolates identified to species by biochemical testing and exhibiting 
phenotypic resistance to avilamycin were selected from a bank of strains isolated from 
Farm 1. They were isolated on Slanetz and Bartley plates containing 64 or 128p,g/ml 
of avilamycin as described in Chapter 5. They were identified to species using 
commercial biochemical kits (API, Biomerieux) and subsequently by tRNA intergenic
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spacer PCR. Susceptibility to avilamycin was determined by culturing on Mueller- 
Hinton agar plates containing twofold serial dilutions of avilamycin at dilutions 
ranging from 1 to 128p,g/ml, according to NCCLS guidelines, (NCCLS, 2000b). 
These isolates were chosen to include different enterococcal species and were derived 
from different age groups on the farm. They were recovered from storage on 
Microbank beads at -70°C and grown overnight on nutrient agar before use. The 
strains selected are shown in Table 7.1.
Table 7.1 Identification, origin and susceptibility to avilamycin of 
enterococcal isolates selected for molecular analysis.
Origin API identification Identification by 
tRNA intergenic 
spacer PCR*
Avilamycin MIC 
(pg/ml)
Piglets, Farm 1 E. gallinarum E. faecium >128
Finishers, Farm 1 E. faecium E. faecium >128
Piglets, Farm 1 E. durans E. hirae >128
Weaners, Farm 1 E. faecium E. faecium 128
Weaners, Farm 1 E. faecalis E. faecalis >128
* Molecular identification of strains carried out by An Martel, DVM, Laboratory of 
Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
7.2.2 Primers
The primers used were identical to those described by Aarestrup and Jensen (2000) 
and were purchased from MWG Biotech (UK) Ltd., Mill Court, Featherstone Road, 
Wolverton Mill, South Milton Keynes MK12 5RD. These primers were used to 
amplify a 414 base pair sequence of the L16 gene.
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Primer 1: 5’-AAA CGT GTA AAA GAG GGT GG-3’
Primer 2: 5’-GAT TGG ATT GAG GAG GGA TT-3’
The primers were diluted in sterile distilled water to a concentration of 100-pmol/p,l 
before use.
7.2.3 Preparation of template DNA
Several colonies from overnight growth of a pure culture were suspended in lOOfxl of 
sterile distilled water and boiled for five minutes. The suspension was then 
centrifuged at 15000g for two minutes. The supernatant was pipetted off and l\x\ was 
added to 45\i\ of Reddy mix Reaction Buffer (lOX) (750mM Tris-HGl, 200mM 
(NH4)2S0 4 , 0.1% (v/v) Tween®20 and 15mM MgGb, red dye and precipitant, 
supplied by Abgene, Blenheim Road, Epsom, Surrey KT19 9AP) and 2fxl of a one in 
ten dilution of each primer. The resultant suspension was mixed by pulsing in the 
micro-centrifuge.
7.2.4 Polymerase chain reaction (PCR)
DNA amplification was performed in a PGRExpress thermal cycler, (Hybaid UK Ltd., 
Action Gourt, Ashford Place, Ashford, Middlesex TW15 IXB). Initial dénaturation 
was carried out by incubation at 95° G for 2 minutes followed by 35 cycles of 
amplification. Each cycle consisted of 30 seconds at 95°G to denature die DNA, 30 
seconds at 55°G to anneal the primers to the template and 30 seconds at 72°G for 
primer extension. After the last cycle, a further incubation for 15 minutes at 72°G was 
performed to allow extension of any partially completed product.
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7.2.5 Analysis and Purification of PCR products
On completion of the amplification, 5p,i of each reaction mixture was electrophoresed 
through a 1 per cent agarose gel and the size of DNA fragments estimated by 
comparison with DNA markers of known length (1KB and (j)X DNA ladders, 
Invitrogen Ltd., 3 Fountain Drive, Inchinnan Business Park, Paisley, UK). The DNA 
was visualised by staining with ethidium bromide and exposure to ultraviolet light 
(312nm). The DNA fragments were excised from the agarose gel using a scalpel 
blade, transferred to a microcentrifuge tube and weighed. Amplified products were 
recovered from the gel fragments using the QIAquick Gel Extraction Kit (Qiagen Ltd. 
(UK), Boundary Court, Gatwick Road, Crawley, West Sussex RHIO 9AX).
7.2.6 Preparation of single stranded DNA for sequencing
Sequencing reaction mixtures were prepared using 8pl of purified PCR product, 3.2^1 
of a lpmol/p.1 dilution of primer, 4pil of ABI Prism® BigDye™ Terminator Ready 
Reaction Mix (Applied Biosystems, 850 Lincoln Centre Drive, Foster City, CA 94404 
U.S.A), 2fxl of 5X buffer and 2.8[xl of sterile distilled watet. The control reaction 
mixture was prepared using \\û  of DNA from the pGEM®-13Zf(+) Vector (Promega 
UK Ltd., Delta House, Chilworth Science Park, Southampton S016 7NS), 4\x\ of 
0.8pmol/fxl primer, 4p,l of Big Dye Terminator Ready Reaction Mix, 2fil of 5X buffer 
and 9fxl of MQ water. Twenty five cycles of amplification were performed using a 
PGRExpress thermal cycler (Hybaid) with an initial temperature of 96°G for 30 
seconds to denature the DNA, an annealing temperature of 55°G for 30 seconds and 
an extension temperature of 60°G for 4 minutes. The amplified DNA fragments were
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purified using the Spin Performa DTR Gel Filtration System (Edge BioSystems, 
19208 Orbit Drive, Gaithersburg, MD 20879-4149, U.S.A).
7.2.7 DNA Sequencing
The purified DNA was freeze dried (Edwards Pirani 501 Freeze Drier, Edwards High 
Vacuum International Ltd., Manor Royal, Crawley, West Sussex, RHIO 2LW) and 
then resuspended in 25p,l of deionised H i-D iform am ide (Applied Biosystems) 
before being transferred to a 96 well plate. The sequencing reactions were carried out 
in an ABI Prism 3100 Genetic Analyzer (Applied Biosystems).
7.3 Results
7.3.1 Amplification of target DNA by polymerase chain reaction (PCR)
Amplified products were generated from all 5 isolates and corresponded to the target 
sequence of the L16 gene (Figure 7.1).
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Figure 7.1 PCR products after electrophoresis through a 1 per cent agarose 
gel. The gel was stained with ethidium bromide and photographed when 
transilluminated with UV light (312nm). Lanes 1- 7: 1KB ladder, Piglet E. 
faecium, Weaner E. faecium. Finisher E. faecium, Weaner E. faecalis. Piglet E. 
hirae and <j)X ladder, respectively.
7.3.2 DNA sequencing
The PCR products were each sequenced using forward and reverse primers identical 
to those used in the initial PCR. Sequences were analysed and compared with the 
published L16 sequence of the human derived reference strain E. faecium CCUG 
(Culture Collection of the University of Goteborg, Sweden) using the Vector NTl 
software program (InforMax Inc., The Magdalen Centre, Robert Robinson Avenue, 
The Oxford Science Park, Oxford 0X4 4GA) (Figures 7.2 and 7.3). In all 10 cases, 
sequences of between 350 and 400 base pairs were produced with overall good 
correlation of sequence data between primers and a high degree of homology with the 
reference strain.
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13 AAACGTGTAA AACACCGTCG TGAATTCCGC GGAAAAATGC
GCGGGGAAGC TAAAGGCGGA AAAGAAGTAG CATTCGGTGA
ATACGGTTTG CAAGCTGTTG
113 ATTCACATTG GATCACAAAC CGCCAAATCG AAGCTGCTCG
TATCGCAATG ACTCGTTACA TGAAACGTGG TGGGAAAGTA
TGGATTAAAA TTTTCCCTCA
213 CAAATCTTAT ACTGCCAAAG CAATTGGGGT ACGTATGGGT
TCTGGTAAAG GGGCACCTGA AGGATGGGTT GCACCAGTAA
313 GAAATCGCAG GCGTTCCTGA AGAAGTAGCT CGTGAAGCGT
TACGTCTAGC TTCTCACAAA TTACCAATGA AAACTAAGAT
CGTAAAACGT GAGGAAATGG
413 GTGGTGAATC GAAT
Figure 7.2 L16 sequence of E,faecium  CCUG542. Position of primers
indicated (bold and underlined). Position of amino acids 52 and 56 indicated in 
bold.
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E. faecium CGUG542 
142
GAAGCTGCTCGTATCGCAATGACTCGTTACATGAAACGTGGTGGGAAAG
Weaner E. faecium Forward Primer 
112
GAAGCTGCTCGTATCGCAATGACTCATTACATGAAACGTGGTGGGAAAG
Weaner E. faecium Reverse Primer 
130
GAAGCTGCTCGTATCGCAATGACTCATTACATGAAACGTGGTGGGAAAG
Finisher E. faecium Forward Primer 
116
GAAGCTGCCCGTAÏNGCAATGACTCGTTATATGAAACGTGGCGGGAAAG
Finisher E. faecium Reverse Primer
130
GAAGCTGCTCGTAÇCGCAATGACrCGTTACATGAAACGTGGTGGGAAAG
Weaner E. faecalis Forward Primer 
125
GAAGCAGCCCGTATTGCAATGACTCATTACATGAAACGTGGCGGGAAAG
Weaner E. faecalis Reverse Primer
131
GAAGCAGCCCGTATTGCAATGACTCATTACATGAAACGTGGCGGGAAAG
Piglet E. faecium Forward Primer 
110
GAAGCTGCCCGTATTGCAATGACTCGTTATATGAAACGTGGCGGGAAAG
Piglet E, faecium Reverse Primer
132
GAAGCTGCCCGTATTGCAATGACTCGTTATATGAAACGTGGCGGGAAAG
Piglet E. hirae Forward Primer 
110
GAAGCTGCTCGTATCGCAATGACTCGTTACATGAAACGTGGTGGGAAAG
Piglet E. hirae Reverse Primer 
131
GAAGCTGCTCGTATCGCAATGACTCGTTACATGAAACGTGGTGGGAAAG
Figure 7.3 Alignment of L16 sequences of test isolates and reference strain E, 
faecium CCUG542, with position of amino acids 52 and 56 indicated in bold type. 
Base pair number is indicated on the left hand side. Nucleotide substitutions 
leading to amino acid substitutions are underlined.
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7.4 Discussion
The sequence data described in this chapter shows that considerable variation exists 
between the isolates tested in codons 52 and 56 of the L16 gene (Figure 7.3),
The effect of these variations on amino acid sequence is shown in Table 7.2.
Table 7.2 Amino acids corresponding to nucleotide sequences of control 
strain E. faecium CCUG542 and test isolates.
Isolate Amino acid 52 Amino acid 56
E. faecium CCUG542 Isoleucine Arginine
E. faecium (weaner) Isoleucine Histidine
E. faecium (finisher) Threonine /Isoleucine Arginine
E. faecalis (weaner) Isoleucine Histidine
E, faecium (piglet) Isoleucine Arginine
E. hirae (piglet) Isoleucine Arginine
The weaner E. faecium isolate had a nucleotide substitution at codon 56, (CGT -  
CAT), which would have the effect of substituting arginine with histidine at this 
residue. The weaner E. faecalis isolate had the same nucleotide substitution at amino 
acid 56, (CGT, Arg -  CAT, His). The weaner E. faecalis isolate and the piglet E. 
faecium isolate exhibited a different sequence from the other isolates at amino acid 
52, (ATC -  ATT). However, this substitution would not have any effect on the 
corresponding amino acid. The finisher E. faecium isolate may also have possessed a 
substitution at amino acid 52, (ATC -  ACC), which would result in the substitution of 
isoleucine with threonine. However, the nucleotides present at the second residue of
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this codon were different in the forward and reverse primer sequences and it was 
unclear from the sequence data which nucleotide was present in the third residue of 
the forward primer sequence. Finally, the sequence obtained from the piglet E. hirae 
isolate appeared to be identical to codons 52 and 56 of the reference strain.
Therefore, examination of the effect of the nucleotide substitutions observed on the 
corresponding amino acid sequences revealed that only 3 of the 5 avilamycin-resistant 
isolates, (weaner E. faecium, finisher E. faecium and weaner E. faecalis), had different 
amino acids from the sensitive reference strain at these residues (Table 7.2). 
Furthermore, the sequence data obtained was used to predict the amino acid sequence 
over a larger portion of the L16 protein for each of the isolates. As the L16 sequence 
is known for several reference organisms (Adrian et al., 2000), the amino acid 
sequences could be compared (Table 7.3). Even over this larger region of the L16 
protein, only 3 of the five avilamycin-resistant isolates, (weaner E. faecium, finisher 
E. faecium and weaner E. faecalis) exhibited differences in amino-acid sequence from 
the evernimicin-sensitive reference strains, suggesting that the molecular basis for 
avilamycin resistance is not in this region of L16 for the piglet E. hirae and E. 
faecium isolates.
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Table 7.3 Comparison of amino acid sequence of the L16 protein from 
residues 43 to 60 for test isolates and reference strains, (S. pneumoniae, E. 
faeca lis, S, aureus and E, coli). Amino acid residues differing from the 
evernimicin-sensitive S, pneumoniae and E. faecalis are highlighted in bold type 
and underlined.
Organism Amino Acid Sequence
S. pneumoniae 43 TNRQIE AARIAM TRYMKR 60
E. faecalis 43 TNRQIE AARIAM TRYMKR 60
S. aureus 43 TSRQIE SARIAM TRYMKR 60
E. coli 43 TARQIE AA% AM  TRAVKR 60
Piglet E. hirae. Piglet E. faecium. 43 TNRQIE AARIAM TRYMKR 60
Weaner E. faecium, Weaner E. faecalis 43 TNRQIE AARIAM THYMKR 60
Finisher E. faecium 43 TNRQIE AARTAM TRYMKR 60
;ï
Key: T=threonine; N=asparagine; R=arginine; Q=glutamine; I=isoleucine;
E=glutamic acid; A^alanine; M-methionine; Y=tyrosine; K=lysine; S=serine; 
V=valine; H=histidine.
In summary, the sequence data obtained indicates that phenotypic avilamycin 
resistance cannot be explained by a single mutation in the sequence of the L16 gene 
or even by different substitutions at the same locus in this gene. Even when three 
isolates of the same bacterial species (E. faecium) isolated from the same animal 
species and from the same farm were tested, three different nucleotide substitutions 
were observed. Moreover, two of the 5 resistant isolates including one E. faecium, 
exhibited sequences identical to the sensitive reference strain and would be 
indistinguishable from sensitive isolates if molecular detection was aimed at these two 
residues of L I6 (52 and 56). The assertion that different molecular determinants of 
avilamycin resistance exist has since been confirmed by recent work describing 
mutations in helices 89 and 91 of rRNA in Halobacterium halobium that confer
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resistance to evernimicin. These regions lie close to the L16 region of 23S rRNA and 
the mutations described have also been shown to give cross-resistance to avilamycin 
(Kofoed and Vester, 2002). In addition, a gene encoding a methyltransferase {emtA) 
that confers high-level evernimicin resistance by méthylation of 23S rRNA and that is 
plasmid-borne has been cloned from an avilamycin-resistant E. faecium strain isolated 
from a broiler in Denmark (Mann et al., 2001). However, the prevalence of high-level
evernimicin resistance mediated by the emtA gene in human and animal isolates in 
Denmark is thought to be low (Aarestrup and McNichoIas, 2002).
The findings of the small study described in combination with the recent descriptions 
of avilamycin resistance mechanisms in enterococci suggest that the detection of 
avilamycin resistance in enterococci by PCR would be difficult. As several different 
mutations are responsible for avilamycin resistance, a single PCR would have a poor 
sensitivity as some resistant organisms would be missed. The development of a 
multiplex PCR to detect resistance would depend on all the molecular determinants of 
avilamycin resistance in enterococci being fully described and this has not yet been 
accomplished.
However, the substitutions identified at residues 52 and 56 in the E. faecium and E. 
faecalis isolates are identical to those described in Danish pig and broiler isolates 
(Aarestrup and Jensen, 2000) and this suggests that these may be the most prevalent 
genetic determinants of avilamycin resistance in E. faecium and E. faecalis in pigs. 
The study has also highlighted the problems of detecting subtle differences at the 
molecular level, such as the substitution of one nucleotide, in antimicrobial resistance 
studies. When the finisher E. faecium isolate was sequenced, even using both forward 
and reverse primers, it was not possible to say with certainty that a substitution was 
present at residue 52 without further sequencing analysis taking place. If sample size
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calculations suggested that a large number of isolates needed to be tested and a large 
proportion of tests then had to be repeated, this approach to resistance detection would 
become quite labour intensive.
The conversion of nucleotide sequences to the corresponding amino acid sequence 
also illustrates some of the problems of relying on molecular differences for resistance 
detection. First, nucleotide substitution does not necessarily lead to amino acid 
substitution. For example, the weaner E. faecalis and piglet E. faecium isolates tested 
above have a different sequence from the other organisms tested but the same amino 
acid at residue 52. Second, even when amino acid substitution does take place, the 
effect on antimicrobial sensitivity may be dependent on which amino acid is inserted. 
For instance, three different amino acid substitutions at residue 52 in S. pneumoniae 
and their effect on the MIC of evernimicin have been described (Adrian et al., 2000) 
and whilst substitution of isoleucine with serine or asparagine caused an increase in 
MIC from 0.03 to 1.5^g/ml, clones with arginine at this residue were sensitive to 
evernimicin and the replacement of isoleucine with threonine caused a much smaller 
increase in MIC to 0.38jrg/ml. The substitution with threonine is identical to the 
finisher E./«eczMm isolate described above and that described in avilamycin-resistant 
E. faecium isolates from Danish broilers (Aarestrup and Jensen, 2000). These findings 
suggest that the phenotypic determination of resistance is still important and that 
genotypic determinants should be related to this.
It is also important to consider the likely functional effects of mutations on 
antimicrobial action. Avilamycin inhibits protein synthesis by preventing the 
attachment of tRNA to the ribosome (Wolf, 1973), and has a binding site close to L16 
(Kofoed and Vester, 2002). Therefore, substitutions in the sequence of L16 are likely 
to be responsible for resistance by disrupting avilamycin binding.
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":.:5It can be seen from Table 7.3, that E. coli, which is naturally resistant to avilamycin, ;ï
differs from naturally sensitive organisms such as E. faecalis at several residues even 
in this short sequence of amino acids in L16. Any or none of these differences could 
be responsible for resistance to avilamycin. In addition, the amino acid sequence of S. 
aureus differs at several residues from that of E. faecalis and yet is also sensitive to 
avilamycin and evernimicin. This suggests that molecular analysis of resistant
I
organisms must be coupled with phenotypic determination of resistance and that
molecular determinants should be related to functional effects.
However, despite the problems of using molecular analysis as a tool for detecting 
resistance, examining the genetic composition of resistant organisms can be useful in 
epidemiology. By describing the genetic basis for resistance, organisms that were 
phenotypically indistinguishable have been shown to have different genetic 
mechanisms of resistance and it therefore seems unlikely that resistance to avilamycin 
in these organisms has arisen by transfer between different enterococcal species. The 
genetic basis for avilamycin resistance in the piglet E.faecium and E. hirae isolates 
remains unknown. However, the absence of a common genetic mechanism conferring 
resistance to avilamycin in the enterococci analysedemphasises the importance of |
speciating enterococcal isolates accurately and, as demonstrated by the discrepancies 
between biochemical and molecular identification of these isolates, this is not always 
straightforward.
In summary, the mechanisms of resistance to avilamycin and their molecular basis 
appear to be relatively complex, with both intra and inter-species differences.
Although sequencing of resistant isolates has provided additional information on the 
mode of action of avilamycin and mechanisms of resistance to it, it would not at
149
present be possible to use this information to screen enterococcal isolates for 
avilamycin resistance by molecular means alone.
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CHAPTER 8
EPIDEMIOLOGICAL MODELS
8.1 Introduction
Having applied standard statistical techniques to determine the sample numbers 
required to detect resistance (Chapter 3), it was apparent from the findings of the farm 
studies discussed in Chapters 4, 5 and 6 that the sensitivity and specificity of some of 
the conventional bacteriological techniques routinely used in antimicrobial resistance 
studies were poor and that even the genotypic detection of resistance as discussed in 
Chapter 7 would have a low sensitivity. It was also clear that resistance could be 
estimated within several different populations including farm, production group, 
animal and bacterial species. Epidemiological modelling was an alternative approach 
considered to determine sample sizes whilst taking into consideration the different 
population levels and incorporating some of the features of the tests applied. 
Modelling is the representation of physical processes, designed to increase 
appreciation and understanding (Thrusfield, 1995) and models can range from simple 
pictorial representations of a process to complex mathematical algorithms that require 
computers to be implemented. Epidemiology is the study of disease in populations 
and thus the epidemiological models developed relate resistance to the underlying 
animal and bacterial populations.
In veterinary medicine, the use of modelling has largely been directed towards 
infectious disease and several different types of mathematical model have been 
applied to disease transmission in different animal species including differential 
equation models (Cherry et a l, 1998), matrix models (Lesnoff et a l, 2000), network
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models and simulation models (Horst et a l, 1999; Cohen et a l,  2000; de la Rua- |
Domenech et a l, 1999; Ferez et a l, 2002). These models have been used to explore 
the dynamics of disease transmission in endemic and epidemic situations and also to 
predict the effects of different intervention strategies such as vaccination (Vonk 
Noordegraaf et a l, 2000; Mangen et a l, 2001). An epidemiological model is defined 
as a mathematical model, which may be a computer simulation model, of a disease for 
the purpose of studying the behaviour of the disease in an animal population under 
variable conditions of climate, density of population, mix of population and so on,
-A
(Blood and Studdert, 1996). However, recently, simulation models have also been
:
applied to veterinary public health and this approach has been a useful adjunct to risk 
assessment in quantifying the microbial hazards associated with meat production 
(Cassin e ta l,  1998; Jordan et a l, 1999; Hartnett et a l , 2001).
In simulation modelling, scenarios as similar as possible to reality are reproduced by 
selecting inputs, either deterministicaliy or stochastically, and calculating the model 
output. This process can be repeated a large number of times using iterations with 
different input values in order to assess changes in model output. The benefits of 
developing simulation models are twofold in that not only is it possible to imitate 
reality and thereby predict outcomes in statistical terms, but all the factors important 
in determining the output of the model are highlighted as the model is developed. This 
improves understanding of the disease process or production process being modelled.
The importance of surveillance of antimicrobial resistance in farm animals is well 
documented (Williams and Ryan, 1998; House of Lords Select Committee on Science 
and Technology, 1998; ACMSF, 1999) but it is acknowledged that the understanding 
of the development, persistence and dynamics of antimicrobial resistance in bacterial 
and animal populations needs to be improved (Lipsitch and Levin, 1997a; Lipsitch et
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a l,  2002; Humphry et a l, 2002). The deficiencies in currently available data have 
also been described and the need for a population based approach to the design of 
antimicrobial resistance studies highlighted (Davison et a l, 2000). However, there is 
little published information in the scientific literature on the application of 
epidemiological models to the design of sampling regimes.
The consideration of test performance in infectious disease models has also been 
limited. The importance of test sensitivity and specificity when the health status of a 
herd is determined by tests applied to individual animals has been highlighted 
(Martin et a l, 1992) and herd level sensitivity and specificity have been investigated 
using a modelling approach (Jordan and McEwen, 1998). However, this approach has 
not been applied to antimicrobial resistance.
Modelling of antimicrobial resistance has been limited to the population dynamics of 
resistant bacteria and the effect of different antimicrobial treatment regimes on the 
development and spread of resistant organisms, (Bonlioeffer et a l, 1997; Lipsitch and 
Levin, 1997b; Levin et a l, 1997; Lipsitch and Levin, 1998; Levin, 2001). Whilst the 
same principles used in infectious disease modelling apply, the modelling of 
antimicrobial resistance requires the consideration of an additional population level, 
the bacterial population. Transferable resistance can be considered to act like an 
infectious agent within bacterial populations, which, may, in turn act as infectious 
agents within animal populations, or may be part of the normal flora.
This chapter describes the development of epidemiological models that consider the 
underlying animal and bacterial populations and the performance of diagnostic tests in 
the detection of antimicrobial resistance. It is envisaged that such an approach could 
be used to help structure and interpret future surveillance programs for antimicrobial 
resistance in farm animals.
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8.1.2 Models Developed
Two types of model were considered. In probability models, a single point estimate is 
used for each input variable. Various possible scenarios can then be explored by 
combining different estimates for each variable and considering their effect on the 
model outcome. Commonly, minimum, maximum and expected values are estimated 
for each variable in order to model best case, worst case and most likely scenarios. 
However, the drawbacks of adopting this probabilistic approach include the fact that 
all possible values for each variable are not represented and the likelihood of each 
input variable taking an estimated value is not taken into account. In addition, in order 
to represent some of the various possible scenarios that may arise, large numbers of 
combinations of inputs become necessary and this becomes quite cumbersome to 
compute.
In stochastic models, random variation in each input variable is taken into account, 
such that the model outcome occurs with an associated probability distribution. In 
order to achieve this, each input variable consists of a probability distribution rather 
than a point estimate. One method of modelling stochastic processes is to use 
simulation (Vose, 2000). This technique involves sampling from each probability 
distribution within the model to produce many scenarios or iterations. In Monte Carlo 
sampling, the distribution of each input parameter is sampled at random without 
taking into account previous samples, whilst in Latin Hypercube sampling each 
distribution is split into sections of equal probability and the same number of samples 
is taken from each section. Latin Hypercube sampling ensures that all portions of the 
distribution are represented with the appropriate probability and was therefore the
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method used in the stochastic simulation models presented here. Such sampling is 
also computationally more efficient.
8.2 Probability Models
8.2.1 Individual Animal Probability Model
8.2.1.1 Model Description
The first step in developing the model was to consider the situation for an individual 
animal. In its simplest form, the probability of an individual animal being detected as 
harbouring or excreting resistant bacteria depends upon the prevalence of resistant 
bacteria within the animal and the number of those bacteria that are tested for 
resistance. The prevalence of resistant bacteria in the animal can also be considered as 
the proportion of the bacterial population that is resistant. The probability of the 
animal being detected as harbouring or excreting resistant bacteria is effectively the 
probability that at least one bacterium isolated from that animal tests positive for 
resistance. Assuming that the test for resistance is accurate, in other words that it 
correctly identifies resistant bacteria every time and does not misclassify a sensitive 
bacterium as resistant, then the probability of detection can be represented by 
Equation 8,1.
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P  —(Y — p) Equation 8.1
where P is the probability of detecting at least one resistant bacterium in an individual 
animal, p  is the proportion of bacteria in the animal that are resistant and b is the 
number of bacteria tested.
The principle behind this model is that the probability of an event occurring must lie 
between 0 and 1, where a probability of 1 means it will certainly occur and a 
probability of 0 means it will certainly not occur. Furthermore, where two events are 
mutually exclusive, in this case a bacterium testing resistant or not, then the 
probability of either is equal to 1 minus the probability of the other. Therefore, the 
probability of at least one bacterium testing resistant is equal to one minus the 
probability that all of the bacteria tested are not resistant. For each bacterium, the 
probability of not being resistant is equal to one minus the probability of being 
resistant and when a number of bacteria are tested, this is the same as one minus the 
proportion of bacteria that are resistant.
8.2.1.2 Analysis of the Model
The simplest application of this model is to estimate values for the input parameters 
and consider how these would affect the model output. Where one bacterium from the 
animal is tested for resistance, the probability of detecting resistance is equal to the 
proportion of resistant bacteria. As the number of bacteria tested is increased, the 
probability of at least one testing resistant increases (Figure 8.1).
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Figure 8,1 Plot showing the relationship between probability of detection, P, 
and number of bacteria tested, b, in the individual animal probability model 
when prevalence, p, is 0.05.
When the proportion of resistant bacteria is 0.05, 45 or more bacteria must be tested 
to attain a probability of detection of 0.9. When the proportion of resistant bacteria is 
reduced to 0.01 (Figure 8.2), testing as many as 50 bacteria only gives a probability of 
detection of less than 0.4.
CL 0.8 ~
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bacteria tested, b
Figure 8.2 Plot showing the relationship between probability of detection, P, 
and number of bacteria tested, 6, in the individual animal probability model 
when prevalence,/?, is 0.01.
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In contrast, testing 22 bacteria gives a probability of detection of 0.9 when the 
proportion of resistant bacteria is increased to 0.1, but 29 must be tested to increase 
the probability to 0.95 (Figure 8.3).
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Figure 8.3 Plot showing the relationship between probability of detection, P, 
and number of bacteria tested, 6, in the individual animal probability model 
when prevalence, p, is 0.1.
Thus, it can be seen from the application of this individual animal probability model 
that in order to be confident of detecting resistance, high numbers of bacteria should 
be tested, particularly when the proportion of resistant bacteria is low.
8,2.2 Farm and Region Probability Models
Second, the detection of resistance in a group of animals was considered. The group 
of animals could represent a pen or batch of animals within a farm or an entire herd or 
flock.
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8.2.2.1 Model Description
The individual animal probability model in Equation 8.1 was expanded to model the 
situation in a group of animals. The probability of detecting resistance in a group is 
modelled by Equation 8.2.
( 1 - P l ) ^ ‘ X x i i - p r i f " Equation 8.2
where P is the probability of detecting at least one resistant bacterium in a group of 
animals, p  is the prevalence of resistant bacteria, b is the number of bacteria tested 
from each animal and n is the number of animals tested.
In this instance, the probability of detecting resistance in the group is equal to one 
minus the probability that for each animal sampled, all the bacteria tested are not 
resistant and p  and b may be different for individual animals. The group model was 
further developed to model the situation in a region (Equation 8.3).
Equation 8.3
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where P is the probability of detecting resistance in a region, p  is the prevalence of }
resistant bacteria and assumed constant for each animal and farm, b is the number of 
bacteria tested from each animal, n is the number of animals tested from each farm 
and /is  the number of farms tested.
Note that in this model it is assumed that there is no animal to animal variation in the 
prevalence of resistant bacteria.
8.2.2.2 Model Analysis
Again, the effect of alterations in the prevalence of resistance and in the numbers of 
bacteria tested per animal on the probability of detecting resistance can be assessed.
When the aim was to detect resistance at the farm level with the number of bacteria 
tested per animal set at 1, the probability of detection could be improved by 
increasing the number of animals tested (Figure 8.4), whilst at region level, with the 
number of bacteria tested per animal set at 1 and the number of animals tested per 
farm set at 2, the probability of detection could also be improved by increasing the 
number of farms tested (Figure 8.5). However, when the prevalence of resistance was 
low, e.g., 0.05, even when up to 7 animals (Figure 8.4) or 8 farms (Figure 8.5) were 
tested, the probability of detection was still poor, at 0.30 and 0.56 respectively.
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Figure 8.4 Probability of detecting resistance on a farm with one bacterium 
tested per animal.
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Figure 8.5 Probability of detecting resistance in a region with one bacterium 
tested per animal and two animals tested per farm.
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8.3 Stochastic Models
8.3.1 Group Model with Variation in Prevalence
Stochastic models allow for the incorporation of random variation to input variables. 
Therefore, any of the probability models described above can be converted to 
stochastic models by introducing variation. For example, using the group probability 
model (Equation 8.2) the effect of using three different sampling regimes on the 
probability of detecting resistance (sampling 2 animals, 5 animals or 7 animals) was 
considered. At each point, the probability of detecting resistance was calculated for a 
given prevalence of resistance using each sampling regime. However, in this approach 
the assumption was made that the prevalence of resistant bacteria was the same for 
every animal in the group.
In reality, it is likely that there will be random variation in the prevalence of resistant 
bacteria between animals so that if the mean prevalence in the group is 0.01, some 
animals will have a higher proportion of resistant bacteria and some will have a lower 
proportion. This variation can be modelled by substituting the point estimates of 
prevalence with a probability distribution. For example, if one considers the mean 
prevalence in the group of animals to be 0.01 and to be Normally distributed, the 
model output becomes as shown (Figure 8.6). As the output generated is also a 
probability distribution, probability intervals can be placed around it. The spread of 
the output is dependent on the variance used for the Normal distribution. In the 
models that follow, when the Normal distribution is used with a mean proportion of 
resistant bacteriap, the binomial variancep{l-p) has been assumed.
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Figure 8.6 Probability of detecting resistance on a farm with two animals 
tested and prevalence Normally distributed with a mean of 0.01.
The model suggests that if 10 bacteria are tested from each of two animals from a 
group where the prevalence is Normally distributed with mean 0.01, on average the 
probability of detection will be 0.66. However, as the model output was generated by 
simulation, on 5 percent of occasions the same sampling regime gave a probability of 
detection of 0.98 or above and on another 5 percent of occasions the probability of 
detection was 0.11 or less. Thus, incorporating variability in one of the inputs has 
enabled the modelling of the magnitude and probability of the variation that might be 
seen in the model output and in this case there is considerable variability in the 
probability of detection.
83.2 Incorporating Test Performance
Having explored various sampling regimes for different population levels: animal, 
farm and region, and also having examined how variation in the prevalence of 
resistance might affect the probability of detection, the next phase in developing the 
model was to consider what other sources of variation contributed to the model
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output. In all the models discussed thus far, the test for resistance was assumed to be 
perfect. In reality, it is likely that whatever test is used will not be perfect and will 
detect resistant bacteria with an associated sensitivity and specificity. Therefore, the 
model was developed further to incorporate test performance.
Two approaches were considered.
8.3.2.1 Algebraic Solution
Taking test performance into account, the probability of at least one bacterium testing 
resistant is equal to 1 minus the probability that all the bacteria tested test negative for 
resistance. The probability of a bacterium testing negative for resistance is equal to 
the probability that it is truly not resistant (1-p) and is correctly identified as such by 
the test (the test specificity S p \  or, it is truly resistant (p) and is incorrectly identified 
as not resistant (1- «Se where Se is the sensitivity), (Equation 8.4).
P  =  1 — — p^Sp  + p ( l  — j  Equation 8.4
where P is the probability of detecting resistance in a group of animals, p  is the 
prevalence of resistance, Sp is the test specificity, Se is the test sensitivity and N  is the 
number of bacteria tested.
8.3.2.2 Modelling Approach
An alternative approach considered was to use stochastic simulation to model the 
number of truly resistant bacteria or true positives, and truly sensitive bacteria or true 
negatives, in a bacterial population and to use this as a basis for estimating the
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%probability of detection. In this instance, the probability that at least one bacterium 
will test positive for resistance is equal to one minus the probability that all the truly 
sensitive bacteria test negative for resistance and all the truly resistant bacteria also 
test negative for resistance (Equation 8.5).
F = l -5 p ^ ( l -S e ) X Equation 8.5
where P is the probability of detecting resistance in a group of animals, Sp is the test 
specificity, Se is the test sensitivity, x is the number of truly positive bacteria tested 
and y is the number of truly negative bacteria tested.
The number of truly negative bacteria and truly positive bacteria tested could then be 
modelled by sampling from a Binomial distribution where p  is the probability of a 
bacterium being truly resistant and b is the number of bacteria tested. The number of 
resistant and sensitive bacteria simulated, x and y, could then used as model inputs 
(Equation 8.5). However, by considering the factors influencing the numbers of 
resistant and sensitive bacteria sampled, prevalence of resistance and number of 
bacteria tested, it was possible to adjust the model so that stochastic simulation was 
not required in order to estimate the number of truly positive and truly negative 
bacteria in a sample and it was felt that this was a more accurate approach (Equation 
8 .6).
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P = l -Sp^ ^ ^ Equation 8.6
where F is the probability of detecting resistance in a group of animals, p  is the 
prevalence of resistance, Sp is the test specificity. Se is the test sensitivity and N is the 
number of bacteria tested.
When the exact model (Equation 8.4) and approximate model (Equation 8.6) were 
compared, given the same inputs for prevalence, bacteria tested, test sensitivity and 
test specificity, slightly different outputs were generated, as expected (Figure 8.7).
a  0.2-
 95th percentile, exact model
 median, exact model 5th percentile, exact model
 95th percentile, approximate model
 median, approximate model
 5th percentile, approximate model
bacteria tested, b
Figure 8.7 Probability of detecting resistance in a group of animals when 1 
animal is tested, prevalence of resistance is Normally distributed with mean 0.05, 
sensitivity is 0.9 and specificity is 0.9.
This can be explained by the fact that the algebraic model is more accurate as it is not 
dependent upon the numbers of truly positive and truly negative bacteria in a sample 
and the approximate model is simply an average model.
It was decided that, as the precise model was more accurate, this model should be the 
one used as a basis for further development and as the model output is the probability
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of at least one bacterium testing resistant it will be referred to as the test positive- 
model.
8.3.3 Variation in prevalence, sensitivity and specificity
Having developed a basic model that incorporated test performance, it was possible to 
manipulate the model inputs and analyse the effect on model output. Just as 
prevalence of resistant bacteria is likely to vary from animal to animal, there is also 
likely to be variation in the estimated test sensitivity and specificity. This variation 
includes uncertainty as well as variability. Variability refers to the random variation in 
test performance each time the test is used and may be influenced by the type of test 
used - several different methods of testing bacteria for resistance are available 
(Greenwood, 2000), and also by variation in test conditions. In disc diffusion testing 
for instance, this might include variation in inoculum density and volume, depth of 
agar, incubation temperature and time, and operator variation. Uncertainty refers to 
the level of ignorance about test performance. In the case of antimicrobial resistance 
testing, there is very little quantitative data available on test performance or 
variability. For this reason, variability and uncertainty were considered together in the 
models that follow and the probability distributions chosen modelled the total 
uncertainty surrounding parameter estimates.
The incorporation of variability in prevalence made it possible to simulate what might 
happen when animals from a population such as a pen or farm, are sampled as 
opposed to an individual animal. When a probability distribution was used as the 
input prevalence in the test positive-model the probability of detection modelled was 
the probability of detecting resistance in a group of animals when a number of 
bacteria from one animal were tested, or, a number of bacteria from a thoroughly
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mixed sample from all the animals in the group were tested. An example of a mixed 
group sample could be slurry. One of the components of variation in the model output 
is therefore the variation that exists in the underlying animal population.
By introducing variation in test performance parameters as well as variation in 
prevalence, the magnitude of variation in model output was also increased (Figure 
8.8).
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Figure 8.8 Probability of detecting resistance when prevalence is Normally 
distributed with mean 0.01, sensitivity is Normally distributed with mean 0.9, 
Binomial variances are assumed for the Normal distribution and specificity is 
Normally distributed with mean 0.9.
For example, the model suggests that if 5 bacteria were tested, the 90 percent 
probability interval for detecting resistance would be large, lying between 
approximately 0.279 and 0.996. Therefore, if the uncertainty surrounding test 
parameters could be reduced, the variability in model output could also be reduced.
8.3.4 Estimating number of bacteria to be tested
All the models discussed have been manipulated to estimate the probability of 
detecting resistance given a certain set of conditions such as prevalence, bacteria
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tested, animals tested and test performance etc. However, a more useful manipulation 
of the model is to consider the design of a sampling regime to detect resistance with a 
given probability. In order to do this, the test positive-model (Equation 8.4) was 
rearranged, (Equation 8.7).
lo g ( l -F )N  = ----=--------   :-----------------------------------------------Equation 8.7
This model was then used to estimate the number of bacteria that must be tested to 
attain a 95% probability of detecting resistance, for three different prevalence levels 
with a Normal distribution (mean 0.001,0.01 and 0.05) and three different levels of 
test sensitivity and test specificity (Normal distribution with mean 0.4, 0.7 and 0.9), 
(Table 8.1). The Normal distribution was chosen to model prevalence of resistance 
because it was thought to be a good representation of a commensal bacterial 
population in the absence of selection pressure from antimicrobial use, with very few 
animals having a high proportion of resistant bacteria and most having a low 
proportion of resistant bacteria close to the mean value (Danmâp, 2001; Humphry et 
aL, 2002). As before, the variance used was associated with the binomial distribution 
i.e. if mean is p, variance is p{l-p). The Normal distribution was chosen to model test 
sensitivity and specificity to account for random variation in test performance and the 
median number of bacteria to be tested was considered the most appropriate measure 
because the distribution of sample size from the simulation was skew.
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Table 8.1 To nearest whole number, median (5*** percentile, 95*** percentile) 
number of bacteria that must be tested in order to attain a probability of 
detection of at least 95% for various prevalences, test sensitivities and test 
specificities modelled using Normal distributions with binomial variance.
Test Specificity, Sp
Prevalence, p Test Sensitivity, Se 0.4 0.7 0.9
0.001 0.4 4(1,31) 6(1,48) 10 (3, 86)
0.01 0.4 4(1,25) 6 (2, 37) 10(3, 53)
0.05 0.4 4(1,21) 5 (2, 29) 9(3,41)
0.001 0.7 4(1,30) 6(1,46) 10(3,79)
0.01 0.7 4(1,25) 5(1,34) 10 (3, 53)
0.05 0.7 4(1,17) 5 (2,24) 8(3,40)
0.001 0.9 4(1,29) 6(1,44) 10 (3, 72)
0.01 0.9 4(1,21) 5(1,29) 9(3,42)
0.05 0.9 3(1,16) 5(1,20) 7 (3, 33)
However, in order to represent a commensal population following the withdrawal of 
an antimicrobial from use, a Gamma distribution was used to account for small 
numbers of animals with a higher proportion of resistant bacteria that may persist 
following withdrawal. The analysis was repeated using two prevalence levels with a 
Gamma distribution (mean 0.05, mode 0.001 and mean 0.05, mode 0.01) (Table 8.2).
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Table 8.2 To nearest whole number, median (S*** percentile, 95“* percentile) 
number of bacteria that must be tested in order to attain a probability of 
detection of at least 95% for various prevalences, test sensitivities and test 
specificities with prevalence modelled by Gamma distributions and test 
sensitivity and specificity modelled by Normal distributions with binomial 
variance.
Test Specificity ,Sp
Prevalence, p: Test Sensitivity, Se 0.4 0.7 0.9
mode, mean
0.001, 0.05 0.4 4(1,30) 6 (2,46) 10 (3, 82)
0.010, 0.05 0,4 4(1,29) 6(1,42) 10 (3, 67)
0.001, 0.05 0.7 4(1,27) 5(1,43) 10 (3, 66)
0.010, 0.05 0.7 4(1,26) 6(1,42) 10 (3, 66)
0.001, 0.05 0.9 4(1,26) 5 (1, 36) 9(3,56)
0.010, 0.05 0.9 4(1,23) 5 (1, 39) 9 (3, 63)
:
This manipulation of the model highlighted a number of points. First, the number of 
bacteria to be tested was greatest when specificity was high, sensitivity was low and 
prevalence was low. Increasing mean prevalence from 0.001 to 0.05 had only a 
limited effect on the median number of bacteria it was necessary to test. For example, 
reducing the number to be tested from 6 to 5 when sensitivity was 0.9 and specificity 
was 0.7 (Table 8.1). However, increasing prevalence did significantly reduce the 
number it was necessary to test to have a probability of detection on 95% of occasions 
- from 44 to 20 using the same test parameters.
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Similarly, increasing test sensitivity had very little effect on the median number of 
bacteria to be tested but had a greater effect on the 95^ percentile. For example, 
increasing sensitivity from 0.4 to 0.9 reduced the bacteria to be tested from 53 to 42 
when specificity was 0.9 and mean prevalence was 0.01, (Table 8.1).
However, the model suggests that test specificity is very important in determining the 
number of bacteria it is necessary to test. When specificity was 0.9 and mean 
prevalence was 0.001, 86 bacteria had to be tested to be confident of detecting 
resistance as compared to 31 bacteria when specificity was 0.4 (Table 8.1).
Finally, the estimates for the number of bacteria that must be tested (median, 5^*^ 
percentile and 95*’^ percentile) were very similar in Table 8.1 and Table 8,2, 
suggesting that the choice of underlying distribution for prevalence (Normal or 
Gamma) is less important than the mode prevalence itself.
8.3.5 Decay of Resistance
In the models described thus far, a static estimate of mean prevalence, with and 
without an underlying distribution, has been used as an input. This has enabled the 
consideration of what sampling regimes might be appropriate- at a particular point in 
time. However, unless antimicrobial use in a population of animals is constant, it is 
likely that the proportion of resistant bacteria will change with time, either reducing or 
increasing depending on factors influencing bacterial growth and fitness. A particular 
scenario in which the prevalence of resistance might change is following the 
withdrawal of an antimicrobial that has previously been in constant use such as an 
antimicrobial growth promoter.
Two types of change in the prevalence of resistance were considered -  linear decay 
(Figure 8.9) and log linear decay (Figure 8.10).
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Figure 8.9 Number of bacteria that must be tested to attain 95% probability 
of detection when prevalence is Normally distributed and decays linearly from a 
mean of 1; sensitivity is Normally distributed with a mean of 0.9 and specificity is 
Normally distributed with a mean of 0.9.
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Figure 8.10 Number of bacteria that must be tested to attain 95% probability 
of detection when prevalence is Normally distributed and decays log linearly 
from a mean of 1; sensitivity is Normally distributed with a mean of 0.9 and 
specifîcity is Normally distributed with a mean of 0.9.
Regardless of how mean prevalence decays, more bacteria need to be tested as mean 
prevalence decreases and for the same mean prevalence, the same number of bacteria
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must be tested in either case. Prevalence reaches a minimum of only 0.01 in Figure 
8.9 compared to 1.721 x 10 * in Figure 8.10 and therefore the number of bacteria that 
must be tested is much higher at this point in Figure 8.10.
As prevalence declines, the variability in probability of detection also increases. 
Therefore, the number of bacteria it is necessary to test to be confident of detecting 
resistance increases not only because prevalence is lower but also because uncertainty 
about model output is higher. When mean prevalence was 0.99, the 90 percent 
probability interval of detection lay between 1 and 7 bacteria whereas when mean 
prevalence was only 0.03 it lay between 3 and 33 bacteria.
Just as in the models considering a static prevalence, test performance is very 
important in determining how many bacteria must be tested. When specificity was 
poor, the number of bacteria to be tested actually decreased initially as prevalence 
decreased before rising again (Figure 8.11).
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Figure 8.11 Number of bacteria that must be tested to attain 95% probability 
of detection when prevalence is Normally distributed and decays log linearly 
from a mean of 1; sensitivity is Normally distributed with a mean of 0.7 and 
specificity is Normally distributed with a mean of 0.4.
174
At high prevalence levels, very few truly negative bacteria are present and the 
detection of resistance depends largely on test sensitivity whereas as prevalence 
decreases, some truly negative bacteria are misclassified as resistant, reducing the 
number of bacteria that need to be tested for at least one to test resistant. This effect 
was less apparent when test sensitivity was increased to 0.9 and test specificity was 
increased to 0.7 (Figure 8.12). However, it was still important at very high prevalence 
levels, where, for example 9 bacteria must be tested to be confident of detecting 
resistance when mean prevalence was 0.99 compared to 7 when mean prevalence was
0.83.
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Figure 8.12 Number of bacteria that must be tested to attain 95% probability 
of detection when prevalence is Normally distributed and decays log linearly 
from a mean of 1; sensitivity is Normally distributed with a mean of 0.9 and 
specificity is Normally distributed with a mean of 0.7.
Higher test specificity generally increases the number of bacteria it is necessary to 
test. For example, when test specificity was 0.7 and sensitivity was 0.9 (Figure 8.12), 
51 bacteria must be tested when the mean prevalence was 0.01. When test specificity 
and sensitivity were both 0.9 (Figure 8.10) 91 bacteria must be tested. However, in the 
former case, the requirement is reduced simply because of falsely positive test results.
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As in the previous models, increasing test sensitivity also reduced the number of 
bacteria it was necessary to test but when the criterion for detection was that at least 
one bacterium tests resistant, this was less important than test specificity.
8,3.6 Detecting True Positives
When the definition of detecting resistance is that at least one bacterium tests resistant 
and the test specificity is not perfect, it is inevitable that resistance will, on occasion, 
be wrongly “detected” as described in the above models. This is how antimicrobial 
resistance data are currently interpreted. However, when imperfect tests are used to 
detect resistance, predictive values of the test should be considered. In the context of 
antimicrobial resistance, the positive predictive value of a test is the proportion of 
bacteria that test resistant that are truly resistant. This depends on test sensitivity, test 
specificity and prevalence and is represented by Equation 8.8 (Thrusfîeld, 1995).
P P y  = ------------ —---------------   Equation 8.8pSe + (1 — jP)(1 —' Sp^
If the test specificity is low, sensitivity is low, or prevalence is low, then the positive 
predictive value of the test 'will be poor.
However, if the concern is the probability of detecting truly resistant bacteria only, 
test specificity does not matter. For an individual bacterium, the probability of it being 
resistant and being detected as resistant is dependent upon test sensitivity and 
prevalence, (Equation 8.9).
:
i:
J
i
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p  =  pSe  Equation 8.9
where P is the probability of a bacterium being resistant and testing resistant.
For a group of bacteria, the probability of at least one bacterium being resistant and 
being detected is equal to one minus the probability that they are all sensitive or not 
detected, (Equation 8.8).
n
P  = 1 •” ( l  — p S e ^  Equation 8.8
where P is the probability that at least one bacterium is resistant and tests resistant and 
n is the number of bacteria tested.
The model of the probability that at least one bacterium is resistant and is detected 
was compared with the test positive model of the probability that at least one 
bacterium tests resistant (Figure 8.13). When the model output was the detection of at 
least one true positive rather than at least one test positive, unsurprisingly, the 
probability of detection was poorer for the same number of bacteria tested, sensitivity 
and prevalence. Using the test positive model, on average testing 9 bacteria gave a 
probability of detection of 95% but on average approximately 60 bacteria had to be 
tested to achieve a probability of detection of 95% when the true positive model was 
used (Figure 8.13). In order to achieve a similar probability of detection on 95% of 
occasions (5* percentile), using the test positive model testing 71 bacteria gave a 
probability of detection of 95.0% whereas using the true positive model, even testing 
100 bacteria only gave a probability of detection of 34.3%. Therefore, the models 
developed suggest that if the detection of resistance depends upon the detection of at 
least one true positive rather than at least one test positive, the numbers of bacteria 
tested must be increased dramatically. In consideration of decay, the same principles
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hold good for the true positive model as did for the test positive model, i.e., time 
merely reflects reduced prevalence and the arguments regarding sampling must be 
built around a consideration of acceptable prevalence.
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Figure 8.13 Probability of detecting resistance based on the test positives 
model and the true positives model when prevalence of resistance is Normally 
distributed with a mean of 0.01, test sensitivity is Normally distributed with a 
mean of 0.9 and for the test positives model, test specificity is Normally 
distributed with a mean of 0.9.
8.4 Discussion
The models described have shown how the application of mathematical and statistical 
techniques such as simulation modelling to the problem of antimicrobial resistance is 
essential if test systems are to be properly implemented.
First, it demonstrates the factors that should influence the design and interpretation of 
antimicrobial resistance studies. The prevalence of resistant bacteria and the numbers 
of bacteria and animals tested have been shown to be important considerations. 
Moreover, the importance of considering the different population levels, such as
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bacterium, animal, farm or region, and of defining the output of antimicrobial 
resistance studies in relation to them, have been demonstrated and this is in agreement 
with the suggestions of other authors (Davison et al.  ^2000; Humphry et al., 2002).
The performance of diagnostic tests used in antimicrobial resistance studies has also 
been shown to be a significant consideration. The sensitivity and specificity of these 
tests have been shown to have a strong influence on the number of bacteria it is 
necessary to test and the probability of detection and although test performance in 
survey design has been considered before, this has mainly been to determine the 
number of animals to be tested to be confident that a herd is free from disease 
(Cannon, 2001) and has largely been ignored in the design of antimicrobial resistance 
studies in animals. The problems of standardisation of susceptibility testing methods 
have been acknowledged and it has been suggested that even if this were achieved, 
“standard” does not mean “correct” (Greenwood, 2000). However, many diagnostic 
tests used in veterinary and human medicine are not perfect but their interpretation is 
aided by knowledge of their sensitivity and specificity and the absence of a perfect 
test for resistance should not preclude attempts to define test performance, as this 
information is essential if accurate conclusions are to be drawn from surveillance 
studies.
Second, the models have highlighted how variability in these contributing factors has 
a significant effect on resistance detection. Animal to animal variation and the 
uncertainty and variability surrounding estimates of test performance must be 
considered. Calculating sample numbers based on an “average” situation could lead to 
a significant under estimate of the numbers required and allow the findings to be 
misinterpreted. The variability in proportion of resistant bacteria between sub­
populations of animals and between individual animals within these populations has
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rarely been considered but is thought to be significant (Dunlop et al., 1999) and given 
the findings of the models described, such variation would significantly influence the 
estimated prevalence of resistance and should influence the design of sampling 
regimes. The degree of heterogeneity in commensal bacterial populations with respect 
to resistance has not often been quantified but recent data suggest it is significant in E. 
coll (Dunlop et al., 1998c and 1999; Humphry et al., 2002) and the current practice of 
selecting small numbers of colonies from a bacterial population of millions is wholly 
inadequate.
Furthermore, variation in the prevalence of resistance also occurs with time and the 
dynamics of bacterial populations are complex (Lipsitch and Levin, 1997a). The 
effects of both linear and log-linear decay in resistance were considered but the rate of 
decay was not defined because this would vary for different antimicrobials and 
different organisms and would be influenced by many factors as discussed in Chapter
1. Applying the models to the detection of resistance when prevalence is declining has 
indicated that the longitudinal monitoring of resistance in populations requires careful 
consideration of sample size in relation to prevalence. Although statistical methods 
such as time series analysis have been used to monitor changes in the prevalence of 
resistance over time in hospitals (Lopez-Lozano et a l, 2000), this has been based on 
clinical isolates alone, and has not taken into account the bacterial population as a 
whole. The findings also suggest that resistant bacteria that persist at low levels in a 
population may be extremely difficult to detect even if large numbers of bacteria are 
tested. This means that studies attempting to quantify the decline in resistance 
following the withdrawal of an antimicrobial from use should be interpreted with 
caution and findings related to the number of bacteria tested. Failure to detect resistant
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bacteria may be just that, a failure of detection rather than a true reflection of the 
resistance status of the population.
The comparison of models that defined the detection of resistance as the detection of 
at least one test positive with models that defined the detection of resistance as the 
detection of at least one true positive, highlighted important differences. The test 
positive model reflects current practice in the interpretation of antimicrobial resistance 
data (BSAC, 1991; NCCLS, 1999; Bager, 2000; Martel et ah, 2000; Wray and 
Gnanou, 2000). However, the true positive model suggests a more appropriate way to 
interpret these data given that the tests used are imperfect. Just as resistant bacteria 
may be missed due to insufficient sample sizes and poor test sensitivity, susceptible 
bacteria may be misclassified as resistant and therefore it is unreasonable to accept 
that the testing of one bacterium from an animal can confirm the presence of 
resistance. This is likely to be particularly important when commensal bacteria are 
being considered, as the bacterial population does not necessarily expand clonally as 
happens when a pathogenic organism infects an animal and therefore the variation in 
the underlying bacterial population is likely to be greater (Craven and Bamum, 1971; 
Linton et a l, 1978; Langlois et a l, 1983). The true positive model also suggests that 
ideal sample sizes for antimicrobial resistance studies should be further increased to 
account for the occurrence of bacteria that falsely test positive.
Although the models described have been shown to be useful in highlighting current 
deficiencies in the design and interpretation of antimicrobial resistance studies, 
epidemiological modelling techniques are of limited use when considered alone. 
Whilst these techniques have been used as described to explore theoretical scenarios, 
the usefulness of the models developed would be increased by the generation of 
accurate, quantifiable data from laboratory testing and this is a recognised deficiency
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of current antimicrobial resistance surveillance (Wray and Gnanou, 2000). Model
IÎinputs could be based on these data and sample size estimates calculated with greater 
accuracy. Currently, the lack of consensus on definitions of resistance, the poor 
knowledge of the performance of diagnostic tests and the failure to relate organisms 
tested with underlying bacterial and animal populations are limiting the utility of field 
data for this purpose.
Nonetheless, the models developed are significant because they clearly demonstrate 
the epidemiological factors to be considered when designing sampling regimes for 
antimicrobial resistance studies, including the consideration of different population 
strata and the performance of diagnostic tests. In addition, they indicate the magnitude 
of testing required in order to ensure that such studies withstand statistical scrutiny.
Although the technology and resources to carry out the level of testing suggested may 
not be available, ideal sample sizes should not be ignored.
Some sensible conclusions from the models developed that should be considered in 
studies to detect antimicrobial resistance are as follows: 1. the clear definition of the 
aims of a study at the outset, including the bacterial species and antimicrobial of 
interest, as this influences many inputs from the prevalence of resistance to the most 
suitable susceptibility testing method; 2. knowledge of the performance of the tests 
used for resistance are also essential to the design of an appropriate sampling regime, 
with the best test available being used as poor tests make the interpretation of test 
results very difficult as well as increasing sample numbers; 3. ideally, the degree of 
variation in the underlying bacterial and animal populations of interest should also be 
taken into account and the difference between pathogenic and commensal bacteria in 
this respect demonstrates the importance of this; 4. the acceptable level of detection is 
also critical to the sample numbers required and a sensible aim would perhaps be to
detect resistance at the 5 percent prevalence level; 5. where the aim is to detect 
smaller numbers of resistant bacteria, the sample numbers required and therefore 
financial resources necessary increase dramatically and this must be accepted as the 
over-interpretation of data based on insufficient sample numbers is misleading; 6. 
finally sample numbers should be calculated using standard statistical methods once 
these factors have been taken into account.
Testing on the scale suggested is perhaps unlikely to be implemented widely due to 
the nature of current laboratory practices and the financial implications of testing 
large numbers of bacteria and animals. Although some consideration has been given 
to assessing resistance in bacterial populations using novel methods such as spiral 
plating and hydrophobic grids (Dunlop et a l, 1998c; Humphry et a l, 2002) laboratory 
techniques must be advanced in order to reduce labour-intensity as well as to improve 
accuracy. However, despite such practical problems, the application of 
epidemiological models and statistical theory must be considered when designing 
rational surveillance programs for antimicrobial resistance in animal populations.
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CHAPTER 9
GENERAL DISCUSSION
9.1 General Discussion
The aim at the outset of this work was to consider resistance to the growth promoting 
antimicrobial avilamycin, including the measurement of resistance in the field. To 
some extent these aims have been achieved but, more importantly, in attempting to 
meet these objectives several methodologies have been explored and many important 
questions relevant to antimicrobial resistance studies of any kind have been 
highlighted.
First, the application of standard statistical formulae to sample size calculations for 
resistance studies suggested the scale of sampling required if the measurement of 
resistance is to be addressed seriously. Although the application of standard statistical 
formulae has been suggested before (Davison et al., 2000) the consequences for 
resistance surveillance have not been explored. This requires the clear definition of 
the aims of surveillance at the outset including the animal population, the bacterial 
species and the antimicrobial of interest, the achievement of simple random sampling 
or where this is not achievable the necessary adjustments to sample calculations, and 
the consideration of test performance. Test performance has been considered with 
regard to herd disease status (Jordan and McEwen, 1998) but has received only very 
limited consideration in antimicrobial resistance studies (NCCLS, 1999). This not 
only has significant cost and labour implications for future surveillance but also 
suggests the inadequacy of much of the surveillance data on which conclusions on 
antimicrobial resistance transfer via the food chain and legislative decisions have been
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based (Fidler, 1999; Acar et al., 2000). In a small study with limited resources in 
terms of labour one could not hope to achieve the sample numbers suggested and 
therefore the sample design became a compromise between what was ideal and what 
was practical but there is no question that the strength of the conclusions were 
weakened as a result. The practical problems of adhering to sampling designs were 
also highlighted with the variability and inconsistent availability of faecal material on 
farms a major barrier to achieving suggested sample numbers as well as to achieving 
simple random sampling. The findings suggest that the best that can be hoped for 
from on-farm environmental sampling is detection of the presence of antimicrobial 
resistance rather than quantification in any way.
Second, several important conclusions from the initial studies related specifically to 
Enterococcus spp. and these are significant because this genus has been the focus of 
much of the surveillance of resistance to antimicrobial growth promoters in food 
animals (Wegener et al., 1999; SVARM, 2(K)0; Danmap, 2001). The use of Slanetz 
and Bartley medium was shown to be effective in the isolation of enterococci with 
sensitivity of isolation at least as high as that reported by other authors (Devriese et 
al., 1994; Danmap, 2001). However, colonial morphology was shown to be a poor 
indicator of species and to be insufficient in itself to confirm genus and this seriously 
affected the use of conventional colony-counting techniques for enumerating bacteria. 
Counts were shown to be unreliable not only because of the poor specificity of the 
medium but also because of the subjectivity of assessing the visual appearance of 
colonies These factors made the quantification of resistant enterococci, either actual 
or proportionate, very difficult and although these methods have been applied to 
assessing faecal contamination of water supplies (Pagel and Hardy, 1980) this 
suggests that they are inadequate for accurately quantifying resistant bacteria.
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Improved methods of enumerating bacteria for the purpose of antimicrobial resistance 
studies have been suggested (Dunlop et aL, 1998c; Humphry et aL, 2002) but these 
have focussed on E. coli and the limitations of the isolation media available for 
enterococci may limit their adaptation to this genus.
A variety of enterococcal species including E.faecium, E.faecalis and E. durans was 
isolated with different species apparently predominating on different farms. Variation 
in the enterococcal flora of pigs has been suggested before (Devriese et aL, 1994) but 
the majority of surveillance of antimicrobial resistance has been based on E. faecium 
and E.faecalis (SVARM, 2000; Danmap, 2001). The confirmation of avilamycin 
resistance in species other than E. faecium and E. faecalis and in particular in E. 
durans was also significant because it again emphasises the importance of accurately 
speciating enterococci but also raises the question of the relevance of these species to 
public health. It would seem logical that species other than E. faecium and E. faecalis 
are capable of being a reservoir of resistance even if they are less common pathogens 
(Gilad et aL, 1998; Devriese et aL, 2002) and this also suggests a possible deficiency 
in the current approach to resistance surveillance. Although insufficient enterococci 
were isolated to carry out a detailed comparison of resistance patterns amongst 
individual species, the findings suggest that resistance to therapeutic antimicrobials is 
perhaps more prevalent in E. faecium than in other enterococcal species and therefore 
that resistance data should not be compared unless isolates have been carefully 
speciated.
The majority of enterococci isolated were sensitive to avilamycin by conventional 
classification (MIC 16pg/ml) (Danmap, 2001), but the fact that no clear bimodal 
distribution of MICs was observed highlighted the problem of choosing a breakpoint 
MIC for resistance to growth-promoters. This method has been described as the only
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suitable means of determining breakpoints to growth promoting antimicrobials but it 
is accepted that the distinction between resistant and sensitive populations may not 
always be clear (Butaye et aL, 2003) and this is an issue that must be clarified if 
resistance is to be measured in bacterial populations. It might be agreed that the 
breakpoint chosen should depend on the aims of the study, with a low breakpoint of 
say 8pg/ml used when the aim is to detect all resistant organisms. However, these 
data cannot then necessarily be used to quantify the proportion of resistant bacteria in 
a sample.
The conventional technique of MIC determination in individual isolates on which 
most surveillance data is based was shown to be wholly inadequate to detect 
resistance when the prevalence of resistance was low. This suggests that this method 
is unsuitable for the longitudinal monitoring of resistance as low numbers of resistant 
organisms would be missed. However, these are exactly the sort of data that have 
been used to examine the effects of the removal of antimicrobial growth promoters 
from use on bacterial resistance and to justify their withdrawal (Boerlin et aL, 2001; 
Aarestrup et aL, 2001).
Although no resistant isolates were detected using conventional MIC testing of 
individual isolates, avilamycin resistance was detected on a farm that had not used 
avilamycin for at least two years when screening plates were used, suggesting that 
resistance had either persisted for this time or been reintroduced and was present at a 
low prevalence. A similar method has recently been applied to the detection of 
vancomycin-resistant enterococci in broiler flocks and has also suggested that there 
has been no significant decline in vancomycin resistance in the five years following 
the ban on this growth promoter (Heuer et aL, 2002). These findings not only suggest 
that resistance can persist in commensal bacterial populations but also emphasise the
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importance of using a sensitive method of detection if such resistant isolates are not to 
be missed.
The use of screening plates containing avilamycin was useful in confirming the 
presence of resistant organisms when the prevalence of resistance was very low but 
unfortunately the poor specificity of the media made this a highly sensitive but poorly 
specific test that could not be relied on without confirmation of the identity of the 
presumptive enterococcal isolates. A similar method has recently been used to assess 
resistance in faecal E. coli populations in conjunction with molecular methods to 
detect resistance genes, with the authors also suggesting that this approach offers 
advantages over conventional individual isolate MICs in assessing resistance in 
commensal bacteria (Blake et aL, 2003). However, despite the use of automated 
counters and the availability of isolation media highly specific to E. coli meaning that 
further confirmation of species identity was not performed, the labour intensity of 
performing such detailed analyses meant that faeces from only three animals could be 
examined fully or where animal numbers were increased to twenty, molecular 
analysis could be performed on only a small number of bacterial colonies. Therefore, 
whilst this method offers a means of improving bacterial sample numbers, it is not 
suitable for application to realistic animal sample numbers due to the labour involved 
in preparing media and in particular in culturing many colonies to purity and 
identifying them to species.
The small-scale studies on resistance to therapeutic antimicrobials (Chapter 6) 
highlighted the problem of attaining sufficient sample numbers to achieve statistical 
power. In these studies, standard statistical techniques were strictly applied to the 
results and very few firm conclusions could be drawn. It has been suggested 
elsewhere that legislative decisions regarding antimicrobial growth promoters have
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Ibeen taken based on small data sets (Acar et aL, 2000). There was no evidence to 
suggest that avilamycin use was associated with resistance to therapeutic 
antimicrobials but the most important finding was probably the difficulty in proving 
clear association because of the many factors possibly influencing antimicrobial 
resistance. Again, it has been suggested elsewhere that these other factors have not 
always been taken into account before conclusions have been drawn from 
antimicrobial resistance surveillance data (Phillips, 1997). These findings highlight 
some of the limitations of interpreting field data, particularly when only small sample 
numbers are available or when resources are limited, and also when many 
uncontrolled factors may be influencing resistance.
In addition to the problems of confidently estimating the prevalence of resistance, an 
equally significant problem was how best to express the findings. Although it has 
been suggested that resistance should be related to underlying bacterial and animal 
populations (Davison et aL, 2000), the most appropriate way to do this has not been 
described. Should resistance be related to isolates or samples, or, in the case of 
commensal organisms that are not consistently isolated, to samples from which the 
species of interest was isolated? Whilst this may seem pedantic, the findings suggest 
that the prevalence of resistance suggested were quite different and could easily 
influence interpretation of resistance data. Perhaps the most appropriate measure is 
dependent on the aim of the study and the relevance of the organism. For instance, for 
enterococci the main significance of resistance is the potential for transfer to humans 
via faecal contamination of meat and therefore a faecal sample from which no 
resistant enterococci were isolated could be considered a significant negative finding. 
However, when dealing with commensal organisms it is assumed that they are
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omnipresent in all animals and therefore a failure to isolate resistant enterococci may 
be due to poor isolation technique rather than the true absence of these organisms. 
Another important finding of the farm studies on both enterococci and Escherichia 
spp. was the heterogeneity in the bacterial population with regard to resistance. This is 
a feature that has clearly been ignored by conventional microbiological methods 
designed to measure resistance in a clonally expanding pathogen (Hedges et aL, 1977; 
Humphry et aL, 2002; Blake et aL, 2003). The measurement of resistance in 
commensal organisms has been suggested for some time but only recently has the 
importance of measuring resistance in the bacterial population rather than in 
individual isolates been suggested (Blake et aL, 2003) and although the problem of 
how best to achieve this has not yet been resolved it should not be ignored. The recent 
application of mathematical modelling techniques to the problem of antibiotic 
resistance in commensal organisms in animals and man has suggested that very small 
increases in the prevalence of resistant bacteria in animals could have a significant 
and irreversible impact on the spread of resistant bacteria to humans and this has 
again highlighted the inadequacies of current surveillance practices suggesting that 
they would fail to detect such a change (Smith et al., 2002).
Having attempted to quantify resistance using conventional microbiological 
techniques, the possibility of measuring resistance to avilamycin in enterococci by 
molecular techniques was explored following the detection of substitutions in 
ribosomal protein L16 conferring resistance to avilamycin by other authors (Aarestrup 
and Jensen, 2000). However, the findings suggest that resistance to avilamycin in 
commensal enterococci is very complex with more than one genetic mechanism 
responsible and this has since been confirmed by the description of other resistance 
mechanisms (Mann et aL, 2001). With the small time and labour available, it was not
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possible to consider the genetic mechanism of resistance in a large population of 
isolates but the heterogeneity observed in the small number of isolates tested was 
perhaps surprising, if not daunting and effectively precluded the possibility of 
screening isolates or samples for resistance by PCR. Classically, resistance has been 
viewed as an all or nothing event with isolates classified simply as resistant or 
sensitive (NCCLS, 1999; BSAC, 2003) but a practical consequence of the multiple 
genetic mechanisms of resistance in many organisms is the increasing complexity of 
probes for the genetic detection of resistance (Phillips, 1997). Although such 
techniques have offered important advances in our understanding of resistance and its 
detection and offer advantages in specificity over conventional microbiological 
techniques, phenotypic detection of resistance remains more sensitive and is therefore 
currently more suitable for the surveillance of avilamycin resistance in enterococci. 
Finally, taking all the factors discussed into account, epidemiological modelling 
techniques were applied to the design of sampling regimes and this again highlighted 
the importance of applying standard statistical theory to antimicrobial resistance 
studies if quantification is to be achieved. The definition of the population of interest 
-  region, farm, animal, bacterial species was shown to be critical as was consideration 
of prevalence and test performance. Exploration of these modelling techniques 
highlighted several gaps in our knowledge of antimicrobial resistance that must be 
addressed -  the proportion of commensal bacteria expressing resistance, the 
variability in bacterial and animal populations and the performance of diagnostic tests. 
Some of these aspects have been raised before (Davison et aL, 2000; Dunlop et aL,
1999) but have not been thoroughly explored. The use of epidemiological modelling 
again highlighted the inadequacy of current antimicrobial resistance surveillance, with 
the testing of a few colonies from a commensal bacterial population of millions with
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the aim of monitoring the prevalence of resistance over time shown to be futile and 
the ignorance of test specificity and sensitivity when surveillance data is interpreted 
potentially misleading.
In summary, the measurement of antimicrobial resistance in bacterial and animal 
populations has been shown to be extremely complex with many factors including the 
calculation of suitable sample sizes, the definition of bacterial and animal populations
■ Îand the consideration of diagnostic tests all critical to improving the quantification of '
resistance. Avilamycin resistance has been shown to be present in the enterococcal 
flora of pigs in the UK and to be detectable on pig farms where it has been withdrawn 
from use. The relevance of this finding to public health is uncertain but it is clear that 
conventional surveillance is of very limited use in monitoring resistance in 
commensal bacterial populations of animals.
9.2 Future Work
In order to improve understanding of the relevance of resistance in enterococci in 
farm animals to public health, there are several areas of work considered in this thesis 
that need to be expanded upon.
First, the quantification of resistant enterococci has not been fully achieved and there 
are several reasons for this. It would be useful to improve the specificity of the media 
for the isolation of enterococci perhaps by utilising some of their biochemical 
properties such as the hydrolysis of aesculin in conjunction with a chromogenic 
medium such as Slanetz and Bartley and then to develop improved counting 
techniques. These could perhaps be based on the work of other authors on E. coli 
(Dunlop et aL, 1998c; Humphry et aL, 2002) and involve hydrophobic grids or spiral 
plating technology.
192
 ■■ •..--''i'' ''I'"' '' " ""
Molecular technology also offers possibilities for the quantification of bacteria with 
techniques such as real-time PCR described (Ibekwe and Grieve, 2003). If molecular 
methods for the spéciation of enterococci (Dutka-Malen et aL, 1995; Baele et aL,
2000) could be combined with the molecular detection of resistance genes then this 
would offer exciting opportunities to improve the quantification of resistance in 
commensal enterococci. However, it would first be necessary to further characterise 
the genetic basis for avilamycin resistance in enterococci, perhaps paying particular 
attention to inter-species differences. This would involve screening a large number of 
isolates of each species, including E. durans, E. hirae and other less commonly 
considered enterococci for the presence of the resistance genes currently described 
(Aarestrup and Jensen, 2000; Kofoed and Vester, 2002) as well as considering other 
as yet undescribed genetic mechanisms of resistance.
A useful extension of the epidemiological modelling work would be to develop a 
quantitative risk assessment of the probability of antimicrobial growth-promoter use 
in farm animals leading to increased morbidity and mortality in humans due to 
infectious disease. However, it would perhaps be more useful to consider an 
antimicrobial closely related to a human therapeutic antimicrobial, such as avoparcin, 
in this risk analysis as the relevance of avilamycin resistance to human health remains 
uncertain.
All of the future work suggested would require considerable financial resources as 
well as labour. Whilst it would help to address some of the questions raised in this 
thesis, it seems unlikely that such resources will be available as there is little evidence 
to suggest that avilamycin use is a significant threat to public health. Finally, 
following recommendations made in a recent report by the World Health Organisation 
(WHO, 2003), an EU regulation enforcing the phasing out of the four remaining
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antimicrobial growth promoters, avilamycin, monensin, salinomycin and 
flavophospholipol, was adopted in July 2003 (EC, 2003). This legislation was agreed 
as part of the EU strategy to combat the threat to human, animal and plant health 
posed by antimicrobial resistance and will come into force later this year although the 
time-scale for withdrawal has not been firmly agreed. This legislation will perhaps 
reduce the need for surveillance of resistance to avilamycin in the longer term, but 
some of the work described could be applied to monitoring the effects of avilamycin 
withdrawal, and many of the findings are relevant to antimicrobial resistance 
surveillance of any kind in animal populations.
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